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CHAPTER I 
 
INTRODUCTION 
 
Introduction  
 As obligate intracellular parasites, viruses must co-opt basic cellular processes to 
enter into host cells and deliver their genomes to the appropriate intracellular site (1). 
Viral entry steps include attachment of the virus to the cell surface, penetration of the 
virus into the cell interior, disassembly of the viral capsid, and activation of the viral 
genetic program. These events are essential for the virus to transition from the 
extracellular environment to the cellular compartment in which viral transcription and 
replication occur. Entry steps also play key roles in viral pathogenesis, as these events 
often determine cell tropism within the infected host.  
Mammalian orthoreoviruses (reoviruses) are important models for studies of virus 
cell entry and the pathogenesis of viral disease. Reovirus entry is initiated by attachment 
to both carbohydrate and proteinaceous cell-surface receptors. Binding events trigger 
internalization of virions into endosomes where uncoating takes place. Following 
removal of the viral outer capsid, viral proteins breach the endosomal membrane, 
releasing the transcriptionally active core into the cytoplasm. Recent work in our lab and 
others has defined cellular components necessary for uncoating and membrane 
penetration in cell culture. However, the role of these cellular factors in vivo is not 
understood. For my dissertation research, I have investigated the function of endosomal 
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cathepsin proteases, enzymes required for uncoating of the reovirus outer capsid, in 
reovirus pathogenesis and disease. 
 
Reovirus Structure and Background 
Reoviruses are nonenveloped, icosahedral viruses that contain a genome of 10 
double-stranded (ds) RNA gene segments encased in two concentric protein shells (3, 5) 
(Figure I-1). The viral core is composed primarily of the λ1 and σ2 proteins with the λ3, 
μ2, and λ2 proteins localized to the icosahedral vertices providing polymerase (6-11) and 
capping (14, 15) functions. The outer capsid is exquisitely designed for stability in the 
environment. The σ3 protein is most prominent, protruding from the virion in tetrameric 
and hexameric clusters over the surface of the particle. The σ3 protein forms a 
heterohexamer with μ1, the viral component responsible for membrane penetration. The 
interaction of σ3 with μ1 prevents the premature exposure of hydrophobic residues within 
μ1 and therefore aids in the proper timing of membrane penetration. Trimers of the viral 
attachment protein σ1 protrude from the pentamers of λ2 at the icosahedral vertices.  
There are three reovirus serotypes, which can be differentiated by the capacity of 
anti-reovirus antisera to neutralize viral infectivity and inhibit hemagglutination (16, 17). 
The three serotypes are each represented by a prototype strain isolated from a human 
host: type 1 Lang (T1L), type 2 Jones (T2J), and type 3 Dearing (T3D). Other strains of 
reovirus commonly used for studies of reovirus entry and pathogenesis include field 
isolates and viruses selected for resistance to pharmacologic inhibitors of disassembly. In 
addition, reassortant genetics (18), and now reverse genetics (19), allow for exchange of 
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genetic material between strains. These techniques allow identification of viral gene 
segments that segregate with various biological and biochemical phenotypes. 
An important control for studies of reovirus entry is the infectious subvirion 
particle (ISVP) (Figure I-1). ISVPs are a naturally occurring intermediate in the 
uncoating process (20-23) that can be generated in vitro by treatment of virions with 
proteases such as chymotrypsin and trypsin (24, 25). These particles are thought to 
penetrate cells directly at the cell surface as they are resistant to inhibitors of uncoating 
(21, 26-29) and release 51Cr from preloaded cells (30, 31). Infection by ISVPs in the 
absence of infection by virions attests to the viability of cells and their capacity to support 
the stages of reovirus infection beyond uncoating and membrane permeabilization. 
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Figure I-1. Reovirus structure. (A) Schematic of a reovirus virion.  The outer capsid 
and core are shown with 10 segments of dsRNA within. (B) Structure of reovirus 
virions, ISVPs, and cores.  Surface-shaded representations of cryo-EM image 
reconstructions of reovirus are shown, as viewed along a twofold axis of symmetry.  
Density, representing σ1, can be seen extending from turrets of λ2 at the icosahedral 
axes of virions and ISVPs.  Cores lack σ1.  Image adapted from Dryden et al (3). 
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 α-helix β-spiral β-barrel
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Figure I-2. Crystal structure of σ1 and JAM-A. (A) Ribbon drawing of the σ1 
trimer with σ1 monomers shown in red, orange, and blue.  Each monomer consists of 
a head domain formed by a compact β-barrel and a fibrous tail with three β-spiral 
repeats. Predicted structure of residues 1-245 is shown in grey. Binding sites for JAM-
A and sialic acid (predicted) are noted. Image adapted from Chappell et al (2). (B) 
Ribbon drawing of the σ1 trimer in complex with monomers of the D1 head domain of 
JAM-A as viewed from the side (left) and three-fold axis of symmetry (right). σ1 
monomers shown as in (A) and JAM-A monomers shown in green. Image adapted 
from Kirchner et al (12). 
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Reovirus Attachment 
Reovirus entry is initiated by the binding of σ1 to its cognate cell-surface 
receptors. The σ1 protein is a fibrous, trimeric molecule with distinct head-and-tail 
morphology (Figure I-2 A). Although structural information is available only for the C-
terminal half of the molecule (residues 246-455) (2, 32), sequence analysis has facilitated 
the development of a model of the full-length protein (2). The N-terminal tail region 
consists of approximately 160 residues of predicted α-helix that anchors σ1 to the virion 
(33-36) and approximately 150 residues that form triple β-spiral repeats responsible for 
binding to cell-surface carbohydrate (2). For many type 3 strains, this carbohydrate is 
sialic acid in either α2,3 or α2,6 linkages (37-39). Interaction with sialic acid is required 
for hemagglutination (39, 40) and optimal infection of murine L cells (38, 41, 42) and 
murine erythroleukemia (MEL) cells (43) by strain T3D.  
The remaining σ1 sequence forms the head domain, which is composed of two 
Greek-key motifs that fold into a β-barrel (2, 32). Residues in the loops connecting β-
strands D and E, along with residues in the most C-terminal β-spiral, make contacts with 
junctional adhesion molecule-A (JAM-A) (12) (Figure I-2 B), a member of the 
immunoglobulin superfamily (44). Human and murine homologs of JAM-A serve as 
receptors for all three reovirus serotypes, including all strains tested to date (45).  
 
Internalization of Reovirus Virions Is Mediated by β1 Integrins 
Following attachment to cell-surface carbohydrate and JAM-A, reovirus is 
internalized by receptor-mediated endocytosis (21, 22, 46-49). Expression of a JAM-A 
truncation mutant lacking a cytoplasmic tail allows reovirus to infect nonpermissive cells 
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(48), suggesting that molecules other than JAM-A mobilize the internalization apparatus 
that promotes reovirus cell entry. Based on similarities in the structures of the reovirus 
and adenovirus attachment proteins and receptors (50), it was hypothesized that reovirus 
and adenovirus employ similar integrin-dependent internalization mechanisms to enter 
cells. In keeping with this hypothesis, reovirus λ2 protein contains conserved integrin-
binding motifs, RGD and KGE (51, 52). These sequences are displayed on surface-
exposed loops of λ2 (53), where they could interact with integrins. Interestingly, the λ2-
encoding L2 gene segment is genetically linked to viral shedding in infected mice and 
spread to littermates (54), suggesting a role for λ2 in reovirus-induced disease. 
 Treatment of cells with antibodies specific for β1 integrin reduces reovirus 
infection, while antibodies specific for the other integrin subunits expressed on 
permissive cells, including those specific for α integrin subunits, have no effect (48). 
However, antibodies specific for β1 integrin do not alter infection by in vitro generated 
ISVPs (48). These findings suggest that β1 integrin blockade inhibits endocytic uptake of 
virions. In comparison to β1 integrin-expressing cells, β1-null cells are substantially less 
susceptible to infection by reovirus virions, while infection by ISVPs is equivalent in 
both cell types (48). Diminished reovirus replication in β1-null cells correlates with 
diminished viral uptake, indicating that β1 integrin is required for efficient reovirus cell 
entry.  
Most available evidence suggests that reovirus is internalized by a clathrin-
dependent pathway (21, 22, 46, 47, 49). Reovirus virions are observed to colocalize with 
clathrin in living cells (47), and treatment of cells with chlorpromazine, a clathrin-
specific chemical inhibitor (49), inhibits reovirus internalization and infection (49 and E. 
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Johnson, unpublished observations). However, there is mounting evidence that both 
clathrin- and caveolin-dependent mechanisms can be employed by some viruses to enter 
host cells (55, 56). Although there are no published reports of clathrin-independent 
uptake strategies for reovirus, a role for caveolae in reovirus cell entry has not been 
conclusively excluded (E. Johnson, unpublished observations and B. Mainou, 
unpublished observations). 
Vesicles containing internalized reovirus virions are transported via microtubules 
(57) and accumulate in late endosomes (21, 22, 46, 57, 58). In the endocytic 
compartment, reovirus virions undergo stepwise disassembly forming sequential 
disassembly intermediates, the first of which is the ISVP (Figures I-1 B and I-3). ISVPs 
are characterized by the loss of outer-capsid protein σ3, a conformational change in 
attachment protein σ1, and cleavage of outer-capsid protein μ1 to form particle-
associated fragments, δ and φ (25). Following further processing, ISVP-like particles 
(called ISVP*s) breach the endosomal membrane, leading to release of transcriptionally 
active core particles, which lack σ1 and μ1 (59, 60), into the cytoplasm. Thus, the 
disassembly process consists of a highly coordinated series of events that are dependent 
on host cell functions that act upon discrete components of the viral outer capsid. 
cCore
JAM-A
Carbohydrate
σ1
ISVP
δ/φ
Virion
σ3/μ1
λ2
β1 Integrin
ISVP*
δ
a
b d e
Figure I-3. Stepwise disassembly of reovirus.  (a) Following attachment to cell-surface carbohydrate (α-linked sialic acid for type 
3 reoviruses) and junctional adhesion molecule-A (JAM-A), reovirus virions enter cells by receptor-mediated endocytosis, a 
process requiring β1 integrin (b).  Within an endocytic compartment, the viral outer-capsid undergoes acid-dependent proteolysis.  
(c) The first disassembly intermediate is the ISVP, which is characterized by loss of σ3 and cleavage of μ1C into particle-
associated fragments δ and φ.  (d) The ISVP then undergoes further conformational changes to form the ISVP*.  The ISVP* is 
characterized by conformational rearrangements of the μ1 fragments to expose hydrophobic residues, release of μ1N and φ, and 
loss of attachment protein σ1.  (e) The μ1 cleavage fragments mediate penetration through the endosomal membrane releasing the 
transcriptionally active core into the cytoplasm.   
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Reovirus Disassembly Requires Acidic pH and Endocytic Proteases 
Treatment of murine L cells (21, 61, 62) or rat insulinoma cells (21, 61, 62) with 
the weak base ammonium chloride (AC), which raises the pH of endosomes and 
lysosomes (63, 64), blocks growth of reovirus when infection is initiated with virions. 
However, ISVPs can infect AC-treated cells (21). This finding indicates that the block to 
reovirus growth mediated by AC occurs following attachment but prior to disassembly. 
Concordantly, treatment of L cells with inhibitors of vacuolar proton ATPase activity, 
such as bafilomycin A1 and concanamycin A, blocks infection by virions but not by 
ISVPs (65). Thus, acidic pH is required for reovirus disassembly in some types of cells. 
Pharmacologic treatments also have been used to demonstrate an important 
function for endocytic proteases in reovirus disassembly. Treatment of L cells with E64, 
an inhibitor of cysteine proteases (66), blocks growth of reovirus virions. Similar to 
findings made in studies using acidification inhibitors, ISVPs generated in vitro can 
infect E64-treated cells (26, 67-69), suggesting that one or more endocytic cysteine 
proteases can catalyze reoviruses disassembly. However, pepstatin A, an inhibitor of 
aspartyl proteases (70), is incapable of blocking reovirus infection and uncoating in 
multiple cells types (71). Moreover, in vitro treatment of reovirus virions with cathepsin 
D, an aspartyl protease, does not lead to generation of ISVPs (71). Thus, aspartyl 
proteases appear to be incapable of mediating virion-to-ISVP conversion. 
 
Studies of Persistent Reovirus Infections  
Support for a critical role of cysteine proteases in reovirus disassembly comes 
from studies of persistent reovirus infections in cultured cells. Although usually cytolytic, 
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reoviruses are capable of establishing persistent infections in many types of cells in 
culture (72). These cultures are maintained by horizontal transmission of virus from cell 
to cell and can be cured of persistent infection by passage in the presence of anti-reovirus 
serum. Cured (LX) cells, and the viruses isolated from persistently infected L-cell 
cultures (PI viruses), harbor mutations that affect viral disassembly (72). 
Parental L cells support growth of reovirus after infection by virions or in vitro 
generated ISVPs. In contrast, LX cells do not support growth of reovirus after infection 
by virions of wildtype virus but do so after infection by PI virus virions or wildtype 
ISVPs (28, 73). Since LX cells allow growth of wildtype reovirus only when infection is 
initiated by ISVPs, these cells are altered in the capacity to support steps in viral 
replication leading to ISVP formation. L cells and LX cells do not differ in the capacity 
to bind or internalize virions or distribute them to a perinuclear compartment (73). 
Intravesicular pH is equivalent in both cell types, and virions colocalize with an acid-
sensitive fluorophore in both L cells and LX cells. However, LX cells do not support the 
proteolytic disassembly of the viral outer-capsid following internalization of virus into 
the endocytic pathway (73, 74), suggesting a defect in proteolytic activity in LX cells. 
The major cysteine proteases in the endocytic compartment of fibroblasts such as 
L cells are cathepsins B, H, and L, with cathepsin L being the most abundant in several 
cell types (66, 75-78). These enzymes are first produced as inactive proenzyme 
precursors that are processed to yield single-chain intermediates that are subsequently 
cleaved in lysosomes to form two-chain mature forms consisting of heavy and light 
chains (79-84). In LX cells, only the precursor form of cathepsin L is found (73). The 
mature, double-chain form of cathepsin B is found in these cells; however, the enzyme is 
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inactive (74). Neither cathepsin B nor cathepsin L is genetically altered in LX cells, 
indicating an extrinsic block to the function of these enzymes. Mixed lysates of L cells 
and LX cells lack activity of both cathepsin B and cathepsin L (74), suggesting the 
presence of an inhibitor of cathepsin function in LX cells. These findings indicate that a 
mutation in LX cells selected during persistent reovirus infection alters the activity of 
cathepsin B and cathepsin L, suggesting a critical function for these enzymes in reovirus 
disassembly in fibroblasts. Consistent with a role for cysteine proteases in reovirus 
uncoating, treatment of virions with either cathepsin B or cathepsin L in vitro results in 
the formation of particles that have similar biochemical and growth properties to ISVPs 
generated by treatment of virions with chymotrypsin or trypsin (4, 73). 
 
Proteases that Mediate Disassembly 
The involvement of cathepsin B and cathepsin L in the disassembly of reovirus 
virions in fibroblasts was confirmed in studies using pharmacologic inhibitors and 
genetically deficient cell lines (4). Infection of either L cells treated with the cathepsin L 
inhibitor A-Phe-Tyr(t-Bu)-diazomethyl ketone or cathepsin L-deficient mouse embryo 
fibroblasts results in inefficient proteolytic disassembly and decreased viral yields. In 
contrast, L cells treated with the cathepsin B inhibitor CA-074Me and cathepsin B-
deficient mouse embryo fibroblasts support reovirus disassembly and growth. However, 
removal of both cathepsin B and cathepsin L activity completely abrogates disassembly 
and growth of reovirus. Concordantly, cathepsin L mediates reovirus disassembly more 
efficiently than cathepsin B in vitro (4). These results demonstrate that either cathepsin B 
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or cathepsin L can promote reovirus entry into murine fibroblasts and indicate that 
cathepsin L is the primary mediator of reovirus disassembly in these cells. 
Cathepsins B and L are expressed in all major organs and mediate unique, tissue-
specific activities (85). Cathepsin B modulates pathological trypsinogen activation (86) 
and apoptosis induced by TNF-α (87). Cathepsin L is required for hair follicle cycling 
and epidermal homeostasis (88).  
The function of several cathepsin proteases intersects in their roles in adaptive 
immunity. Both cathepsins B (89, 90) and L (91) process endocytosed antigen for display 
by MHC II molecules. However, cathepsin B-deficient mice (Ctsb-/-) do not display overt 
immunodeficiency (85). Involvement of cathepsin L in MHC II presentation has been 
well characterized. This enzyme cleaves the invariant chain in cortical thymic epithelial 
cells (92) and is hypothesized to mediate efficient endosomal protein fragmentation to 
ensure diverse peptide generation in the thymus (93, 94). Through these functions, it 
serves to facilitate positive selection of CD4+ T cells (95, 96). Cathepsin L also 
participates in NK1.1+ T cell selection through proteolytic processing in thymocytes 
(97). As a result, cathepsin L-deficient (Ctsl-/-) mice have reduced numbers of both CD4+ 
and NK1.1+ T cells.  
Proteases other than cathepsin B and cathepsin L also are capable of ISVP 
formation. In P388D cells, a macrophage-like cell line, cathepsin S, also a cysteine 
protease, mediates uncoating of some strains of reovirus (98). Expression of cathepsin S 
is more limited to cells and tissues of the immune system. It is primarily expressed in 
bone-marrow-derived, professional antigen-presenting cells (APCs), namely dendritic 
cells, B cells (95), and macrophages (99). In addition, cathepsin S is active in intestinal 
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epithelial cells (100), which can act as non-professional APCs. The role of cathepsin S in 
reovirus disassembly is important because during enteric infection, primary replication is 
thought to occur in mononuclear cells of Peyer’s patches and intestinal epithelium (101-
104). Cathepsin S is known to be  expressed in mononuclear cells, including alveolar 
macrophages in the lung (105, 106) and microglial cells in the brain (107). 
Like cathepsins B and L, cathepsin S is required for processing internalized 
antigens by APCs (108). In addition, cathepsin S cleaves the invariant chain in these 
cells, leading to CD4+ T cell activation (109). Like cathepsin L, cathepsin S participates 
in NK1.1+ T cell selection in the thymus through proteolytic processing in APCs (110). 
Thus, cathepsin S-deficient (Ctss-/-) mice have impairments in both CD4+ and NK1.1+ T 
cell activities. Cathepsin S also processes antigen in endosomes for cross-presentation via 
the MHC I pathway (111).  
 
Outer-Capsid Protein σ3 Regulates Reovirus Disassembly 
The first step in the disassembly of reovirus virions is the cathepsin-mediated 
removal of outer-capsid protein σ3. The σ3 protein is a major outer-capsid component 
that protects the virion from degradation in the environment (112) and forms a protective 
cap for the μ1 protein (3). The latter function is especially important during entry as μ1 is 
responsible for penetration of ISVPs into the cytoplasm. By capping the μ1 protein, σ3 
controls the timing of penetration: if too early, the resulting particle may not be primed to 
initiate transcription; if too late, the particle may be proteolytically degraded in the 
lysosome before it gains access to the cytoplasm where transcription occurs. 
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The σ3 protein contains two large domains separated by a flexible hinge (3, 113) 
(Figure I-4 A). The N-terminus of σ3 is in the smaller, virion-proximal lobe, and the C-
terminus is in the larger, virion-distal lobe. These domains are not discrete in primary 
sequence as the peptide chain passes back and forth between the two lobes. A σ3-specific 
monoclonal antibody that sterically inhibits the σ1-mediated property of sialic acid 
binding engages the very tip of the virion-distal lobe (114). 
Studies of PI viruses have shed light on mechanisms of σ3 cleavage during 
reovirus disassembly. In contrast to wildtype reoviruses, PI viruses can infect cells treated 
with either AC (28, 73, 115) or E64 (26). In most cases, growth of PI viruses in the 
presence of AC or E64 segregates with the S4 gene segment (26, 115), which encodes σ3 
(116, 117). In addition, passage of wildtype reovirus in the presence of E64, resulting in 
selection of E64-resistant viruses (D-EA viruses) (68), or AC, resulting in selection of 
AC-resistant viruses (ACA-D viruses) (27), enriches populations of viruses that contain 
mutations in the σ3-encoding S4 gene. Therefore, mutations in σ3 protein confer the 
capacity of variant reoviruses to grow in the presence of pharmacologic inhibitors of 
reovirus disassembly. 
All PI viruses analyzed to date have a mutation of Tyr to His at residue 354 near 
the C-terminus of σ3 (26, 115) (Figure I-4 A). This mutation is also selected in D-EA 
viruses (68) and some ACA-D viruses (27). PI, D-EA, and ACA-D viruses exhibit altered 
kinetics of disassembly with degradation of σ3 and cleavage of μ1 occurring much more 
rapidly both in vitro and in cells (27, 68, 115). Image reconstructions of cryo-EM images 
of PI viruses indicate that the Tyr354 to His mutation leads to an alteration in σ3 structure 
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at the hinge region between the two lobes (118). These findings suggest that the C-
terminus of σ3 regulates susceptibility of the protein to cleavage. 
The σ3 C-terminus also dictates strain-specific differences in the susceptibility of 
σ3 to proteolytic attack (69, 119). The σ3 protein of strain T1L is cleaved more rapidly 
than that of T3D. Analysis of ISVPs recoated with chimeric σ3 proteins generated from 
T1L and T3D revealed that the C-terminus is primarily responsible for the rate of σ3 
proteolysis. Sequence polymorphisms at residues 344, 347, and 353 in σ3 contribute to 
this effect (119). 
Treatment of reovirus virions in vitro with either cathepsin B or cathepsin L leads 
to an initial cleavage of σ3 at a terminus (4). Given that sequence polymorphisms in the 
C-terminus determine susceptibility to proteolysis, the initial cleavage of σ3 probably 
occurs in this region. During proteolysis by cathepsin L, subsequent cleavages occur 
between residues 243-244 and 250-251 (4). These cleavage sites are physically located 
near the C-terminus in the σ3 crystal structure (113) (Figure I-4 A). Because of this 
proximity, the small end fragment released following initial cathepsin L cleavage likely 
exposes the other two sites, rendering them susceptible to subsequent cleavage events. 
The C-terminus therefore appears to act as a “safety latch” that controls access to 
internal, proteolytically sensitive sites in σ3. Because reovirus disassembly in some cell 
types is an acid-dependent process, the safety latch might be primed for movement at 
acidic pH. In viruses with mutations near the C-terminus, such as PI, D-EA, and ACA-D 
viruses, the safety latch may be altered by structural rearrangements. 
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Figure I-4. Crystal structure of outer-capsid proteins σ3 and μ1. (A) Crystal 
structure of a σ3 monomer as viewed from the side. The C-terminus is highlighted 
in red with the Tyr at position 354 shown as a space-filling model. Cathepsin L 
cleavage sites are shown in black with the primary amino acid positions noted. 
Image adapted from Ebert et al (4). (B) A σ33μ13 heterohexamer, viewed from the 
side. The bottom of the complex would contact σ2 proteins on the surface of the 
reovirus core. Three σ3 proteins (shown in gray) bind to the upper part of the 
underlying trimer of μ1 (with individual monomers shown in yellow, red, and 
blue). The three μ1 chains are wound tightly around each other. Each σ3 contacts 
two μ1 proteins. Image adapted from Liemann et al (13) (C) Regions of μ1 as 
determined by cleavage sites. μ1N is colored blue, δ is yellow, and φ is red. The 
N-terminal myristoylation site and cleavage sites at positions 42 and 580 are 
indicated. 
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Outer-Capsid Protein μ1 Mediates Membrane Penetration 
Insight into mechanisms employed by reovirus to penetrate into the cytoplasm 
first came from studies of ISVPs generated in vitro. ISVPs, but not intact virions, release 
51Cr from preloaded L cells (46), lyse red blood cells in the presence (67, 69, 120) and 
absence (121, 122) of cesium ions, and form ion-permeant channels in planar 
phospholipid bilayers (123). ISVPs also facilitate entry into cells of the toxin alpha-sarcin 
in the presence of inhibitors of reovirus uncoating (65, 122, 124, 125). These 
observations suggest that ISVPs are the immediate precursor to the disassembly 
intermediate that facilitates delivery of the core particle into the cytoplasm. 
Following formation of ISVPs in endosomes, transcriptionally active cores, which 
lack both μ1 and σ1, are released into the cytoplasm (Figure I-3). The mechanism of 
penetration and the shedding of these outer-capsid proteins has been the focus of recent 
work. This research has led to the identification of an additional intermediate particle 
formed subsequent to the ISVP, the ISVP* (124-126). 
Most of the μ1 protein on mature virions is autocatalytically cleaved near the N-
terminus to generate two fragments, μ1N and μ1C (60, 127) (Figure I-4 C). This cleavage 
is not required for virion assembly (125) and may occur physiologically during the 
transition from the ISVP to the ISVP* (128). In ISVPs, μ1C is further cleaved by either 
endocytic (4, 21) or intestinal (129) proteases to form fragments δ and φ, which remain 
particle-associated (25). However, the role of this cleavage in viral penetration is not 
understood, as core particles recoated with mutant forms of μ1 incapable of δ/φ cleavage 
can establish productive infection (120). In addition, μ1 is not cleaved at the δ/φ junction 
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in ISVPs generated in the presence of alkyl sulfate detergents (dpSVPs), yet dpSVPs are 
infectious (67). 
Transition from the ISVP to the ISVP* in vitro is triggered by differential cationic 
concentration or interactions with membranes (124, 126). In contrast to ISVPs, ISVP*s 
lack σ1 and have an altered conformer of μ1 in which internal hydrophobic residues are 
exposed. ISVP*s are capable of membrane penetration and transcription initiation (124, 
126). The conformational change in μ1 may be the driving force for both the loss of σ1 
and the initiation of transcription (13). Mechanisms underlying these events are 
unknown, but it is possible that μ1 rearrangement induces a conformational change in λ2, 
the pentameric turret that anchors σ1, causing σ1 release. A μ1-induced conformational 
change in λ2 also may activate the transcriptional machinery through interactions with 
either or both of the core proteins λ1 and σ2. 
Cleavage of intact μ1 to form μ1N and μ1C is required for generation of ISVP*s 
(125, 128). Particles recoated with mutant forms of μ1 incapable of μ1N/μ1C cleavage 
can facilitate each of the entry steps including μ1 conformational changes and 
transcription initiation but are deficient in membrane penetration (125). In addition to σ1, 
the N-terminal μ1 fragment, μ1N, is released from the ISVP* and interacts with 
membranes, most likely through the myristoyl group at the N-terminus (124). Association 
of μ1N with artificial membranes is sufficient to form small pores (130), although not 
large enough to facilitate virion translocation (131). The φ fragment of μ1 is also released 
during ISVP* production and appears to function as a chaperone for μ1N, facilitating 
membrane penetration (130). The precise mechanism of membrane breach is not known 
and may result from osmotic lysis as a consequence of multiple small pores in the 
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endosomal membrane. Alternatively, cellular factors may assist the viral components to 
build larger endosomal membrane pores. 
HSC70 is a cellular chaperone that contributes to removal of the δ fragment from 
the ISVP* (132). Following the transition from ISVP* to core and viral membrane 
translocation, δ is lost from the particle and localizes to the cytoplasm (124). The 
cytoplasmic distribution of δ is diffuse, which differs from the punctate distribution of the 
released cores. HSC70 is hypothesized to aid the movement of the particle into the 
cytoplasm concomitant with removal of δ in an ATP-dependent fashion (132). 
Amphipathic helices and other hydrophobic residues in μ1 thought to be involved 
in membrane penetration are located in the center of μ1, including the myristoylated Gly2 
at the N-terminus (13). Cleavage of μ1 to μ1N and μ1C does not appear to result in 
conformational rearrangements, but this cleavage, along with the loss of σ3, may render 
the μ1 trimer metastable. Since the μ1N/μ1C cleavage sites in the three monomers of the 
μ1 trimer are adjacent to each other, cleavage may open this area of the molecule by 
altering protein-protein contacts to allow influx of solvent into an area at the center of the 
trimer structure. When the steric hindrance imposed by σ3 is released, μ1 may then 
undergo the conformational alterations necessary to allow membrane penetration. 
 
Pathogenesis of Reovirus Infection in Mice 
Newborn mice are exquisitely sensitive to reovirus infection and have been used 
as the preferred experimental system for studies of reovirus pathogenesis (18). While less 
is known about the respiratory route of inoculation, infection following peroral 
inoculation has been well characterized, and basic principles are understood. Proteolytic 
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enzymes are required for reovirus infection when mice are infected by the peroral route 
(129, 133). Virions are converted to ISVPs in the intestinal lumen by the resident 
proteases chymotrypsin and trypsin. ISVPs generated by chymotrypsin or trypsin in vitro 
or in the gut lumen (129, 133) are similar to ISVPs generated in the endocytic 
compartment of cells (73, 74). ISVPs produced in this fashion transcytose through 
intestinal M cells and are released basolaterally (134-137). Underlying dendritic and 
mononuclear cells of the Peyer’s patch stain positive for reovirus antigen (101, 103, 137, 
138). These cells may support viral replication or transport virus to other sites such as the 
mesenteric lymph node. 
Subsequent to infection of Peyer’s patches, reovirus infects the adjacent epithelial 
cells of the ileum (104), most likely initiating at the crypts of Lieberkuhn and spreading 
progressively to the villus tips. Spread of virus to the epithelia may occur via lymphatic 
or cell-to-cell spread. Epithelial cells are infected from the basolateral surface (104, 139-
141), and progeny virions are released apically (104, 139). This mechanism accounts for 
the efficient spread of virus both within and between hosts. Transport of virus to the 
basolateral surface of M cells and infection of Peyer’s patches also allows virus to spread 
via hematogenous and lymphatic routes to sites of secondary infection. The release of 
virus back into the lumen of the gut facilitates viral excretion. 
Following infection of the intestine, reovirus spreads to other organs throughout 
the animal. However, the route of spread varies with serotype and is dependent on σ1 
(142-144). T1L spreads from the intestine to the mesenteric lymph nodes and spleen, 
presumably via hematogenous routes (143). However, T3C9 spreads to the myenteric 
plexus and vagus nerve and infects the brain via the dorsal motor nucleus of the vagus 
 21
within the brain stem (101). Once in the brain, T1 and T3 strains infect different 
populations of cells. T1L infects primarily ependymal cells (144, 145), causing 
hydrocephalus (146), whereas T3D infects neurons (101, 144, 145, 147), leading to 
encephalitis (146, 148). 
 
Reovirus Immunity and Clearance 
The immune response to reovirus infection has been studied primarily using adult 
animals. Various infection models have been explored including different routes of 
inoculation and virus strains. Studies using peroral inoculation infection models have 
enhanced our knowledge of the mucosal immune response to viral infection and immune 
factors that regulate spread and disease within the infected host. Following peroral 
inoculation with reovirus strains T1L or Type 3 clone 9 (T3C9), there is a strong local T 
helper cell type 1 (TH1) response (149-151). Cytotoxic T lymphocytes (CTL), natural 
killer cells, TH1 cells, and IgA-producing plasma cells are present in the Peyer’s patches 
and intestinal epithelium (150, 152-156). Viral replication and immune cells also can be 
found in peripheral lymph nodes and lamina propria (149, 150). IgG2a and IgG2b, 
antibody isotypes elicited during a TH1 response, are also prevalent in infected mice (151, 
155, 157). The CTL response to reovirus can provide cross-protection against type 1 and 
type 3 strains of reovirus (154). 
To understand the relative importance of the various components of the immune 
response in clearing viral infection, mice deficient in various components of the immune 
system have been used. Adult SCID mice infected perorally with reovirus strain T3C9 die 
within 6 weeks primarily due to liver disease, although there is prolonged replication in 
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many organs (158-161). However, SCID mice infected intraperitoneally with strain T3D 
develop chronic infection and survive for approximately 100 days (160). Transfer of pre-
immune or non-immune Peyer’s patch cells results in decreased virulence following 
peroral inoculation of SCID mice (158, 159), suggesting that the immune response in the 
gut is of particular importance in controlling reovirus infection.  
To elucidate the role of CD8+ T cells in reovirus infection, β2 microglobulin 
deficient (β2-/-) mice have been used. Infection of adult mice results in normal viral 
clearance from the intestine and limited spread of the virus to sites of secondary 
replication (155, 158), indicating that a CTL response is not necessary for control of virus 
replication and spread following peroral inoculation. However, β2-/- mice exhibit 
enhanced IgG2a and IgG2b production and increased numbers of CD4+ T cells with 
respect to wt controls (155), suggesting that these mice compensate for the lack of CTL 
responses with alternate immune effector mechanisms. 
Mice deficient in the production of IgM (MuMT mice), and therefore functional B 
cells, have been used to determine the importance of B cells in reovirus immunity. These 
adult mice exhibit delayed clearance of reovirus T3C9 from the intestine (158). This 
result suggests that a humoral response is necessary for early control of infection, 
whereas the CTL response is responsible for later clearance.  
Depletion of CD4+ and/or CD8+ T cells from neonatal animals using cell-type-
specific antibodies has varying effects depending on the strain of mouse used (162). 
Depletion of both CD4+ and CD8+ T cells from BALB/c pups had no effect on viral 
infection or clearance following infection with strains T1L, T3C9, or T3D. However, 
depletion of one or both cell types had more profound effects on NIH Swiss mice and 
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CAF1 mice (BALB/c AnNCR x A/JCr F1 progeny). Following peroral infection with 
T3C9, depletion of either CD4+ T cells, CD8+ T cells, or both resulted in increased liver 
disease. Depletion of CD8+ T cells had a more pronounced effect than depletion of CD4+ 
T cells on viral titer in the heart and liver. Therefore, both the CTL and humoral 
responses are of critical importance to reovirus immunity in neonatal animals. Whether 
an IgA or IgG response more effectively mediates timely clearance, however, is debated 
(149, 150, 158, 162-165). 
Most studies of reovirus pathogenesis use neonatal animals. Pre-immune dams are 
capable of transferring immunity through transplacental transfer and via milk (166). This 
passive immunity lessens IgA production in the gut of perorally infected pups. However, 
if the dam is not pre-immune to reovirus, there is no effect on IgA production by her pups 
despite inevitable infection of the dam from exposure to infected pups. IgA production by 
pups is equivalent whether nursed by a naive immuno-competent or immuno-deficient 
dam. Therefore, the primary immune response elicited in the dam does not affect the 
concurrent primary immune response of her pups. This point is necessary for the 
interpretation of studies in neonatal animals since pathogenesis studies are conducted in 
mice with varying levels of immune function. 
 
Significance of the Research 
With the knowledge that cathepsin proteases cleave outer-capsid components σ3 
and μ1, I sought to determine the role of these proteases in vivo. In addition to reovirus, 
cathepsins catalyze proteolytic events required for membrane fusion of several important 
pathogens. Ebola virus requires both cathepsins B and L for efficient cell entry (167), 
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while SARS coronavirus requires cathepsin L but also can utilize cathepsins B and S 
(168, 169). Hendra (170) and Nipah (171) viruses use cathepsin L for fusion protein 
processing, most likely at the stage of virion assembly (172). Despite the importance of 
cathepsins in viral growth, nothing is known about the function of these proteases in the 
pathogenesis of viral disease. 
Although basic principles of reovirus pathogenesis in mice are known, the role of 
cellular and viral factors that promote viral cell entry during infection in vivo are largely 
unexplored. Furthermore, the results of in vivo experiments conducted thus far have not 
been predictable based upon in vitro results. For example, although JAM-A is required 
for infection of cells in culture, JAM-A-/- mice support reovirus infection in the intestine 
and brain (147). JAM-A-/- mice display a defect in hematogenous dissemination, most 
likely due to inefficient infection of endothelial cells.  
As a means of testing the role of viral factors related to cell entry in vivo, mice 
were infected intracranially with PI viruses (173). Interestingly, although PI viruses 
establish persistent infection in culture and display resistance to inhibitors of viral entry, 
these viruses do not establish persistence in vivo and are eventually cleared. Prolonged 
replication is not associated with increased virulence or altered tropism within the brain. 
Interestingly, the virus is not found in organs other than the brain, suggesting that 
mutations in PI viruses prevent either spread out of the CNS or growth in other organs.  
The role of cathepsin proteases B and L in reovirus uncoating in mouse 
fibroblasts is well established (4, 21, 26, 67-69, 73, 74, 119). The utilization of cathepsin 
S, however, is limited to specific cell types and virus strains (98). Furthermore, though 
cathepsin S activity appears to be required for reovirus uncoating in P388D cells, the 
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process is not optimally efficient as infection by ISVPs is greater than infection by 
virions (98). Because cellular and viral factors that modulate growth of reovirus in vitro 
do not exert the same growth phenotype in vivo, it is essential to test hypotheses about 
their activity as virulence factors using intact animal hosts. 
To determine the function of cathepsin proteases in viral virulence, I used 
mammalian reovirus as a model system. I studied reovirus disease following infection of 
mice lacking cathepsins B, L, or S. To further investigate whether cathepsin utilization is 
affected by viral tropism, I used two different strains of virus, T1L and T3SA+. I found 
that following peroral inoculation, serotype specificity influences the requirement for 
cathepsin proteases in reovirus disease. Reovirus strain T1L was largely unaffected by 
cathepsin-deficiency, whereas yields of strain T3SA+ were diminished at sites of 
secondary replication. Furthermore, treatment of wt mice with an inhibitor of cathepsin L 
reduces T3SA+ disease severity. These studies demonstrate that cathepsin activity plays a 
key role in the pathogenesis of some reovirus strains and identify a new target for 
antiviral drug development.  
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CHAPTER II 
 
CATHEPSIN PROTEASES ARE REQUIRED FOR EFFICIENT 
GROWTH OF T3SA+ AT SITES OF SECONDARY REPLICATION 
 
 
Introduction 
 Cathepsins B, L, and S catalyze removal of the reovirus outer-capsid and prime 
the membrane-penetration machinery in the endocytic compartment of host cells (4, 98). 
However, the role of these enzymes in reovirus pathogenesis is unknown. In this study, I 
used wildtype (wt) and cathepsin-deficient mice to determine whether cathepsin proteases 
are individually required for reovirus infection in vivo. I chose reovirus strain T3SA+ for 
these studies because it is highly pathogenic and, unlike the prototype virus T3D, is 
capable of spread to all organs following peroral inoculation. It is also capable of binding 
sialic acid, which correlates with increased virulence in the liver and may contribute to 
virulence in the brain (174). Results of these experiments demonstrate that cathepsin 
proteases are required for maximal viral yields at sites of secondary replication and 
highlight a role for adaptive immunity in reovirus clearance and disease. 
 
Results 
Processing of reovirus virions by purified cathepsin proteases. Cathepsins B (4), 
L (4), and S (98) can catalyze reovirus disassembly in vitro and in certain types of cells. 
Reovirus strain T3SA+ is a reassortant virus that contains a genome consisting of nine 
gene segments from strain T1L and the S1 gene segment from strain T3C44-MA (175). 
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Following peroral inoculation of newborn mice, T3SA+ replicates in the intestine and 
disseminates systemically from that site to the brain, heart, and liver (174). To determine 
whether T3SA+ is susceptible to cathepsins B, L, and S, I incubated purified virions with 
each enzyme over a time course and resolved the resultant digestion mixtures by SDS-
PAGE. Following incubation for 24 hours with each protease, complete degradation of 
σ3 and cleavage of μ1 to δ was observed (Figure II-1). Therefore, treatment of T3SA+ 
virions with cathepsins B, L, or S results in formation of ISVPs. 
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Figure II-1. Treatment of reovirus virions with cathepsins B, L, and S. 
Purified virions of T3SA+ were treated with 400 μg/ml cathepsin B (A), 100 μg/ml 
cathepsin L (B), or 300 μg/ml cathespin S (C) at 37°C for the times shown. Equal 
numbers of viral particles were loaded into wells of 10% polyacrylamide gels and 
electrophoresed. Viral proteins are labeled on the right. 
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Cathepsin deficiency differentially affects survival following reovirus infection. To 
determine the function of cathepsin proteases in reovirus disease, I inoculated wt, Ctsb-/-, 
Ctsl-/-, and Ctss-/- mice perorally with 107 plaque-forming units (PFU) of reovirus T3SA+. 
Mice were monitored for 21 days post-infection for morbidity and mortality. The 
cathepsin-null mice displayed differential survival patterns in comparison to wt animals. 
Following a 21-day observation interval, 82% of Ctsb-/- mice survived in comparison to 
61% for wt mice (Figure II-2 A). In contrast, only 7% and 39% of Ctsl-/- and Ctss-/- mice, 
respectively, survived T3SA+ infection. However, the mean survival time for each strain 
of cathepsin-deficient mice was increased in comparison to wt animals (Table 1). The 
disease phenotype in all strains did not notably differ, with all strains of mice displaying 
weakness and lethargy during the period of illness. All pups of wt and cathepsin-deficient 
strains inoculated with PBS and observed under identical conditions survived and did not 
display symptoms (data not shown). As a surrogate marker for disease severity, Ctsb-/- 
mice displayed less weight loss in comparison to wt animals (Figure II-2 B). However, 
Ctsl-/- and Ctss-/- mice had more weight loss in comparison to wt mice, and subsequent 
weight gain, indicative of recovery of these juvenile animals, was delayed. The increased 
weight loss in Ctsl-/- and Ctss-/- mice is particularly evident in comparison to the weight 
of mock-infected animals (Figure II-2 C). These findings suggest that despite the 
increased mortality of Ctsl-/- and Ctss-/- mice, these animals display slower kinetics of 
disease development. Thus, expression of cathepsins B, L, and S influences reovirus 
pathogenesis.  
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Figure II-2. Survival of wt and cathepsin-deficient mice following peroral 
inoculation. C57/Bl6 wt and cathepsin-deficient mice, 2-4 d old, were 
inoculated perorally with 107 PFU T3SA+ (A,B) or PBS alone (C). Mice (n = 
14 to 21) were monitored for (A) survival and (B,C) weight gain. (A) *, P < 
0.01 as determined by log rank test in comparison to wt. (B,C) Results are 
expressed as mean weight of all living, infected animals. (B) Statistical 
significance (P < 0.05 as determined by student’s t test) was achieved in 
comparison to wt mice for Ctsb-/- mice between days 2 and 8; for Ctsl-/- mice at 
days 1, 13, and 14; and for Ctss-/- mice at days 4-8, 11, and 14. 
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Table II-1. Mean survival time following reovirus infection.a  
wt 21 38.1 9.0 ± 1.2
Ctsb -/- 17 17.6 18.3 ± 0.9 0.0017
Ctsl -/- 15 93.3 12.6 ± 0.5 0.0041
Ctss -/- 13 61.5 13.3 ± 0.7 0.0098
Mean survival 
time (d)c P  Valued
Mouse 
strain
No. of 
mice
Mortality 
(%)b
 
 
aC57/Bl6 wt and cathepsin-deficient mice, 2-4 d old, were inoculated perorally with 107 
PFU T3SA+. Mice were monitored for survival for 21 d.  
bMortality, percent animals dead after 21 d.  
cMean survival time, as defined by the average day of death for animals that succumbed 
to infection, in d ± SEM.  
dP value as determined by student’s t test in comparison to wt. 
 
 
Peak reovirus titers are diminished in cathepsin-deficient mice. To understand 
differences in susceptibility to reovirus infection among the cathepsin-deficient mice, I 
inoculated three-day-old mice perorally with a lower dose of T3SA+, 102 PFU, and 
quantified viral growth in selected organs. In comparison to wt mice, Ctsb-/- mice 
demonstrated equivalent growth of reovirus in the intestine, the site of primary 
replication, at all time points tested (Figures II-3 A, II-5, and II-6). Although titers were 
lower at day 4 in the liver of Ctsb-/- mice, peak titers at day 8 were equivalent to those in 
wt mice. In contrast, peak titers in the heart and brain of Ctsb-/- mice were lower than 
those in wt mice, reaching statistical significance at day 12 in the brain. In concordance 
with these results, Ctsb-/- mice exhibited greater weight gain than wt mice at day 12 
(Figure II-5), suggesting that lower titers in the heart and brain are associated with 
diminished disease and lead to enhanced survival. In these experiments, neither wt nor 
Ctsb-/- mice displayed signs of illness or succumbed to infection.  
 32
In contrast to Ctsb-/- mice, peak titers in all organs of Ctsl-/- mice were decreased 
in comparison to wt mice, reaching statistical significance in the heart at day 8 (Figures 
II-3 B, II-5, and II-7). However, viral titers in Ctsl-/- mice were greater than those in wt 
mice at days 12, 16, and 20 post-inoculation, reaching statistical significance in the 
intestine and liver at day 12. As expected from these results, the average weight of Ctsl-/- 
mice was significantly less than that of wt mice at day 20 (Figure II-4). Despite the lower 
dose of T3SA+ used in these experiments, several Ctsl-/- animals displayed overt signs of 
illness, including weakness and lethargy, and some died. 
The kinetics of viral growth in Ctss-/- mice were similar to those in Ctsl-/- mice. 
Peak titers in all organs of Ctss-/- animals were lower than those in wt mice, reaching 
statistical significance in the liver at day 4, in the heart at days 4 and 8, and in the brain at 
day 8 (Figures II-3 C, II-5, and II-8). As in Ctsl-/- mice, viral titers did not decrease in 
Ctss-/- mice between days 8 and 12, and titers in the intestine of Ctss-/- mice were actually 
greater than those in wt mice at days 12 and 16. Also, like Ctsl-/- mice, Ctss-/- mice 
infected with T3SA+ displayed signs of illness including weakness and lethargy, 
diminished weight gain (Figure II-4), and mortality. Thus, peak reovirus titers were 
decreased in all strains of cathepsin-deficient mice, but mice deficient in cathepsin L or 
cathepsin S had higher viral titers at late times after inoculation. 
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Figure II-3. Reovirus 
titers in organs of wt and 
cathepsin-deficient mice 
following peroral 
inoculation. C57/Bl6 wt 
and cathepsin-deficient 
mice, 2-4 d old, were 
inoculated perorally with 
102 PFU T3SA+. Organs 
were resected at the times 
shown and homogenized 
by freeze-thawing and 
sonication. Viral titers in 
organ homogenates were 
determined by plaque 
assay. Results are 
presented as mean viral 
titer in whole organs of 6 
to 20 mice. Error bars 
represent SEM. *, P < 
0.05 as determined by 
Mann-Whitney test in 
comparison to wt at the 
same time after 
inoculation. The limit of 
detection was 102 
PFU/organ. 
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Figure II-4.  Weight of mice following peroral inoculation with T3SA+. 
C57/Bl6 wt and cathepsin-deficient mice, 2-4 d old, were inoculated perorally with 
102 PFU T3SA+. Mice were weighed only on the d of harvest as indicated. Results 
are displayed as the mean weight of 6-20 animals. *, P < 0.05 as determined by 
student’s t test in comparison to wt at the same time after inoculation. 
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Figure II-5. Reovirus titers in organs of wt mice following peroral 
inoculation. C57/Bl6 wt mice, 2-4 days old were inoculated perorally with 102 
PFU T3SA+. Organs were resected at the times shown and homogenized by 
freeze-thawing and sonication. Viral titers in organ homogenates were 
determined by plaque assay. Each data point represents one animal. Horizontal 
bars indicate the arithmetic mean of log-transformed data. The limit of 
detection was 100 PFU/ml. 
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Figure II-6. Reovirus titers in organs of Ctsb-/- mice following peroral 
inoculation. Ctsb-/- mice, 2-4 days old were inoculated perorally with 102 
PFU T3SA+. Organs were resected at the times shown and homogenized by 
freeze-thawing and sonication. Viral titers in organ homogenates were 
determined by plaque assay. Each data point represents one animal. 
Horizontal bars indicate the arithmetic mean of log-transformed data. The 
limit of detection was 100 PFU/ml. 
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Figure II-7. Reovirus titers in organs of Ctsl-/- mice following peroral 
inoculation. Ctsl-/- mice, 2-4 days old were inoculated perorally with 102 PFU 
T3SA+. Organs were resected at the times shown and homogenized by freeze-
thawing and sonication. Viral titers in organ homogenates were determined by 
plaque assay. Each data point represents one animal. Horizontal bars indicate 
the arithmetic mean of log-transformed data. The limit of detection was 100 
PFU/ml. 
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Figure II-8. Reovirus titers in organs of Ctss-/- mice following peroral 
inoculation. Ctss-/- mice, 2-4 days old were inoculated perorally with 102 
PFU T3SA+. Organs were resected at the times shown and homogenized by 
freeze-thawing and sonication. Viral titers in organ homogenates were 
determined by plaque assay. Each data point represents one animal. 
Horizontal bars indicate the arithmetic mean of log-transformed data. The 
limit of detection was 100 PFU/ml. 
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Inflammation in the liver is more severe in cathepsin L- and cathepsin S-deficient mice. 
To better understand why Ctsl-/- and Ctss-/- mice had increased susceptibility to reovirus 
infection in comparison to wt or Ctsb-/- mice, we examined histologic sections of heart 
and liver from mice inoculated perorally with 106 PFU T3SA+. Animals chosen for 
histologic analysis were matched for viral titer in the liver. Viral antigen staining in the 
hearts of all genotypes of mice localized primarily to the subepicardial myocardium with 
little to moderate involvement of the deeper myocardium (Figure II-9). The extent of 
inflammatory cell infiltrates associated with infectious foci was consistent across all 
strains of mice.  
In all mouse strains, infection in the liver centered on the bile duct epithelium 
(Figure II-10), as has been previously reported (174). Viral antigen and inflammation was 
more pronounced along large portal tracts; however, smaller portal tracts also were 
involved. Hepatic lobular involvement was present in all strains of mice in regions of 
increased reovirus antigen staining and inflammation. Although there was variability 
within each genotype of mice and some overlap between them, inflammation centered at 
the portal triads was more severe in Ctsl-/- and Ctss-/- mice in comparison to wt and Ctsb-/- 
mice (see Figure II-10 low magnification insets showing increased numbers of leukocytes 
in panels C and D versus A and B).  
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A B
C D
Figure II-9. Histological analysis of reovirus growth in the heart. C57/Bl6 wt 
and cathepsin-deficient mice, 2-4 days old, were inoculated perorally with 106 PFU 
T3SA+. Hearts were resected at day 8 post-infection and processed for 
histopathology. Consecutive sections were stained with hematoxylin and eosin or 
polyclonal reovirus antiserum. Boxes indicate areas of enlargement shown in the 
panels on the right. Original magnifications 10x and 40x. (A) wt; (B) Ctsb-/-; (C) 
Ctsl-/-; (D) Ctss-/-. 
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Figure II-10. Histological analysis of reovirus growth in the liver. C57/Bl6 wt and 
cathepsin-deficient mice, 2-4 d old, were inoculated perorally with 106 PFU T3SA+. 
Livers were resected at d 8 post-infection, and a small wedge of liver was removed for 
titer determination by plaque assay. The remaining liver was processed for 
histopathology, and consecutive sections were stained with hematoxylin and eosin or 
polyclonal reovirus antiserum. Representative samples from titer-matched livers are 
shown. Boxes indicate areas of enlargement shown in the panels on the right. Arrows 
indicate areas of inflammation. Original magnifications 10x and 40x.  
(A) wt; (B) Ctsb-/-; (C) Ctsl-/-; (D) Ctss-/-. 
 
Table II-2. Bilirubin and liver enzyme levels in serum following reovirus infection.a 
Mouse Strain TBIL ALK ALT AST TBIL ALK ALT AST
wt 1.5 634 127 461 0.9 (0.3) 768 (140.8) 295 (224.8) 495 (231.2)
Ctsb -/- 2.0 475 73 417 1.9 (0.2) 783 (109.0) 97.5 (31.1) 460.5 (105.1)
Ctsl -/- 1.5 567 57 409 9.2* (1.1) 1282.4 (300.3) 60 (20.8) 439 (43.8)
Ctss -/- 0.9 574 99 330 6.9* (2.0) 1709* (258.9) 858 (665.5) 2083.75 (856.8)
Mock-Infected Reovirus-Infected
 
 
a C57/Bl6 wt and cathepsin-deficient mice, 2-4 d old, were inoculated perorally with PBS 
alone or 106 PFU T3SA+. At d 12 post-inoculation, the liver was resected and blood was 
collected. A small wedge of liver was removed for titer determination by plaque assay. 
Mean values from 2 mock-infected mice or 3-5 reovirus-infected mice with 
approximately equivalent viral titer in the liver are shown. TBIL, total bilirubin (mg/dl); 
ALK, alkaline phosphatase (u/l); ALT, alanine aminotransferase (u/l); AST, aspartate 
aminotransferase (u/l). *, P < 0.05 as determined by student's t test in comparison to wt. 
SEM is shown in parentheses. 
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Liver enzyme levels are increased in Ctsl-/- and Ctss-/- mice. To obtain 
biochemical evidence of biliary or hepatic injury in reovirus-infected mice, we assessed 
levels of total bilirubin (TBIL), alkaline phosphatase (ALK), alanine aminotransferase 
(ALT), and aspartate aminotransferase (AST) in mice that were either mock-infected or 
infected with 106 PFU T3SA+. No biomarker of liver injury was elevated in mock-
infected mice at any time point or in any strain of reovirus-infected mice at day 8 post-
infection. In contrast, levels of TBIL and ALK were increased in Ctsl-/- mice and levels of 
all four markers were increased in Ctss-/- mice at day 12 post-infection (Table 2). These 
results indicate more severe hepatobiliary damage in reovirus-infected Ctsl-/- and Ctss-/- 
mice in comparison to wt and Ctsb-/- animals. 
 
Hematogenous dissemination of reovirus is unaffected by absence of a single 
cathepsin protease following peroral inoculation. I thought it possible that the capacity of 
reovirus to either disseminate to sites of secondary infection in cathepsin-deficient mice 
or establish infection once reaching those sites might be reduced. To distinguish between 
these possibilities, I quantified viral titers in the blood following peroral inoculation. 
Newborn mice were inoculated perorally with 106 PFU of T3SA+, and blood was 
collected at various times after inoculation. Reovirus established viremia in all strains of 
mice (Figure II-11 A and B), reaching titers that were approximately equivalent in all 
strains tested (Figure II-11 B). Furthermore, the percentage of mice with detectable 
viremia correlated with the percentage of mice with detectable titer in the intestine 
(Figures II-5 - II-8, and II-11 A). Therefore, lack of a single cathepsin protease does not 
appear to alter the efficiency of reovirus hematogenous dissemination in mice. 
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Figure II-11. Viremia in wt and cathepsin-deficient mice following peroral 
inoculation. C57/Bl6 wt and cathepsin-deficient mice, 2-4 d old, were 
inoculated perorally with 106 PFU T3SA+. Blood was collected at the times 
shown and homogenized by freeze-thawing and sonication. Viral titers in blood 
were determined by plaque assay. The limit of detection was 50 PFU/ml. N =  9 
to 14 mice. (A) Results are presented as percent animals with detectable titer in 
the blood. (B) Each data point represents one animal. Horizontal bars indicate 
the arithmetic mean of log-transformed data.  
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Figure II-12. Viral growth in the brain of wt and cathepsin-deficient mice 
following intracranial inoculation. C57/Bl6 wt and cathepsin-deficient mice, 2-4 d 
old, were inoculated intracranially with 102 PFU T3SA+. Brains were resected at the 
times shown and homogenized by freeze-thawing and sonication. Viral titers in brain 
homogenates were determined by plaque assay. Results are expressed as mean viral 
titer in the brains of 9 to 13 mice. Error bars represent SEM. *, P < 0.05 as 
determined by Mann-Whitney test in comparison to wt at the same time after 
inoculation. The limit of detection was 102 PFU/brain. 
Growth of reovirus in the brain is diminished in cathepsin L-deficient mice 
following intracranial inoculation. To determine the effect of cathepsin deficiency on the 
capacity of reovirus to grow at a site of secondary replication, I quantified viral titers in 
the brain following intracranial inoculation of wt and cathepsin-deficient mice. This site 
was chosen for ease of direct inoculation. Titers of T3SA+ in the brains of wt, Ctsb-/-, and 
Ctss-/- mice did not differ statistically (Figure II-12), suggesting that cathepsins B and S 
are not required for reovirus growth in the brain following direct inoculation into that 
site. However, titers of T3SA+ in the brains of Ctsl-/- mice were significantly lower on 
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day 9 post-inoculation, suggesting that cathepsin L is required for efficient growth of 
reovirus in the brain. Thus, cathepsin L contributes to reovirus tropism for the CNS. 
 
Discussion 
Reovirus virions are uncoated in late endosomes or lysosomes by cathepsins B 
(4), L (4), or S (98). I reasoned that deficiency in the proteases that catalyze uncoating 
might lead to decreased viral growth and diminished disease severity. Only mice 
deficient in expression of cathepsin B fit this profile. Ctsb-/- mice had increased survival 
in comparison to wt mice when infected with a high dose of reovirus, whereas Ctsl-/- and 
Ctss-/- mice displayed decreased survival. In concordance with this observation, reovirus 
produced lower titers at sites of secondary replication in Ctsb-/- mice than in wt mice, and 
Ctsb-/- mice displayed greater weight gain. These results suggest that cathepsin B is 
required for reovirus to establish high-titer infection and exert pathological effects.  
The decreased survival of Ctsl-/- and Ctss-/- mice in comparison to wt mice raised 
the possibility that viral loads might be higher in these animals. However, reovirus 
produced lower peak titers at sites of secondary replication in both genotypes of mice in 
comparison to both wt and Ctsb-/- mice. Diminished survival in Ctsl-/- and Ctss-/- mice is 
likely attributable to defects in immune function in these animals (96) with resultant 
failure to resolve viral infection. Indeed, viral titers in the intestine at day twelve were 
significantly higher in both Ctsl-/- and Ctss-/- mice than those in wt animals. As viral titers 
in wt mice decreased from day 8 to 12, viral titers in Ctsl-/- and Ctss-/- mice did not. I 
think it most likely that the absence of functional CD4+ T cells leads to inefficient viral 
clearance. Consequently, tissue injury is sustained for a longer period of time. This 
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conclusion is supported by the kinetics of survival following infection. Although Ctsl-/- 
and Ctss-/- mice die at higher frequency than wt mice, survival times of the cathepsin-
deficient mice are prolonged. Thus, the immune deficiency displayed by mice lacking 
cathepsin L or cathepsin S is associated with enhanced reovirus virulence. 
It is noteworthy that reovirus titers at sites of secondary replication in the 
population of Ctsl-/- and Ctss-/- mice examined have a nearly bimodal distribution 
(Figures II-7 and II-8). This finding is particularly evident in the heart and liver at days 8 
and 12 and in the brain at days 8, 12, and 16. There is a population of animals with titers 
equivalent to wt and a population of almost equivalent size with titers at or below the 
limit of detection. The distribution of data points is wider in these genotypes than in wt or 
Ctsb-/- mice (Figures II-5 and II-6). However, titers in the intestine of Ctsl-/- and Ctss-/- 
mice are only slightly bimodal, with a lower percentage of mice harboring undetectable 
levels of virus at that site. These findings suggest that despite reaching a critical threshold 
of virus in the intestine of Ctsl-/- and Ctss-/- mice, either spread to or growth at sites of 
secondary replication is dependent on individual cathepsins. These data also suggest that 
at least in some animals, redundancy in cathepsin function allows nearly wt levels of viral 
growth. Furthermore, cathepsins B and L are not required for optimal growth in the 
intestine, most likely due to the presence of chymotrypsin in the lumen of the intestine. 
The paradox that Ctsl-/- and Ctss-/- mice display increased disease severity and 
mortality despite lower peak titers suggests that Ctsl-/- and Ctss-/- mice are more 
susceptible to the pathologic effects of reovirus infection than are wt mice. The disease 
phenotype of these mice included lethargy and oily hair effect (174, 176, 177), a 
syndrome associated with viral replication in intrahepatic bile duct epithelium, biliary 
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obstruction, and fat malabsorption (174, 176, 178-180). However, the disease symptoms 
did not include spastic movements of the extremities, overt seizures, or paralysis, 
indicative of encephalitis. I think that death of reovirus-infected animals lacking 
cathepsin L or cathepsin S resulted from damage to the liver and heart. Histological 
analysis of the heart did not reveal striking differences in pathological injury in the 
different strains of mice, perhaps due to the high viral loads in the hearts of all mice. 
However, the increase in inflammatory infiltrate surrounding portal triads coupled with 
the results of liver enzyme profiling support the conclusion that damage to the liver 
contributed to the poor outcome of reovirus-infected Ctsl-/- and Ctss-/- mice. 
The observation that cathepsin-deficient mice inoculated with reovirus had lower 
titers at sites of secondary replication prompted us to investigate how individual 
cathepsins promote viral pathogenesis. I envision two possibilities. First, cathepsin 
expression might allow the virus to disseminate systemically in the host. Second, 
cathepsin expression might be required for growth at sites of secondary replication once 
those sites are reached. All strains of mice had detectable virus in the blood, suggesting 
that cathepsin deficiency does not block reovirus spread from the intestine into the 
bloodstream. However, these proteases could be required for reovirus exit from the 
bloodstream into the surrounding tissues, for example by promoting viral growth in 
endothelium or extravasation of infected lymphocytes from blood vessels into host 
tissues. 
While cathepsins B and S are dispensable for reovirus growth in the brain, 
cathepsin L is not. Following intracranial inoculation, titers in Ctsl-/- mice were decreased 
in comparison to all other strains. Cathepsin S is required for maximal growth of reovirus 
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in the intestine as titers of reovirus in the intestine of Ctss-/- mice are less than those in all 
other strains. It is possible that decreased titer in the intestine of Ctss-/- mice is 
insufficient to allow efficient viral dissemination to sites of secondary replication. 
However, peak reovirus titers in the brain of Ctss-/- mice following peroral inoculation are 
greater than those of Ctsb-/- mice, suggesting that viral spread is independent of titer in 
the intestine. The site in the intestine from which the majority of viral titer originates is 
not known, nor is it apparent whether this virus population is responsible for spread to 
other organs. The virus that spreads within the host most likely arises from infected 
Peyer’s patches. However, if infection of intestinal epithelium produces a majority of 
detectable virus titer, this occurrence would separate the populations of virus contributing 
to spread and titer. Therefore, it is possible that lymphatic or hematogenous spread can 
occur despite low viral loads in the intestine. There is precedence for this concept. Virus 
that spreads within mice infected with murine cytomegalovirus does not originate from 
the liver, the organ with the highest viral titer (181). Cathepsin S is expressed in intestinal 
epithelial cells (100), which may promote reovirus replication at that site. Therefore, 
cathepsin S may be important for reovirus growth at other sites of secondary replication, 
including the heart and liver, at which sites peak titers are less that those in wt mice. 
Cathepsin B also may be important for growth in the heart, as titers in the heart of Ctsb-/- 
mice are decreased in comparison to those in wt mice, while titers in the intestine and 
liver are not. It is noteworthy that in mouse fibroblasts, although both cathepsins B and L 
can mediate reovirus uncoating, cathepsin L is more efficient (4). Our data following 
both peroral and intracranial inoculation support this conclusion in that peak titers in all 
 49
organs tested are lower in Ctsl-/- mice than in Ctsb-/- mice. These findings suggest that 
cathepsin L is required for efficient reovirus growth in tissues other than the intestine. 
I have shown that cathepsin proteases are required for efficient reovirus infection 
in mice. Cathepsins promote optimal growth at specific sites of reovirus replication in the 
host and influence survival following reovirus infection. Organ-specific differences in 
infection of cathepsin-deficient mice highlight distinct roles for these proteases in vivo.  
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CHAPTER III 
 
CATHEPSIN PROTEASES ARE NOT REQUIRED FOR GROWTH 
OF T1L IN VIVO 
 
Introduction 
Different reovirus strains display differential tropism and disease patterns in vivo. 
These differences have been genetically ascribed to various gene segments using 
reassortant genetics. For example, the extent of growth and tissue injury in the heart and 
lungs is determined by genes encoding the proteins of the viral vertex including L1 (λ3), 
L2 (λ2), and M1 (μ2) (160). Tropism in the CNS is determined by the S1 gene segment 
(145), which encodes the attachment protein σ1 and the nonstructural protein σ1s (182-
184). Interestingly for my studies, S1 also influences hepatic tropism and resultant liver 
disease (176). Peroral infection with some type 3 strains, but not T1L, leads to liver 
disease that is similar to biliary atresia in human infants and characterized by oily hair 
effect (174, 176-180). This difference in disease presentation is not related to virulence or 
growth of virus in the liver, as the effect does not correlate with LD50 value or titer of 
virus in the liver (176). However, reovirus strains capable of causing this disease infect 
bile duct epithelial cells, whereas other strains infect hepatocytes in a more diffuse 
pattern (176). This variation in infectivity is determined by differences in the capacity to 
bind sialic acid (174).  
The distinct cell types infected by different strains of reovirus might express 
altered cathepsin activity. Although the relative tissue distribution of the cathepsin 
proteases is known, their activity within specific cell types is less well understood. I 
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hypothesized that if differences in cathepsin activity exist in the different cell types 
infected by reovirus strains, the effect of cathepsin deficiency on reovirus infection in 
vivo would differ among strains.  
To test this hypothesis, I infected cathepsin-deficient mice with a prototype 
serotype 1 strain, T1L. This virus shares 9 gene segments with T3SA+ (175) but differs 
in its S1 gene segment. Because the outer-capsid proteins σ3 and μ1 are identical to those 
of T3SA+, T1L is equally susceptible to cathepsin cleavage in vitro. However, the 
difference in the σ1 protein, which confers serotype specificity, causes T1L and T3SA+ 
to exhibit great differences in animal pathogenesis. T1L is much less virulent than 
T3SA+ (146, 174) and has different tropism patterns in the CNS (101, 144, 145, 147) and 
liver (174, 176).  
 
Results 
To study the role of cathepsins B, L, and S in the pathogenesis of T1L infection, I 
inoculated three-day-old mice perorally with 104 PFU of T1L and quantified viral growth 
in selected organs. Although titers in the intestine, the primary site of replication, of Ctsb-
/- mice were lower than those in wt mice at day 4 post-infection, peak titers were 
equivalent (Figures III-1 A, III-2, and III-3). A similar pattern was observed in the liver, 
heart, and brain. However, at day 12 post-infection, titers in the intestine and liver were 
slightly higher in Ctsb-/- mice than wt mice. In keeping with these findings, Ctsb-/- mice 
exhibited poor weight gain at 12 days post-infection in comparison to wt mice (Figure 
III-1 B). 
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In contrast to Ctsb-/- mice, peak titers in all organs of Ctsl-/- mice were equivalent 
to or greater than titers in wt mice, reaching statistical significance in the liver at day 8 
(Figures III-1 A, III-2, and III-4). Furthermore, viral titers in Ctsl-/- mice were greater 
than those in wt mice at day 12 post-inoculation in all organs, reaching statistical 
significance in the intestine and liver. Accordingly, Ctsl-/- mice had poor weight gain 
throughout the experiment, as the average weight was lower than that of wt mice at all 
timepoints tested (Figure III-1 B). 
Peak titers in Ctss-/- mice were equivalent to wt in all organs tested (Figures III-1 
A, III-2, and III-5). However, titers at sites of secondary replication were higher in Ctss-/- 
mice at days 4 and 12 post-inoculation than those in wt mice, reaching statistical 
significance in the liver on day 4 and in the liver and heart on day 12. As expected from 
these results, the average weight of Ctss-/- mice was lower than wt mice at days 8 and 12 
post-infection (Figure III-1 B). 
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Figure III-1. Infection of wt and cathepsin-deficient mice with T1L. C57/Bl6 wt 
and cathepsin-deficient mice (n = 4 to 7), 2-4 days old, were inoculated perorally with 
104 PFU T1L. (A) Organs were resected at the times shown and homogenized by 
freeze-thawing and sonication. Viral titers in organ homogenates were determined by 
plaque assay. Results are expressed as mean viral titer in whole organs. Error bars 
represent SEM. *, P < 0.05 as determined by Mann-Whitney test in comparison to wt 
at the same time after inoculation. The limit of detection was 102 PFU/organ. (B) Mice 
were weighed at the times shown. Results are expressed as mean weight of infected 
animals. 
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Figure III-2. Reovirus titers in organs of wt mice following peroral infection with 
T1L. C57/Bl6 wt mice (n = 4 to 7), 2-4 days old, were inoculated perorally with 104 
PFU T1L. Organs were resected at the times shown and homogenized by freeze-thawing 
and sonication. Viral titers in organ homogenates were determined by plaque assay. 
Each data point represents one animal. Horizontal bars indicate the arithmetic mean of 
log-transformed data. The limit of detection was 102 PFU/organ.  
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Figure III-3. Reovirus titers in organs of Ctsb-/- mice following peroral infection with 
T1L. Ctsb-/- mice (n = 4 to 7), 2-4 days old, were inoculated perorally with 104 PFU T1L. 
Organs were resected at the times shown and homogenized by freeze-thawing and 
sonication. Viral titers in organ homogenates were determined by plaque assay. Each data 
point represents one animal. Horizontal bars indicate the arithmetic mean of log-
transformed data. The limit of detection was 102 PFU/organ.  
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Figure III-4. Reovirus titers in organs of Ctsl-/- mice following peroral infection with 
T1L. Ctsl-/- mice (n = 4 to 7), 2-4 days old, were inoculated perorally with 104 PFU T1L. 
Organs were resected at the times shown and homogenized by freeze-thawing and 
sonication. Viral titers in organ homogenates were determined by plaque assay. Each data 
point represents one animal. Horizontal bars indicate the arithmetic mean of log-
transformed data. The limit of detection was 102 PFU/organ.  
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Figure III-5. Reovirus titers in organs of Ctss-/- mice following peroral infection with 
T1L. Ctss-/- mice (n = 4 to 7), 2-4 days old, were inoculated perorally with 104 PFU T1L. 
Organs were resected at the times shown and homogenized by freeze-thawing and 
sonication. Viral titers in organ homogenates were determined by plaque assay. Each data 
point represents one animal. Horizontal bars indicate the arithmetic mean of log-
transformed data. The limit of detection was 102 PFU/organ.  
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Discussion 
Data presented in this chapter indicate that viral tropism does affect the 
requirement for cathepsin proteases for maximal viral replication. I discovered dramatic 
differences in the pathogenesis of reovirus following infection of cathepsin-deficient 
mice with T1L in comparison to mice infected with T3SA+. In general, whereas 
cathepsin expression is required for peak growth of T3SA+ at sites of secondary 
replication, deficiency of a single cathepsin does not diminish growth of T1L. Cathepsin 
B may be required for initial infection events in the gastrointestinal tract for T1L, since 
Ctsb-/- mice had lower viral titers in the intestine at day 4. However, peak titers are 
equivalent in all organs tested at day 8, suggesting that cathepsin B alone is not required 
for productive infection of any organ. 
Cathepsins L and S also are individually dispensable for growth of T1L in vivo. 
In contrast to Ctsb-/- mice, there was no delay in establishing infection in the intestine of 
Ctsl-/- and Ctss-/- mice. In fact, titers of T1L are higher in the liver of Ctsl-/- mice at day 4. 
Furthermore, peak titers in all organs tested of Ctsl-/- and Ctss-/- mice are equivalent to or 
greater than peak titers in wt mice.  
It is intriguing that infection with T1L is not hampered by the loss of a single 
cathepsin, whereas infection with T3SA+ is substantially diminished. There are several 
possible explanations for this observation. First, T1L and T3SA+ differ in the route of 
spread from the intestine to target tissues. Whereas T1L uses hematogenous routes (143), 
T3SA+ uses both hematogenous and neural pathways (101, 147). Titers of T3SA+ in the 
blood of cathepsin-deficient mice did not differ from those in wt mice, suggesting that if 
hematogenous spread is defective in these mice, it would be blocked at the stage of exit 
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of the virus from the bloodstream into the target tissue. Alternatively, hematogenous 
spread may not be affected by lack of a single cathepsin, but neural spread may be 
altered. Titers in the brains of Ctsl-/- mice are lower than those in other genotypes of mice 
following intracranial inoculation of T3SA+. It is possible that cathepsin function is 
required for optimal spread of reovirus through neural routes. The capacity of T1L to 
infect all target organs equally in cathepsin-deficient and wt mice demonstrates that 
hematogenous spread of this virus is not affected.  
Second, T1L and T3SA+ differ in cell and tissue tropism. In the brain, T1L 
infects ependymal cells (144, 145), whereas T3SA+ infects neurons (101, 144, 145, 147). 
In the liver, T1L infects hepatocytes (176), whereas infection with T3SA+ initiates at the 
bile duct epithelium (174, 176). Perhaps the cell types infected by T3SA+ are more 
sensitive to loss of cathepsin function than those infected by T1L. 
Both T1L and T3SA+ are cleared more slowly from the intestine and sites of 
secondary replication in cathepsin L- and cathepsin S-deficient mice. While viral titers of 
T1L and T3SA+ in organs of wt mice decrease between days 8 and 12, titers do not 
diminish in these knock-out mice. At day 12 post-infection, titers of T1L are significantly 
higher in the intestine and heart of Ctsl-/- mice and in the liver and heart of Ctss-/- mice in 
comparison to wt mice. At the same timepoint, titers of T3SA+ are significantly higher in 
the intestine and liver of Ctsl-/- mice and the intestine of Ctss-/- mice in comparison to wt 
mice. The increased titers of T3SA+ at day 12 in cathepsin L- and cathepsin S-deficient 
mice occurs despite lower peak titers in these same organs at day 8 post-infection. This 
result is most likely due to a deficiency in CD4+ T cell help. Both Ctsl-/- and Ctss-/- mice 
display decreased CD4+ T cell activity due to inefficient cleavage of the invariant chain 
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in thymocytes (92) and peripheral APCs (108, 185), respectively. This deficiency in Ctss-
/- mice is known to result in decreased germinal center formation and antibody class 
switching, particularly to isotype IgG2a (185). This antibody isotype has been implicated 
in clearance of reovirus in T3C9-infected adult mice lacking a functional IgM (158). It is 
also possible that an effective CD4+ T cell response is necessary for the development of 
the CD8+ T cell response to reovirus.  
Adult SCID mice infected perorally with T1L develop lethal hepatitis and display 
lesions only in the liver despite the presence of virus in all organs tested (159). Neither 
Ctsl-/- nor Ctss-/- mice efficiently clear infection with either T1L or T3SA+ from the liver 
(though the differences between the cathepsin-deficient and wt mice may not always be 
statistically significant). Transfer of Peyer’s patch cells from immune competent mice to 
SCID mice attenuates T1L infection (159), suggesting that the adaptive immune response 
in the intestine is essential for control of viral growth and spread. The requirement for 
intact adaptive immunity in the intestine is particularly intriguing, as Ctsl-/- mice appear 
unable to control infection with T1L at this site. Viral titer in the intestine of Ctsl-/- mice 
does not decrease from days 8 to 12 post-infection, when titers remain extraordinarily 
high. Infection with T3SA+ is also poorly controlled in the intestine of Ctsl-/- mice. Titers 
at sites of secondary replication of both Ctsl-/- and Ctss-/- mice decrease more slowly than 
in wt mice following infection with both T1L and T3SA+. Thus the lack of intact 
adaptive immunity in Ctsl-/- and Ctss-/- mice may be responsible for their poor control of 
reovirus infection at both the primary and secondary sites of replication following peroral 
inoculation. 
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In contrast to infection with T3SA+, expression of cathepsins B, L, and S 
individually does not appear to be required for efficient growth of T1L in any organ 
tested. It is likely that the deficiency in immune function exhibited by these mice leads to 
increased replication of T1L and inefficient clearance. Thus, in addition to providing the 
enzymatic mechanism for reovirus uncoating, these enzymes indirectly control reovirus 
infection by acting as critical determinants of immune function. Redundancy in cathepsin 
activity for viral replication allows reovirus to infect mice lacking a single cathepsin. 
However, absence of redundancy in cathepsin activity for immune function renders 
cathepsin-deficient animals severely immunocompromised. 
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CHAPTER IV 
 
TREATMENT OF MICE WITH AN INHIBITOR OF CATHEPSIN L 
AMELIORATES REOVIRUS T3SA+ INFECTION IN VIVO 
 
 
 
Introduction 
Cathepsin-specific inhibitors are important tools for studies of cathepsin 
proteases. Techniques such as computer-graphic analysis of crystal structures and the 
generation of small-molecule libraries have facilitated the design of broad-spectrum 
inhibitors for families of proteases (e.g., E-64, a pan cysteine-containing protease 
inhibitor) and inhibitors of specific members of a protease family. One such compound, 
CLIK-148, inhibits cathepsin L specifically (186, 187). This compound was developed by 
altering the structure of E-64 using differences in the substrate-binding pockets of 
cathepsins B, L, and S as a guide. Inhibitors active against specific cathepsin proteases 
are useful for studies to better understand substrate specificity and to determine functions 
of cathepsins in vivo. The pleiotropic effects associated with genetic cathepsin deficiency 
complicate the interpretation of in vivo results. Furthermore, given the large number of 
human pathogens that exploit cathepsin proteases for infection, these inhibitors could be 
developed as antiviral therapeutics. To determine whether a cathepsin inhibitor can block 
reovirus infection, I treated wt mice with CLIK-148 during infection with T3SA+. 
Results from these experiments demonstrate that cathepsin inhibition diminishes reovirus 
disease. 
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Results 
Treatment with an inhibitor of cathepsin L promotes survival following reovirus 
infection. Since titers of reovirus in organs of cathepsin-deficient mice are lower than 
those in wt mice, but mortality is increased in Ctsl-/- and Ctss-/- mice, I hypothesized that 
the immune defects accompanying cathepsin L and cathepsin S deficiency might mask a 
cathepsin requirement for efficient viral growth. Therefore, I sought to determine whether 
reovirus disease could be ameliorated in wt mice by treatment with an inhibitor of 
cathepsin L, CLIK-148, which blocks cathepsin L in vivo (186, 188). Mice were treated 
with CLIK-148 at a dose of approximately 100 μg/g body weight via intraperitoneal 
injection 1 hour prior to peroral inoculation with 107 PFU T3SA+ and then every 24 
hours for 7 days. In comparison to mice treated with vehicle alone, a significantly greater 
percentage of mice treated with CLIK-148 survived (Figure IV-1 A). At day 21, 40% of 
CLIK-148-treated mice succumbed, whereas 80% of vehicle-treated mice died. As a 
surrogate marker for disease, CLIK-148-treated mice exhibited only minimal weight loss 
followed by substantial weight gain through the course of the experiment, whereas 
vehicle-treated mice exhibited more severe weight loss and gained weight more slowly 
during the recovery phase (Figure IV-1 B). Mock-infected mice treated with CLIK-148 
or vehicle alone showed no signs of drug toxicity and had survival rates of 100% (data 
not shown). These results suggest that treatment with a cathepsin inhibitor dampens the 
severity of reovirus disease. 
 
Treatment with an inhibitor of cathepsin L diminishes reovirus growth at sites of 
secondary replication. To determine whether the cause of diminished mortality following 
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treatment with CLIK-148 is related to viral growth, I quantified viral titers in various 
organs in wt mice treated with CLIK-148. Mice were treated with CLIK-148 at a dose of 
approximately 100 μg/g body weight via intraperitoneal injection 1 hour prior to peroral 
inoculation with 10 PFU T3SA+ and then every 24 hours for 7 days. On day 8 post-
infection, organs were harvested and titers determined by plaque assay. Although titers in 
vehicle-treated and CLIK-148-treated mice were equivalent in the intestine, titers were 
reduced at sites of secondary replication in the CLIK-148-treated mice in comparison to 
vehicle-treated mice (Figure IV-2). More striking, perhaps, of the 5 CLIK-148-treated 
animals with detectable titer in the intestine, only 2 exhibited virus dissemination to other 
organs. However, of the 7 vehicle-treated mice with detectable titer in the intestine, 6 had 
disseminated virus. Thus, pharmacologic blockade of cathepsin L activity diminishes 
reovirus dissemination to sites of secondary replication. 
 
Treatment with CLIK-148 inhibits reovirus entry into cells. To characterize the 
block to infection imposed by CLIK-148, murine L cells were treated with varying 
concentrations of CLIK-148 prior to infection with T3SA+ virions and in vitro generated 
ISVPs. ISVPs are capable of penetrating cells at the plasma membrane and are resistant 
to blocks of the entry an uncoating processes (21, 26-28, 115). In comparison to growth 
in untreated cells, treatment with 100μM CLIK-148 diminished viral yields by 1 log 
(Figure IV-3). Treatment with 200 μM E64, which blocks the activity of both cathepsins 
B and L (66), diminished viral yield by 2 logs. The decreased inhibition by CLIK-148 in 
comparison to E64 results from the presence of cathepsin B activity in these cells. 
Infection by ISVPs was not decreased in cells treated with either agent, demonstrating 
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that the block imposed by CLIK-148 is at a stage associated with entry. These results are 
in agreement with those obtained previously using other inhibitors of cathepsin L (4, 26). 
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Figure IV-1. Survival following treatment with an inhibitor of cathepsin L. 
C57/Bl6 wt mice, 2-4 d old, were inoculated intraperitoneally with CLIK-148 at a 
dose of 100 μg/g average litter body weight or vehicle control 1 h prior to peroral 
inoculation with 107 PFU T3SA+. Mice were treated intraperitoneally with CLIK-148 
thereafter for 7 d. Mice (n = 15) were monitored for (A) survival and (B) weight gain. 
(A) *, P < 0.05 as determined by log rank test in comparison to vehicle-treated mice. 
(B) All live mice were weighed each day. 
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Figure IV-2. Viral titers following treatment with CLIK-148. C57/Bl6 wt mice, 2-
4 d old, were inoculated intraperitoneally with CLIK-148 at a dose of 100 μg/g 
average litter body weight or vehicle control 1 h prior to peroral inoculation with 10 
PFU T3SA+. Mice were treated intraperitoneally with CLIK-148 thereafter for 7 d. 
Mice (n = 9-10) were euthanized at d 8 post-inoculation, and viral titer in organs was 
determined by plaque assay. Error bars represent SEM. 
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Figure IV-3. Infection of L cells following treatment with CLIK-148. Monolayers 
of L cells were preincubated for 4 h in medium with or without CLIK-148 or E64 at 
the concentrations shown. The medium was removed, and cells were adsorbed with 
T3SA+ virions or ISVPs at an MOI of 2 PFU per cell. After 1 h, the inoculum was 
removed, fresh medium with or without CLIK-148 or E64 was added, and cells were 
incubated for 0 or 24 h. Viral titers in cell lysates were determined by plaque assay. 
The results are presented as mean viral yields, calculated by dividing the titer at 24 h 
by the titer at 0 h for each concentration of CLIK-148 or E64 for duplicate wells. 
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Discussion 
To eliminate the confounding variables present in the gene-deletion experiments, 
I sought to determine the effect of a cathepsin inhibitor on reovirus pathogenesis. CLIK-
148, a derivative of the pan-cysteine protease inhibitor E-64, inhibits cathepsin L in vivo 
(186, 188). Mice treated with CLIK-148 had increased resistance to reovirus infection in 
comparison to vehicle-treated controls as assessed by both survival and viral titers at sites 
of secondary replication. Because survival was increased in CLIK-148-treated mice but 
decreased in Ctsl-/- mice, I conclude that the inhibition of viral replication is specific and 
that immune functions are preserved. Furthermore, since the mice treated with CLIK-148 
did not display defects in fur growth characteristic of Ctsl-/- mice (88), I conclude that 
pharmacologic inhibition of cathepsin L is not as complete as genetic ablation.  
Successful pharmacologic attenuation of reovirus disease with a cathepsin 
inhibitor raises the possibility that cathepsin-inhibitor therapy could be effective for other 
viruses that require cathepsin proteolysis for cell entry. Ebola virus (167), Nipah virus 
(171, 189), Hendra virus (170), and SARS CoV (168) utilize cathepsin proteases to enter 
cells. Treatment of cells with chloroquine inhibits Hendra and Nipah virus infection 
(190), most likely via interference with viral fusion glycoprotein processing by cathepsin 
L. The absence of inhibitor-associated toxicity in this study and others (186, 188), along 
with the efficacy of CLIK-148 treatment in the amelioration of disease (this study), 
suggests that cathepsin inhibitors should be evaluated for therapeutic efficacy against 
these viruses.  
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CHAPTER V 
 
SUMMARY AND FUTURE DIRECTIONS 
 
Despite their role in the entry of several important human and animal pathogens 
(167-172), the function of cathepsin proteases in viral infection of a host was previously 
unexplored. Reovirus offers an ideal experimental system to define how host factors 
influence viral pathogenesis. In this study, I found that cathepsins B, L, and S influence 
reovirus disease in a serotype-dependent manner (Table V-1). Although these enzymes 
are individually required for development of peak viral titers at sites of secondary 
replication following infection with reovirus strain T3SA+, they are not individually 
required for maximal growth of strain T1L. Following infection with T3SA+, survival is 
enhanced in mice lacking cathepsin B but diminished in mice lacking cathepsins L or S, 
likely reflecting the differential importance of these cathepsins in adaptive immunity. 
Importantly, treatment with an inhibitor of cathepsin activity, which uncouples cathepsin 
functions in reovirus disassembly and immunity, enhances survival. These findings 
indicate a key role for cathepsin proteases in viral pathogenesis. 
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Table V-1. Reovirus pathogenesis in cathepsin-deficient mice. 
 
Results following infection with T3SA+
Intracraniala
Genotype Survival Clearance Viremia
Ctsb -/-b ↑ ↑ ↔ ↔ ↓ ↓ ↔ ↔ ↔
Ctsl -/-b ↓ ↑ ↓ ↓ ↓ ↓ ↓ ↔ ↓
Ctss -/-b ↓ ↑ ↓ ↓ ↓ ↓ ↓ ↔ ↔
wt + CLIK-148c ↑ ND ↔ ↓ ↓ ↓ ND ND ND
Replication 
in brain
Perorala 
Mean survival 
time
Replication 
in intestine
Replication 
in liver
Replication 
in heart
Replication 
in brain
 
 
Results following infection with T1L
Genotype Clearance
Ctsb -/-b ↔ ↔ ↔ ↔ ↔
Ctsl -/-b ↔ ↑ ↔ ↔ ↓
Ctss -/-b ↔ ↔ ↔ ↔ ↓
Perorala 
Replication 
in intestine
Replication 
in liver
Replication 
in heart
Replication 
in brain
 
 
a Route of inoculation 
b In comparison to wt mice 
c In comparison to wt mice treated with DMSO 
ND, not determined 
 
 
Cathepsin Proteases Influence Reovirus Pathogenesis in a Strain-
Specific Manner 
 
Although members of the cathepsin family show some redundancy of function, 
there exist specific roles for each protease. Therefore, I hypothesized that the proteases 
capable of mediating reovirus disassembly would serve nonredundant functions in 
reovirus pathogenesis by virtue of their specialized host functions. I found that, following 
infection with T3SA+, cathepsins B, L, and S are individually required for maximal viral 
growth at sites of secondary replication (Chapter II). Furthermore, the average survival 
time was increased in cathepsin-deficient mice in comparison to wt mice, presumably due 
to the lower viral yield at these sites. However, Ctsl-/- and Ctss-/- mice displayed 
decreased survival in comparison to wt and Ctsb-/- mice following both high- and low-
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dose infections. They also displayed an increase in damage to the liver. These differences 
are presumably due to the requirement for cathepsins L and S for fully functional 
adaptive immunity. Furthermore, cathepsin L appears to play a specific role in reovirus 
infection of the CNS, as titers of T3SA+ were decreased in the brains of Ctsl-/- mice 
following intracranial inoculation.  
To complement studies using genetically-deficient mice, I also studied reovirus 
pathogenesis using wt mice treated with CLIK-148, an inhibitor of cathepsin L. Results 
of these experiments (Chapter IV) show an increase in survival of CLIK-148-treated mice 
in comparison to vehicle-treated animals. This finding contrasts with the results gathered 
in experiments using Ctsl-/- mice. However, as in Ctsl-/- mice, viral titers at sites of 
secondary replication were decreased in CLIK-148-treated mice in comparison to 
vehicle-treated mice. Therefore, following infection with serotype 3 reovirus, cathepsin 
proteases influence reovirus pathogenesis in a cathepsin-specific manner.  
The effect of cathepsin deficiency on the growth of T1L, a serotype 1 strain, 
differed from that of T3SA+ (Chapter III). Peak titers were not decreased in cathepsin-
deficient mice and, in some instances, titers were increased. However, both strains were 
cleared more slowly in infected Ctsl-/- and Ctss-/- mice compared to wt controls. This 
observation most likely is a consequence of poor immune function in these mice. 
The work presented herein establishes several insights into reovirus pathogenesis 
and the role of cathepsin proteases in viral infection. (i) Despite the presence of proteases 
such as chymotrypsin in the lumen of the gut, cathepsin S is required for maximal 
infection by T3SA+ at this site. Cathepsin S is expressed primarily in cells of the immune 
system (96) and also in intestinal epithelial cells (100). The decreased replication of 
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T3SA+ in the intestine of Ctss-/- mice suggests that the route of egress of the virus into 
intestinal epithelial cells is not apical but basolateral. By entering and exiting intestinal 
epithelial cells from the side opposite the lumen of the gut, exposure to chymotrypsin 
would not occur and infection of these cells would require disassembly in endosomes. 
Alternatively, the low titers of T3SA+ in the intestine of Ctss-/- mice may reflect the 
necessity for this protease to mediate infection of lymphocytes of the Peyer’s patches. (ii) 
Redundancy of cathepsin function allows reovirus to infect all organs, though to varying 
degrees. However, other cathepsins cannot compensate for the specific role of cathepsins 
L and S in immune function. (iii) The requirement for individual cathepsins for maximal 
yields of T3SA+ at sites of secondary replication may be a result of the requirement for 
specific cathepsin activity for growth at those sites. Alternatively, cathepsins may be 
important for transport of the virus into infected tissues or along nerves. (iv) Serotype 
specificity of the virus influences the requirement for cathepsin activity for maximal 
infection, but serotype does not affect the requirement for cathepsin activity for proper 
immune function against the virus. 
These findings raise new questions about cathepsin function in reovirus 
pathogenesis. For example, what influences the strain-specific differences in infectivity 
of T1L and T3SA+ in cathepsin-deficient mice? Why is the growth of T3SA+ most 
dramatically affected at sites of secondary replication? Why is cathepsin L required for 
maximal growth of T3SA+ in the brain? What is the role of the immune system in liver 
disease following reovirus infection?  How does the protease susceptibility of viral 
proteins influence reovirus pathogenesis? Future experiments will address these 
questions. 
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Titers of T3SA+ are Reduced in the Brains of Cathepsin-Deficient Mice 
Reovirus serotypes differ in the cell types they infect in vivo. This difference is 
particularly prominent in the brain where type 1 strains infect ependymal cells (144, 145) 
and type 3 strains infect neurons (101, 144, 145, 147). The variation in susceptibility to 
cathepsin deficiency between T1L and T3SA+ growth in the brain may be attributable to 
the distinct cell types infected by these strains. If ependymal cells are more capable than 
neurons to compensate for the loss of a single cathepsin, reovirus would grow more 
efficiently in these cells than in neurons from cathepsin-deficient mice. This 
compensation would be possible if the activity of cathepsins B, L, and S is greater in 
ependymal cells than in neurons. To determine whether cathepsin activity differs between 
these cell types, neurons and ependymal cells should be isolated (191) and the activity of 
cathepsins B, L, and S in each cell type measured using fluorogenic substrates (4, 186). 
The experiment should be conducted with cells isolated from wt and cathepsin-deficient 
mice. Measurement of cathepsin activity in cells from cathepsin-deficient mice will allow 
us to determine whether ependymal cells upregulate the activity of certain cathepsins in 
the absence of another. Results of these experiments will provide insight into the 
susceptibility of virus growth and lead to further studies to identify mechanisms of 
cathepsin regulation. 
That T3SA+, but not T1L, is less infectious in the brain of cathepsin-deficient 
mice in comparison to wt mice raises the possibility that cathepsins contribute to neural 
spread to the brain from the primary site of infection. Both in vivo and in vitro 
approaches can be used to address this question. Type 3 reoviruses disseminate via neural 
routes to the brain following hind-limb inoculation (144, 147, 192). We can track 
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progression through the CNS by measuring viral titer in different parts of the CNS, 
namely the inferior spinal chord, superior spinal chord, and brain. Initial growth in the 
muscle of the hind-limb also should be confirmed. If the block to T3SA+ infection in the 
brain occurs during neural spread from the hind-limb, then viral titers will be diminished 
in the upper regions of the CNS in cathepsin-deficient mice but not in wt mice. 
Virus spread within the CNS of cathepsin-deficient mice could be blocked at one 
of several stages. Possible points of hindrance include entry into neurons, transmission of 
virus between neurons, or egress from infected neurons into target cells. To determine 
whether cathepsins are required for reovirus entry into neurons, neurons should be 
isolated from wt and cathepsin-deficient mice and tested for the capacity to support the 
growth of T3SA+ virions and ISVPs. If the block to reovirus infection is related to entry 
events, neurons from cathepsin-deficient mice would be diminished in the capacity to 
support reovirus growth following infection with virions but not ISVPs. 
Reovirus spreads through motor and sensory neurons (193) and autonomic 
neurons (101) via retrograde and anterograde movement. The virus enters motor neurons 
via motor nerve terminals (194) and travels through neurons using microtubule-
associated system of fast axonal transport (144). The virus then replicates within the cell 
bodies of neurons (144, 194).  
To further characterize the block to neuronal spread, compartmentalized neuron 
chambers (Figure V-1) (195-197) will be used. This system allows axons from neural cell 
bodies seeded in an isolated “soma” chamber to cross barriers and enter a distal “neurite” 
chamber where isolated target cells can be seeded. Use of these chambers will allow 
analysis of viral spread between neurons and from neurons to target cells.  
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To determine whether virus transmission between neurons is restricted in 
cathepsin-deficient mice, superior cervical ganglia (SCG) isolated from day E15 wt and 
cathepsin-deficient mice will be plated in the soma chamber and their axons allowed to 
grow into the neurite chamber for 10 days. Target cell neurons will then be plated in the 
neurite chamber. One day after plating of target neurons, before they are able to extend 
their axons into adjacent chambers, virus will be added to the soma chamber to infect the 
neurons with extended axons. Virus spread to the target neurons will be measured 48 
hours post-inoculation by fluorescence focus assay. To determine whether virus spreads 
from axons into target cells, murine L929 cells should be seeded in the neurite chamber 
as target cells. These studies will reveal information about the role of cathepsins in 
neuronal transport. 
Figure V-1. Compartmentalized 
neuron chamber. The tripartite 
system consists of a Teflon 
chamber sealed onto a tissue culture 
dish with vacuum grease. Neurons 
are seeded in the soma chamber. 
Axons extend through the mid 
barrier and penetrate the neurite 
chamber where target cells are 
seeded. 
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Adaptive Immunity Controls Reovirus Disease 
Cathepsins L and S play active roles in the development of adaptive immunity. 
Cathepsin L is required for positive selection of CD4+ T cells in the thymus, most likely 
though the combined action of processing the invariant chain in cortical thymic epithelial 
cells (92) and fragmentation of endosomal proteins, thereby promoting diverse peptide 
generation for display by MHC II on these cells (93). Cathepsin S is required for cleavage 
of the invariant chain in APCs (109) and processing antigenic endosomal proteins (108), 
thereby contributing to the activation of CD4+ T cells. Diminished T cell help contributes 
to a decrease in germinal center formation and antibody isotype class switching (185). 
Ctsl-/- and Ctss-/- mice fail to clear reovirus as quickly as wt and Ctsb-/- mice (Chapters II 
and III). I hypothesize that this defect in clearance is due to a deficiency in CD4+ T cell 
activity. To test this hypothesis, it will be necessary to define the role of CD4+ T cells in 
reovirus infection in the context of cathepsin deficiency.  
An important first step in these studies is to determine the level of activation of 
CD4+ T cells in the context of reovirus infection in wt and cathepsin L- and cathepsin S-
deficient mice. To do this, wt, Ctsl-/-, and Ctss-/- mice will be infected with reovirus strain 
T3SA+ or mock infected. Two weeks post-infection, spleen cells and blood will be 
harvested. The number of CD4+ T cells will be quantified by flow cytometry, and total 
CD4+ T cells will be enumerated. The number of CD4+ T cells that have differentiated to 
TH1 or TH2 also will be determined by intracellular cytokine staining for IL-2 and IL-4, 
respectively. 
It is unknown whether the alteration in CD4+ T cell helper functions of Ctsl-/- and 
Ctss-/- mice affects humoral or cytotoxic immunity during reovirus infection. To test the 
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effect of decreased CD4+ T cell help on humoral immunity, anti-reovirus antibody levels 
of wt, Ctsl-/-, and Ctss-/- mice will be investigated. Mice of these three genotypes will be 
mock-infected or infected with strain T3SA+. Two weeks post-inoculation, serum will be 
collected, and the amount of reovirus-specific IgG, IgG1, IgG2a, and IgA will be 
measured by ELISA.  
To test the effect of cathepsin L and cathepsin S deficiency on cell-mediated 
immunity, mice will be infected with T3SA+, and the CD8+ T-cell response will be 
measured. Two weeks post-inoculation, isolated splenocytes will be activated by co-
culture with T3SA+-infected fibroblasts, and the level of activation in CD8+ T cells will 
be measured by intracellular cytokine staining for INFγ followed by flow cytometry. 
These experiments will enhance knowledge about the role of cathepsins in 
adaptive immunity in the context of viral infection. This information is especially 
important as cathepsin inhibitors are currently being investigated as therapies for 
osteoporosis (198) and could be targets for the treatment of Alzheimer’s disease (199) 
and cancer (200). An understanding of how long-term cathepsin inhibition affects the 
immune system is important for the safe use of these drugs. 
 
 
Liver Damage Contributes to the death of Cathepsin L- and Cathepsin 
S-Deficient Mice 
Following infection with T3SA+, Ctsl-/- and Ctss-/- mice display decreased 
survival and increased damage to the liver in comparison to wt and Ctsb-/- mice (Chapter 
II). This liver injury most likely contributes to the poor outcome of these animals. 
However, it is not known whether the damage to the liver results from virus-induced 
injury or from an aberrant immune response. T3SA+ infection in the liver originates at 
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the bile-duct epithelium and spreads to neighboring hepatocytes (174 and this study). The 
infection causes an infiltration of inflammatory cells; however, the identity of these cells 
and their specific effects on liver function are unknown. The influx of cells into the portal 
triad results in the collapse of bile ducts, which in turn results in a build-up of bile in the 
liver (174 and this study). Without bile secretion into the intestine, fat absorption in the 
intestine is diminished, which leads to numerous pathological consequences (174, 176, 
178-180).  
Information about the involvement of cathepsin proteases in virus-induced innate 
immunity is lacking. Cathepsin B is involved in the trafficking of TNF-α-containing 
vesicles to the plasma membrane in macrophages following stimulation by LPS (201). 
Cathepsin L is involved in regulating AKT/GSK3β in the heart, most likely through 
regulation of NF-κB (202). Various cathepsins, including cathepsins B, L, and S, have 
been implicated in the processing of TLR 9 following stimulation with CpG DNA (203). 
These findings suggest that cathepsins serve important functions in innate immunity and 
that their activities could contribute to the pathogenesis of reovirus disease independently 
of their function in uncoating. 
To better understand the nature of the inflammatory infiltrate at sites of reovirus 
infection in the liver, histological analysis will be performed. Cathepsin-deficient and wt 
mice will be infected with 106 PFU T3SA+. At day 12 post-inoculation, mice will be 
harvested and livers resected, fixed, and embedded. Sections of tissue will be stained for 
reovirus antigen and various hallmarks of inflammation. These would include cytokines 
such as TNF-α and interferons and cell-specific markers to identify natural killer cells, 
neutrophils, macrophages, and dendritic cells. Sections also will be stained for CD8+ T 
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cells to determine the extent of the local adaptive immune response. Information gathered 
from this experiment will provide clues about the nature of the local immune response. If 
the inflammatory response in Ctsl-/- and Ctss-/- mice differs from that in wt and Ctsb-/- 
mice, further steps will be taken to discover the implications of these differences. One 
possible difference is the lack of expression of IL-10. This cytokine is produced by CD8+ 
T cells to inhibit the function of NK cells. In the absence of T cell help, Ctsl-/- and Ctss-/- 
mice may have fewer CD8+ T cells at the site of infection and, therefore, the signal to 
limit the inflammatory response may be diminished. An exacerbated inflammatory 
response could lead to increased damage of hepatocytes and bile-duct epithelia. Thus, 
information about differences in the innate immune response to reovirus in cathepsin-
deficient mice will provide insight into the role of individual cathepsins in innate 
immunity and viral disease. 
 
Cleavage Susceptibility of σ3 Regulates Uncoating and Pathogenesis 
Reovirus disassembly is initiated by the proteolytic removal of σ3 (21, 26), which 
leads to conformational changes in μ1 that allow viral penetration into the cytoplasm (25, 
124-126). Endocytic protease cathepsin L cleaves σ3 internally between residues 243-244 
and 250-251 and at an unidentified site near the C terminus (4) (Figure I-4). I hypothesize 
that a surface-exposed loop in the C-terminus of σ3 is cleaved first, allowing cathepsin L 
to access a pocket containing the internal cleavage sites (4). Cathepsin L preferentially 
cleaves following a bulky hydrophobic residue at the P2 position and a basic residue at 
the P1 position (204). The σ3 cleavage sites between amino acids 243-244 and 250-251 
confirm this preference at the P2 (Leu242 and Phe249) but not the P1 (Val243 and 
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Gly250) positions (4). It is not understood how variance from an optimal cleavage site 
influences the susceptibility of σ3 to proteolysis. Furthermore, it is not known whether 
both internal cleavage sites are used, nor whether the cleavage events are temporally 
related.  
 
Identification of the C-terminal cathepsin L cleavage site in σ3. The C-terminal 
cleavage site in σ3 will be identified following limited proteolysis of T3D virions with 
cathepsin L (4). Digestion mixtures will be subjected to SDS-PAGE, and bands 
corresponding to full-length σ3 and the large N-terminal σ3 fragment, which can be 
readily detected (4), will be excised from the gel, trypsinized by in-gel digestion, and 
analyzed by MALDI-TOF/TOF mass spectrometry. The two MS spectra will be 
compared, and peptide peaks that differ between the spectra will be sequenced by 
MS/MS to identify the cleavage site. Alternatively, digestion products will be 
fractionated by reverse-phase HPLC to isolate the small C-terminal σ3 fragment, which 
will be sequenced using nanoLC-MS/MS mass spectrometry. Once the C-terminal 
cleavage site is identified, we will use reverse genetics to generate mutant viruses in 
which the P1 and P2 positions have been altered to modulate cleavage (205). Mutant 
viruses will be tested for infectivity (175) and susceptibility to cleavage by cathepsin L in 
vitro (4). These experiments will determine whether cleavage of σ3 at the C-terminus 
controls access to the internal cleavage sites and thus regulates reovirus disassembly. 
 
Analysis of internal cathepsin L cleavage sites in σ3. To determine contributions 
of the internal σ3 cleavage sites to reovirus disassembly, the P1 and P2 positions at each 
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site will be substituted with the residues shown in Table V-2. The resultant σ3 CS 
mutants will be recovered by reverse genetics and tested for infection of Ctsb-/- and Ctsl-/- 
MEFs and susceptibility to cleavage by cathepsins B and L in vitro (4). We anticipate that 
σ3 CS mutants with arginine substitutions at the P1 positions will be more susceptible to 
cathepsin L but display wt susceptibility to cathepsin B. Such mutants should infect wt 
cells more efficiently than wt virus but exhibit wt infectivity in Ctsl-/- cells. Conversely, 
σ3 CS mutants with alanine substitutions at the P2 positions should be resistant to 
cathepsin L but not cathepsin B. Since either cathepsin B or cathepsin L can catalyze 
reovirus disassembly in fibroblasts (4), these σ3 CS mutants should infect cells lacking 
cathepsin L but not those lacking cathepsin B. Use of both cell types, coupled with in 
vitro analyses of proteolysis, will allow us to determine the functional importance of the 
cathepsin L cleavage sites in σ3 and provide insight into mechanisms used by endocytic 
proteases to catalyze viral disassembly. 
 
Table V-2. Planned mutations of σ3 cleavage-site residues. 
Mutant P2-242 P1-243 P2-249 P1-250 Anticipated result 
Wildtype L V F G  
σ3 CS1 A V F G Diminished utilization of 243-244 
σ3 CS2 L V A G Diminished utilization of 250-251 
σ3 CS3 A V A G Diminished utilization of both 243-244 and 250-251 
σ3 CS4 F V L G No change in cleavage site utilization or perhaps a 
reversal in the temporal relationship of the cleavage 
events 
σ3 CS5 L R F G Enhanced utilization of 243-244 
σ3 CS6 L V F R Enhanced utilization of 250-251 
σ3 CS7 L R F R Enhanced utilization of both 243-244 and 250-251 
 
Pharmacologic inhibition of cathepsin activity. I found that treatment of mice 
with CLIK-148, an inhibitor of cathepsin L, lessens the severity of reovirus disease. To 
extend this finding and provide rationale for the development of cathepsin inhibitors as 
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antiviral therapeutics, we must determine whether inhibitors of other cathepsins would 
also inhibit reovirus infection and whether the drugs are effective if administered after 
infection is established.  
To determine whether inhibition of cathepsins B and S attenuates reovirus 
disease, we will test CA-074 and CLIK-60, which have been used in mice to selectively 
inhibit cathepsins B (206) and S (207), respectively, for the capacity to diminish reovirus 
infection and pathology. Wildtype mice will be inoculated perorally with reovirus strain 
T3SA+ and treated by intraperitoneal administration with CA-074, CLIK-60, or DMSO. 
Inhibition of cathepsin activity in harvested tissues will be confirmed using fluorogenic 
substrates (74). Uninfected animals will be treated with each inhibitor alone as a control 
for drug toxicity. In our initial experiments, inhibitor treatment will begin on the day of 
inoculation and continue for 7 days post-inoculation. Combinations of these inhibitors 
will also be tested for toxicity and efficacy against reovirus. 
To determine whether the inhibitors can be administered after infection is 
established, treatment will be initiated at successively longer intervals following 
inoculation. These experiments will establish whether cathepsin inhibitors can serve as 
antiviral agents. 
 
Pathogenesis of σ3 CS mutant viruses. To determine whether alterations in viral 
capsid proteolysis by cathepsin L influence reovirus pathogenesis, we will compare wt 
and σ3 CS mutant viruses for pathologic outcome following infection of wt and 
cathepsin-deficient mice. We anticipate that virulence of cathepsin L-insensitive σ3 CS 
mutant viruses in wt mice will be altered to an extent similar to wt virus in Ctsl-/- mice, 
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which would confirm a requirement for cathepsin L in reovirus pathogenesis. However, 
because of cathepsin L insensitivity, these σ3 CS mutant viruses should be substantially 
more attenuated than wt virus in either Ctsb-/- or Ctss-/- mice. Virulence of cathepsin L-
hypersensitive σ3 CS mutant viruses is more difficult to predict. These 3 CS mutant 
viruses may be more virulent than wt virus as a consequence of enhanced cleavage 
susceptibility or attenuated due to alterations in capsid stability.  
Collectively, these experiments will determine whether strategic alterations in σ3 
affecting cathepsin L sensitivity influence reovirus pathogenesis. In addition to defining 
mechanisms of reovirus disassembly, this work is relevant to the use of reovirus as an 
oncolytic agent. Enhanced replication of reovirus in transformed cells is in part 
attributable to endocytic protease activity (208). Alteration of the cathepsin L cleavage 
sites may make it possible to engineer reovirus vectors with enhanced tumor cell killing 
and diminished toxicity. Moreover, these experiments will advance knowledge about 
substrate utilization by cathepsin L, which will allow refined prediction of cathepsin L 
cleavage sites and foster the design of new cathepsin L inhibitors. 
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CHAPTER VI 
 
MATERIALS AND METHODS 
 
Cells and viruses. L929 cells were maintained in Joklik's minimal essential 
medium supplemented to contain 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 
U/ml penicillin, 100 μg/ml streptomycin, and 25 ng/ml amphotericin B. T3SA+ is a 
reassortant virus containing the S1 gene segment of strain T3C44MA and the remaining 
nine gene segments of strain T1L (175). Virus was purified after growth in L929 cells by 
CsCl-gradient centrifugation (209). Viral titers were determined by plaque assay (210).  
 
Treatment of virions with purified cathepsins. Purified reovirus virions at a 
concentration of 1012 particles per ml in reaction buffer B-L (50 mM sodium acetate [pH 
5.0], 15 mM MgCl2, 100 mM NaCl, 5 mM DTT) were treated with 400 μg/ml bovine 
spleen cathepsin B (Calbiochem-Novabiochem) or 100 μg/ml purified recombinant 
human cathepsin L (211) at 37°C for various intervals. Alternatively, purified virions at a 
concentration of 1012 particles per ml in reaction buffer S (50 mM sodium acetate [pH 
6.0], 15 mM MgCl2, 100 mM NaCl) were treated with 300 μg/ml purified recombinant 
human cathepsin S (Calbiochem) at 37°C for various intervals. Proteolysis was 
terminated by incubation of reaction mixtures on ice and addition of 1 mM E64. A 30-μl 
aliquot of each reaction was incubated with 7 μl 6x sample buffer (350 mM Tris [pH6.8], 
9.3% DTT, 10% SDS, 0.012% bromophenol blue) at 100°C for 5 min. Samples were 
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loaded into wells of 10% polyacrylamide gels and electrophoresed. After electrophoresis, 
gels were fixed and stained using colloidal Coomassie blue (Invitrogen, Carlsbad, CA). 
 
Mice. C57Bl/6J mice (wt) were obtained from Jackson Laboratory. Ctsb-/- (86, 
212) and Ctsl-/- mice (88),  each backcrossed to a C57Bl/6 background at least 8 times, 
were provided by D. Hanahan (San Francisco, CA). Ctss-/- mice, backcrossed at least 10 
times to a C57Bl/6 background (110), were provided by H. Chapman (San Francisco, 
CA).  
 
Infection of mice. Newborn mice, 2-4 days old, weighing approximately 2 g were 
inoculated perorally or intracranially with purified reovirus virions diluted in PBS. 
Peroral inoculations (50 µl) were delivered intragastrically (213). Intracranial 
inoculations (5 µl) were delivered to the left cerebral hemisphere using a Hamilton 
syringe and 30-gauge needle (214). For analysis of virulence, mice were monitored for 
weight loss and symptoms of disease for 21 days post-inoculation and euthanized when 
found to be moribund (defined by rapid or shallow breathing, severe lethargy, or 
paralysis). For analysis of viral replication, mice were euthanized at various intervals 
following inoculation, and organs were harvested into 1 ml of PBS before freezing, 
thawing, and homogenization by sonication. For analysis of viremia, mice were 
euthanized and decapitated at various intervals following inoculation. Whole blood was 
collected from the neck into a 1 ml syringe containing 100 µl Alsever’s solution (Sigma) 
and frozen, thawed, and sonicated. Viral titers in organ and blood homogenates were 
determined by plaque assay (215). Animal husbandry and experimental procedures were 
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performed in accordance with Public Health Service policy and approved by the 
Vanderbilt University School of Medicine Institutional Animal Care and Use Committee. 
 
Treatment of mice with an inhibitor of cathepsin L. Mice were inoculated 
intraperitoneally with approximately 100 μg/g average litter weight of CLIK-148 in 
DMSO or DMSO alone. One hour following treatment, mice were inoculated perorally 
with PBS or reovirus T3SA+. Mice were subsequently treated with CLIK-148 daily for 7 
days. Analysis of virulence was conducted for 21 days or mice were euthanized at 8 days 
post-inoculation and organs resected for determination of viral titer as described. Pups 
with obvious injury from intraperitoneal injections or that died within 6 days post-
inoculation were eliminated from the study.  
 
Statistical analysis. For survival experiments, curves were obtained using the 
Kaplan-Meier method and compared by the log-rank test. For experiments in which viral 
titers were determined in an organ or blood, the Mann-Whitney test was used to calculate 
two-tailed P values. This test is appropriate for experimental data that display a non-
Gaussian distribution (216). Mann-Whitney analysis lacks the power of the t test and, 
therefore, statistical significance is achieved less frequently using this method. All 
statistical analyses were performed using GraphPad Prism software. 
 
Histology. Newborn mice, 2-4 days old, weighing approximately 2 g were 
inoculated perorally with purified reovirus virions diluted in PBS. At various intervals 
following inoculation, mice were euthanized, organs were resected, and a wedge of liver 
 86
was removed for titer determination by plaque assay. Remaining organs were incubated 
in 10% formalin at room temperature for 24 h, followed by incubation in 70% ethanol at 
room temperature. Fixed organs were embedded in paraffin, and 5-µm sections were 
prepared. Consecutively obtained sections were stained with hematoxylin and eosin for 
evaluation of histopathologic changes or processed for immunohistochemical detection of 
reovirus protein (217).  
 
Quantitation of serum hepatic enzymes. Newborn mice, 2-4 days old, weighing 
approximately 2 g were inoculated perorally with purified reovirus virions diluted in 
PBS. At various intervals following inoculation, mice were euthanized and decapitated. 
Blood was collected and allowed to coagulate, and serum was separated by 
centrifugation. Sera were stored at -20°C, protected from light, and submitted in batches 
to Charles River Research Animal Diagnostic Services (Wilmington, MA). A small 
wedge of liver was resected concurrently with blood collection for correlative titer 
determination by plaque assay. 
 
Growth of reovirus in vitro in the presence of cathepsin inhibitors. Monolayers of 
L cells (2x105 cells) in 24-well plates were preincubated in medium supplemented to 
contain 10-100 μM CLIK-148 or 200 μM E64 for 4 h. The medium was removed, and 
cells were adsorbed with T3SA+ or ISVPs of T3SA+ at an MOI of 2 PFU per cell. After 
incubation at 4°C for 1 h, the inoculum was removed, cells were washed with phosphate-
buffered saline, and 1 ml fresh medium supplemented with CLIK-148 or E64 was added. 
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After incubation at 37°C for 0 or 24 h, cells were frozen and thawed twice, and viral titers 
in cell lysates were determined by plaque assay. 
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APPENDIX 
 
A.  JUNCTIONAL ADHESION MOLECULE A SERVES AS A 
RECEPTOR FOR PROTOTYPE AND FIELD-ISOLATE STRAINS 
OF MAMMALIAN REOVIRUS 
 
The discovery that JAM-A is a receptor for reovirus was originally made using 
prototype strains T1L and T3D and reassortant viruses T3SA- and T3SA+ (218). This 
study demonstrated that JAM-A also serves as a receptor for other serotypes of reovirus 
and non-prototype strains. My involvement in this project was to help with plaque-
purification and cultivation of virus stocks and to conduct infectivity studies using the 
prototype and field-isolate strains. 
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Reovirus infections are initiated by the binding of viral attachment protein 1 to receptors on the surface
of host cells. The 1 protein is an elongated fiber comprised of an N-terminal tail that inserts into the virion
and a C-terminal head that extends from the virion surface. The prototype reovirus strains type 1 Lang/53
(T1L/53) and type 3 Dearing/55 (T3D/55) use junctional adhesion molecule A (JAM-A) as a receptor. The
C-terminal half of the T3D/55 1 protein interacts directly with JAM-A, but the determinants of receptor-
binding specificity have not been identified. In this study, we investigated whether JAM-A also mediates the
attachment of the prototype reovirus strain type 2 Jones/55 (T2J/55) and a panel of field-isolate strains
representing each of the three serotypes. Antibodies specific for JAM-A were capable of inhibiting infections
of HeLa cells by T1L/53, T2J/55, and T3D/55, demonstrating that strains of all three serotypes use JAM-A as
a receptor. To corroborate these findings, we introduced JAM-A or the structurally related JAM family
members JAM-B and JAM-C into Chinese hamster ovary cells, which are poorly permissive for reovirus
infection. Both prototype and field-isolate reovirus strains were capable of infecting cells transfected with
JAM-A but not those transfected with JAM-B or JAM-C. A sequence analysis of the 1-encoding S1 gene
segment of the strains chosen for study revealed little conservation in the deduced 1 amino acid sequences
among the three serotypes. This contrasts markedly with the observed sequence variability within each
serotype, which is confined to a small number of amino acids. Mapping of these residues onto the crystal
structure of 1 identified regions of conservation and variability, suggesting a likely mode of JAM-A binding
via a conserved surface at the base of the 1 head domain.
Mammalian orthoreoviruses (referred to as reoviruses in
this article) are nonenveloped viruses with genomes of 10 dis-
crete segments of double-stranded RNA (reviewed in refer-
ence 41). There are at least three serotypes of reoviruses,
which can be differentiated by the capacity of antireovirus
antisera to neutralize viral infectivity and inhibit hemaggluti-
nation (47, 50). Each of the reovirus serotypes is represented
by a prototype strain, namely, type 1 Lang/53 (T1L/53), type 2
Jones/55 (T2J/55), and type 3 Dearing/55 (T3D/55). Reovi-
ruses appear to infect most mammalian species, but disease is
restricted to the very young (reviewed in reference 63). Reo-
virus infections of newborn mice have been used as the pre-
ferred experimental system for studies of reovirus pathogene-
sis. Sequence polymorphisms in reovirus attachment protein
1 play an important role in determining sites of reovirus
infection in the infected host (4, 32, 69, 70).
The 1 protein is an elongated trimer with a head-and-tail
morphology. The N-terminal 1 tail partially inserts into the
virion via “turrets” formed by the pentameric 2 protein, while
the C-terminal 1 head projects away from the virion surface
(1, 25, 26). A crystal structure of the C-terminal half of T3D/55
1 revealed that the head contains three -barrel domains
(one from each trimer), each of which is constructed from
eight antiparallel -strands (16). Sequence analysis and struc-
tural modeling have suggested that the N-terminal half of the
tail is formed from an -helical coiled coil (6, 21, 40) and the
C-terminal half is formed from a triple -spiral (16, 56). The
overall structural topology of the -spiral and head domains of
1 is strikingly similar to that of the adenovirus attachment
protein, fiber (16, 37, 56).
There are two distinct receptor-binding regions in 1. A
region in the fibrous tail domain of type 3 1 binds to -linked
sialic acid (2, 14, 15, 18). A distinct region in the type 1 1 tail
domain also binds to cell surface carbohydrates (14), and re-
cent evidence suggests that sialic acid may be involved in the
binding of T1L/53 to intestinal cells (30). A second receptor-
binding site is located in the head domains of both the type 1
and type 3 1 proteins (3, 39).
An expression-cloning approach was used to identify junc-
tional adhesion molecule A (JAM-A) as a receptor for the
prototype strains T1L/53 and T3D/55 (3). JAM-A is a 35-kDa
type I transmembrane protein that is a member of the immu-
noglobulin superfamily (34, 36). JAM-A contains two immu-
noglobulin-like domains, a single transmembrane region, and a
short cytoplasmic tail. JAM-A is expressed in a variety of
* Corresponding author. Mailing address: Lamb Center for Pediat-
ric Research, D7235 MCN, Vanderbilt University School of Medicine,
Nashville, TN 37232. Phone: (615) 343-9943. Fax: (615) 343-9723.
E-mail: terry.dermody@vanderbilt.edu.
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tissues, including epithelial and endothelial barriers (34, 36,
43), where it is thought to regulate tight-junction permeability
and mediate leukocyte trafficking (17, 34, 36, 43).
The crystal structures of the murine (m) and human (h)
homologs of JAM-A, both of which are functional reovirus
receptors (3), indicate that JAM-A forms homodimers via ex-
tensive hydrophobic and ionic contacts between apposing
membrane-distal (D1) immunoglobulin-like domains (33, 44).
Residues that facilitate interdimer interactions are strictly con-
served between mJAM-A and hJAM-A (33, 44). JAM-A
dimers are thought to be physiologically relevant, perhaps
functioning in tight-junction barrier integrity or the diapedesis
of inflammatory cells (8, 33, 44). Recent biochemical studies of
reovirus–JAM-A interactions suggested that 1 binds to a mo-
nomeric version of JAM-A and contacts residues in the vicinity
of the JAM-A dimer interface (24). This strategy of cell at-
tachment is strikingly similar to that used by adenovirus fiber
to bind to the coxsackievirus and adenovirus receptor (CAR)
(10, 66), an immunoglobulin superfamily member that shares
considerable structural homology with JAM-A (57).
For this study, we determined whether JAM-A serves as a
receptor for the prototype type 2 strain T2J/55 and a panel of
four type 1, two type 2, and four type 3 field-isolate strains. The
results indicate that JAM-A, but not the related JAM family
members JAM-B and JAM-C, is a receptor for prototype and
field-isolate strains of the three reovirus serotypes. An analysis
of conserved and variable sequences in the 1 head, together
with existing structural information for 1 and JAM-A, sug-
gested an especially high tolerance for surface variation in the
protein while maintaining the specificity for receptor utiliza-
tion. These findings enhance our understanding of the molec-
ular basis of reovirus binding to JAM-A and provide clues
about the mechanisms of reovirus attachment.
MATERIALS AND METHODS
Cells, viruses, and antibodies. Spinner-adapted murine L929 (L) cells were
grown in either suspension or monolayer cultures in Joklik’s modified Eagle’s
minimal essential medium (Irvine Scientific, Santa Ana, Calif.) supplemented to
contain 5% fetal bovine serum (Gibco-BRL, Gaithersburg, Md.), 2 mM L-
glutamine, 100 U of penicillin per ml, 100 mg of streptomycin per ml, and 0.25
mg of amphotericin per ml (Gibco-BRL). HeLa cells were maintained in mono-
layer cultures in Dulbecco’s minimal essential medium (Gibco-BRL) supple-
mented to contain 10% fetal bovine serum, L-glutamine, and antibiotics as
described for L cells. Chinese hamster ovary (CHO) cells were maintained in
Ham’s F12 medium supplemented with fetal bovine serum, L-glutamine, and
antibiotics as described for HeLa cells.
The prototype reovirus strains T1L/53, T2J/55, and T3D/55 are laboratory
stocks. The field-isolate reovirus strains used in this study are shown in Table 1.
Variant K, a neutralization-resistant variant of T3D/55, was selected and char-
acterized as previously described (7, 54, 55). Viral stocks were prepared by
plaque purification and passage in L cells (67). Purified virions were prepared by
using second- and third-passage L-cell lysate stocks as previously described (26,
49). Viral particle concentrations were determined by measurements of the
optical density at 260 nm, using a conversion factor of 2.1  1012 viral particles
per optical density unit (52). The particle-to-PFU ratio of stocks used for viral
infectivity assays was approximately 250 to 1.
Rabbit hCAR-specific antiserum was provided by Jeffrey Bergelson (Univer-
sity of Pennsylvania). Rabbit polyclonal hJAM-B- and hJAM-C-specific antisera
were generated as previously described (28). The murine hJAM-A-specific
monoclonal antibody (MAb) J10.4 was purified from mouse ascites by using
protein A-Sepharose (34). The immunoglobulin G (IgG) fractions of polyclonal
rabbit antisera raised against T1L/53 and T3D/55 (71) were purified by using
protein A-Sepharose (2). A mixture of these sera was capable of recognizing all
strains of reovirus used in this study.
Fluorescent-focus assays of viral infectivity. Monolayers of HeLa cells in
96-well plates (Costar, Cambridge, Mass.) (3  104 cells per well) were pre-
treated for 1 h with phosphate-buffered saline (PBS), hCAR-specific antiserum,
or the hJAM-A-specific MAb J10.4 at various concentrations prior to the ad-
sorption of virus at room temperature for 1 h. Following removal of the inocu-
lum, the cells were washed with PBS and incubated at 37°C for 20 h to permit the
completion of a single round of viral replication. Monolayers were fixed with 1 ml
of methanol at 20°C for a minimum of 30 min, washed twice with PBS, blocked
with 2.5% immunoglobulin-free bovine serum albumin (Sigma-Aldrich, St.
Louis, Mo.) in PBS, and incubated at room temperature for 1 h with protein-
A–affinity-purified polyclonal rabbit antireovirus serum at a 1:800 dilution in
PBS–0.5% Triton X-100. The monolayers were washed twice with PBS–0.5%
Triton X-100 and incubated with a 1:1,000 dilution of goat anti-rabbit immuno-
globulin conjugated with the Alexa Fluor 546 fluorophore (Molecular Probes,
Eugene, Oreg.). The monolayers were washed twice with PBS, and infected cells
were visualized by indirect immunofluorescence using an Axiovert 200 inverted
microscope modified for fluorescence microscopy (Carl Zeiss, New York, N.Y.).
Infected cells were identified by the presence of intense cytoplasmic fluorescence
that was excluded from the nucleus. No background staining of uninfected
control monolayers was noted. Reovirus antigen-positive cells were quantified by
counting the fluorescent cells in at least three random fields of view per well in
triplicate at a magnification of 20.
Transient transfection and infection of CHO cells. CHO cells were transiently
transfected with an empty vector or with plasmids encoding receptor constructs
by the use of Lipofectamine PLUS reagent (Invitrogen, San Diego, Calif.) as
previously described (3). After 24 h of incubation to allow receptor expression,
transfected cells were allowed to adsorb to the virus at a multiplicity of infection
(MOI) of 1 fluorescent focus unit (FFU) per cell, incubated for an additional
20 h, fixed with methanol, and stained for reovirus proteins by use of an anti-
reovirus serum at a 1:800 dilution. Images were captured at a magnification of
20 with a Zeiss Axiovert 200 inverted microscope.
Flow cytometric analysis of receptor expression. CHO cells were transiently
transfected with receptor constructs, incubated for 24 h, and detached from the
plates by incubation with 20 mM EDTA in PBS. Cells (106) were incubated with
the hCAR-specific antiserum, the hJAM-A-specific MAb J10.4, or an antibody
specific for hJAM-B or hJAM-C (28), washed with PBS, and incubated with a
phycoerythrin-conjugated goat anti-rabbit or anti-rat IgG secondary antibody
(Molecular Probes) at a 1:1,000 dilution on ice for 30 min. The cells were washed
twice with PBS and analyzed with a FACScan flow cytometer (Becton-Dickinson,
Palo Alto, Calif.).
Sequence analysis of the S1 gene. Viral genomes were extracted from infected
L-cell lysates by the use of Trizol (Life Technologies, Rockville, Md.) according
to the protocol supplied by the manufacturer. S1 gene segments were amplified
by reverse transcription-PCR (RT-PCR) using 10 U of avian myeloblastosis virus
reverse transcriptase (Promega Biosciences, San Luis Obispo, Calif.), 2.5 U Taq
DNA polymerase (Promega Biosciences), and primers complementary to the 5
and 3 nontranslated regions of the S1 genes of the reovirus prototype strains.
The type 1 S1 forward primer was 5 GGATCCGCTATTCGCGCCTATGG
TABLE 1. Strains used for studies of JAM-A utilization
by reoviruses
Virus straina Abbreviation
GenBank
accession
no.
Reference
T1/Human/Ohio/Lang/1953 T1L/53 M35963 45, 50
T1/Bovine/Maryland/clone23/1959 T1C23/59 AY862134 31
T1/Bovine/Maryland/clone50/1960 T1C50/60 AY862133 31
T1/Human/Netherlands/1/1984 T1Neth/84 AY862136 29
T1/Human/Netherlands/1/1985 T1Neth/85 AY862135 29
T2/Human/Ohio/Jones/1955 T2J/55 M35964 46, 50
T2/Human/Netherlands/1/1973 T2Neth/73 AY862137 29
T2/Human/Netherlands/1/1984 T2Neth/84 AY862138 29
T3/Human/Ohio/Dearing/1955 T3D/55 NC_004277 46, 50
T3/Human/Wash.D.C./clone93/1955 T3C93/55 L37675 31
T3/Human/Wash.D.C./clone87/1957b T3C87/57 L37677 48
T3/Bovine/Maryland/clone18/1961 T3C18/61 L37684 31
T3/Murine/France/clone9/1961 T3C9/61 L37676 31
a Strain nomenclature is as follows: serotype/species of origin/place of origin/
strain designation/year of isolation.
b This strain has also been designated T3/Human/Wash.D.C./Abney/1957.
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ATG, and the reverse primer was 5 GGGTTCGCGCTAGATTCA. The type 2
S1 forward primer was 5 GCTATTCGCACTCATGTCGGATCTAGTGC
AGC, and the reverse primer was 5 GATGAGTCGCCACTGTGCCGAGT
GGA. The type 1 5 forward primer contained nucleotides that resulted in a
primer-derived sequence for the first two amino acids (M and D), and the type
2 5 forward primer contained nucleotides that resulted in a primer-derived
sequence for the first six amino acids (M, S, D, L, V, and Q). The amplification
products were cloned into the pCR 2.1 vector (Invitrogen). Sequences of at least
two independent RT-PCR clones for each S1 gene segment were determined by
automated sequencing.
Phylogenetic analysis of S1 gene nucleotide sequences. Sequences were
aligned by using the program ClustalX (62). Phylogenetic trees were constructed
from variations in the 1-encoding S1 gene nucleotide sequences by the maxi-
mum parsimony method using the heuristic search algorithm within the program
PAUP v4.0b10 (58). Trees were rooted at the midpoint. The branching orders of
the phylograms were verified statistically by resampling the data 1,000 times in a
bootstrap analysis using the branch and bound algorithm as applied in PAUP.
Sequence alignment and structural modeling methods. Sequences were
aligned by using the program ClustalW (http://www.ebi.ac.uk/clustalw/). Align-
ments were rendered in ALSCRIPT (5), using different colors to highlight
different degrees of sequence similarity. Sequence changes were mapped onto
the crystal structure of T3D/55 1 (16) by using the program GRASP (42).
RESULTS
JAM-A serves as a receptor for prototype strains of the
three reovirus serotypes. Our previous work indicated that
JAM-A serves as a receptor for the prototype reovirus strains
T1L/53 and T3D/55 (3). To confirm these observations and to
test whether JAM-A is used as a receptor by T2J/55, we treated
HeLa cells with PBS, an hCAR-specific antiserum as a control,
or the hJAM-A-specific MAb J10.4 prior to viral adsorption.
Infected cells were quantified by indirect immunofluorescence
using an antireovirus serum (Fig. 1A). The treatment of cells
with the CAR-specific antiserum had no effect on the capacity
of the prototype strains to infect HeLa cells. In sharp contrast,
the treatment with MAb J10.4 resulted in a concentration-
dependent inhibition of infection for all three strains. The
minimum concentrations of MAb J10.4 required to reduce the
infectivities of these strains by 50% were between 0.1 and 1.0
	g per ml (Fig. 1B). The infectivities of all three strains were
reduced approximately 90% following the treatment of cells
with 100 	g per ml MAb J10.4.
JAM-B and JAM-C do not serve as receptors for prototype
strains of reovirus. JAM-A is the only JAM family member
tested to date that functions as a receptor for T1L/53 (44). To
determine whether other JAM family members in addition to
JAM-A serve as reovirus receptors for other reovirus proto-
type strains, we transfected CHO cells, which are poorly per-
missive for reovirus infection (24), with a cDNA encoding
hJAM-A, hJAM-B, or hJAM-C. Cells also were transfected
with hCAR as a negative control. After confirmation of the cell
surface expression of the receptor constructs (Fig. 2A), the
transfected cells were tested for the capacity to support reovi-
rus infection. Infected cells were quantified by indirect immu-
nofluorescence using an antireovirus serum (Fig. 2B). Only
CHO cells transfected with hJAM-A were capable of support-
ing an efficient infection of each of the three prototype reovirus
strains, whereas cells transfected with hJAM-B and hJAM-C
did not support the infection of any of these strains in excess of
that supported by cells transfected with hCAR (Fig. 2C).
Therefore, the JAM family member JAM-A, but not JAM-B
or JAM-C, functions as a receptor for prototype strains of
reovirus.
JAM-A serves as a receptor for field-isolate strains of reo-
virus. Strains of each of the three reovirus serotypes have been
isolated from many mammalian hosts over a period in excess of
50 years (29, 31). A type 3 reovirus strain isolated from the
cerebrospinal fluid of a child with meningitis is capable of using
JAM-A as a receptor (64). However, the receptor-binding
properties of other field-isolate strains have not been reported.
To determine whether JAM-A is used as a receptor by other
field-isolate strains of reovirus, we transfected CHO cells with
hJAM-A, hJAM-B, or hJAM-C and tested them for the capac-
ity to support reovirus infection. Ten strains, encompassing
four type 1, two type 2, and four type 3 viruses (Table 1), were
used in these experiments. In parallel with the findings for
prototype reovirus strains, each of the field-isolate strains
tested was capable of utilizing hJAM-A, but not hJAM-B or
hJAM-C, as a receptor (Fig. 3).
Analysis of deduced 1 amino acid sequences for JAM-A-
binding reovirus strains. To gain insight into the 1 residues
that mediate interactions between reoviruses and JAM-A, we
analyzed the amino acid sequences of the 1 proteins of the 3
prototype and 10 field-isolate strains chosen for study. For
these experiments, we determined the 1-encoding S1 gene
sequences of the strains T1C23/59, T1C50/60, T1Neth/84,
T1Neth/85, T2Neth/73, and T2Neth/84 and compared these
sequences to those reported previously (Table 1). RT-PCR
primers complementary to the nontranslated regions of the
type 1 and type 2 S1 genes were designed to facilitate the
amplification of entire S1 genes from infected L-cell lysates.
To define the evolutionary relationships of the S1 gene se-
quences determined for this study with those of the other
reovirus strains sequenced to date, we constructed phyloge-
netic trees by using variation in the 1-encoding S1 gene nu-
cleotide sequences and the maximum parsimony method as
applied in the program PAUP (Fig. 4). The most noteworthy
feature of the S1 phylogenetic tree is that the strains clustered
into distinct lineages based on their serotypes. A phylogenetic
tree generated by using the same data set and the neighbor-
joining algorithm of the phylogenetic analysis program
MacVector (MacVector 2001, version 7.1.1) had a topology
identical to that of the tree generated by PAUP (data not
shown). Therefore, our phylogenetic analysis indicates that the
S1 genes of reovirus strains cluster tightly into three lineages
defined by serotype. Concordantly, changes in the deduced
amino acid sequences of the 1 protein within a given serotype
are confined to a small number of residues. Since each of the
strains investigated for this study was capable of using JAM-A
as a receptor, the locations of these changes provide clues
about areas that can vary in surface structure without impeding
the capacity to engage this molecule. Thus, these changes de-
fine areas that are unlikely to interact with JAM-A.
Sequence variability within type 3 1 protein. Structural
information is available for the T3D/55 1 protein (16). We
therefore carried out a structure-based comparison of the de-
duced amino acid sequences of the 1 proteins of type 3
field-isolate strains with that of the prototype T3D/55 to define
regions of conserved and variable sequences within a serotype
(Fig. 5). Substantial variability is seen between residues 240
and 250, a region that lies just N-terminal to the first -spiral
repeat in the crystallized fragment and is disordered in the
crystal structure. The 1 fragment was obtained by trypsin
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cleavage of a longer construct after residue Arg245 (16). The
fact that trypsin cleaves 1 at only this position suggests that
Arg245 lies in an exposed loop that likely possesses some
flexibility. Exposed areas in the second and third -spiral re-
peats of the crystallized fragment also contain several substi-
tutions. Because these areas are variable, they are unlikely to
contribute significantly to JAM-A binding.
Most of the remaining substitutions are located at the top of
the 1 trimer, forming a highly variable “plateau” that is also
unlikely to bind to JAM-A. Some of the observed variations on
FIG. 1. JAM-A blockade reduces infection of prototype reovirus strains. HeLa cells at equivalent degrees of confluence were pretreated with
PBS, an hCAR-specific antiserum as a control, or the hJAM-A-specific MAb J10.4 prior to adsorption with T1L/53, T2J/55, or T3D/55 at an MOI
of 0.1 FFU per cell. After incubation for 20 h, the cells were fixed and permeabilized with methanol. Newly synthesized viral proteins were detected
by the incubation of cells with a polyclonal rabbit antireovirus serum followed by incubation with an anti-rabbit immunoglobulin–Alexa-546 serum
for the visualization of infected cells by indirect immunofluorescence. (A) Representative fields of view. (B) Reovirus-infected cells were quantified
by counting fluorescent cells in a minimum of three random fields of view per well for three wells at a magnification of 20. The results are
presented as the mean FFU per field. Error bars indicate standard deviations.
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the plateau are anticipated to alter the structure of the mole-
cule. For example, the replacement of Ser435 with Met in
T3D9/61 and T3D18/61 is likely to cause significant structural
changes, as Ser435 is partially buried in the T3D/55 structure
(16). Because they are exposed at the protein surface, the
polymorphisms seen on the plateau may allow viral escape
from antibody recognition. In contrast, the lower portion of the
head domain is highly invariant, suggesting that the base of the
1 head is primarily responsible for interactions with JAM-A.
Sequence variability within 1 proteins of the three reovirus
serotypes. An alignment of the deduced 1 amino acid se-
quences for all of the strains chosen for study showed that only
36 of the 210 residues in the crystallized fragment of T3D/55
1 (16) are conserved (Fig. 6). There is substantially more
variability among the serotypes than that within each serotype.
Mapping of the conserved residues onto the crystal structure of
T3D/55 1 showed that many of these residues are buried,
especially those located at the base of the 1 head-trimer
interface (Fig. 6). A large fraction of the remaining conserved
residues cluster in a single, solvent-exposed region at the lower
edge of the -barrel. Again, the regions that are most variable
within type 3 1 (the -spiral region and the “top” of the
trimer) are also most variable among the different serotypes. In
contrast, an extended, contiguous area of conserved residues is
located at the base of the head domain, and additional, smaller
areas of conservation are found along the side of this domain.
Because these regions are conserved in the JAM-A-binding
strains investigated here, they mark potential contact points for
this receptor.
The large conserved area at the base of the head domain is
formed primarily by a stretch of residues (Asn369 to Glu384 in
T3D/55 1) within a 310 helix and a long loop between
-strands D and E (16) (Fig. 6). This region also includes
Trp421 at the end of -strand F. The conserved region is fairly
hydrophobic, with the side chains of Val371, Leu379, and
Trp421 accounting for a large portion of the surface area
predicted to be involved in JAM-A binding. A second, smaller
cluster of conserved residues (Leu331, Trp333, Ile360, and
His438 in T3D/55 1) lies above this putative JAM-A-binding
surface, near the top of the trimer (Fig. 6). While most of the
side chains of these residues are buried, the structural features
of this cluster may contribute to receptor engagement. The
remaining surface area of the 1 trimer, especially near the top
of the head and the head-to-head contacts, is almost entirely
devoid of conserved residues.
A neutralization-resistant variant of reovirus T3D/55 uses
JAM-A as a receptor. Variants of T3D/55 selected for their
resistance to neutralization by the use of MAb 9BG5 (55) have
a mutation at Asp340 or Glu419 in the 1 head (7) (Fig. 5B).
These variants have alterations in central nervous system
(CNS) tropism following infections of newborn mice (54). The
single mutation in variant K of 1, Glu419 to Lys (7), segre-
gates genetically with the altered growth and tropism of this
virus in the murine CNS (32). To determine whether a neu-
tralization-resistant variant of T3D/55 retained the capacity to
use JAM-A as a receptor, we treated HeLa cells with PBS, an
hCAR-specific antiserum as a negative control, or the hJAM-
A-specific MAb J10.4 prior to infection with variant K. In-
fected cells were quantified by indirect immunofluorescence
using an antireovirus serum (Fig. 7). The treatment of cells
with increasing concentrations of the JAM-A-specific MAb
J10.4 resulted in a dose-dependent inhibition of viral infection,
while the CAR-specific antiserum had no effect on viral infec-
tivity. At the maximal concentration of MAb J10.4 used (100
	g per ml), infectivity was nearly abolished, demonstrating that
variant K is capable of using JAM-A as a receptor (Fig. 7).
FIG. 2. CHO cells transfected with hJAM-A support growth of
prototype reovirus strains. (A) CHO cells were transiently transfected
with a plasmid encoding hCAR, hJAM-A, hJAM-B, or hJAM-C. Fol-
lowing incubation for 24 h to permit receptor expression, cells were
incubated with receptor-specific MAbs, and the cell surface expression
of receptor constructs was assessed by flow cytometry. (B) Transfected
CHO cells at equivalent degrees of confluence were adsorbed with
T1L/53, T2J/55, or T3D/55 at an MOI of 0.1 FFU per cell. Reovirus
proteins were detected by indirect immunofluorescence at 20 h postin-
fection. Representative fields of view are shown. Magnification, 20.
(C) Reovirus-infected cells were quantified by counting fluorescent
cells in five random fields of view per well for three wells. The results
are presented as the mean FFU per field. Error bars indicate standard
deviations.
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Thus, the mechanism of the altered pathogenicity of variant K
appears to be independent of JAM-A utilization.
DISCUSSION
An examination of receptor usage by diverse virus families,
including arenaviruses (11, 53), adenoviruses (9, 27, 51, 72),
and measles virus (20, 35, 61), has led to the discovery that
receptor usage by some viruses varies based on the viral clade,
serotype, or adaptation to passaging in cell culture. We under-
took this study to determine whether JAM-A is used as a
receptor by both prototype and field-isolate strains of reovi-
ruses. The results demonstrate that each of the prototype and
field-isolate reovirus strains tested, regardless of their sero-
type, species, or geographical region of isolation, is capable of
utilizing JAM-A as a receptor.
Prior to this work, sequence information for the S1 gene
segments of type 1 and type 2 reovirus strains was limited to
the prototype strains T1L/53 and T2J/55. In this study, we
determined the S1 sequences of four type 1 and two type 2
field-isolate strains. A phylogenetic analysis of the deduced
1-encoding S1 gene sequences revealed that these reovirus
field-isolate strains are associated with discrete lineages de-
fined by serotype. Given that all reovirus strains tested to date
FIG. 3. Expression of JAM-A confers infectivity on field-isolate reovirus strains. CHO cells were transiently transfected with a plasmid
encoding hCAR, hJAM-A, hJAM-B, or hJAM-C. Following incubation for 24 h to permit receptor expression, the cells were adsorbed with the
indicated field-isolate strains at an MOI of 1 FFU per cell. Reovirus proteins were detected by indirect immunofluorescence at 20 h postinfection
and quantified by counting of the fluorescent cells in three random fields of view per well for three wells. The results are presented as the mean
FFU per field. Error bars indicate standard deviations.
FIG. 4. Phylogenetic relationships among S1 gene nucleotide sequences of 13 reovirus strains. A phylogenetic tree for the 1-encoding S1 gene
sequences of the strains shown in Table 1 was constructed by using the maximum parsimony method as applied in the program PAUP. The tree
is rooted at its midpoint. Bootstrap values of 
50% (indicated as a percentage of 1,000 repetitions) for major branches are shown at the nodes.
Bar, distance resulting from 10 nucleotide changes.
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FIG. 5. Sequence conservation and structural variability within the type 3 1 protein. (A) Alignment of deduced amino acid sequences of the
1 proteins of prototype strain T3D/55 and four type 3 field-isolate strains. The alignment was generated by using the program ALSCRIPT (5),
with default conservation parameters applied according to the following color scheme: red, identical residues; orange, conserved residues at 80%
conservation; yellow, conserved residues at 60% conservation; white, nonconserved residues. The 80% conservation threshold identifies closely
related amino acids (e.g., Ile and Leu), whereas the 60% threshold identifies more distantly related amino acids (e.g., Ser and Ala, both of which
have small side chains). The amino acid positions in the alignment are numbered above the sequences. The gray line indicates residues present
in the crystallized fragment of T3D/55 1 (16). (B) Structure of the 1 trimer, with residues colored according to the same color code as that
used for panel A. Four different views are shown. For each of the views, two 1 monomers are shown in surface representation, and the other
is depicted as a blue ribbon tracing corresponding to the -carbon backbone. The first three views each differ by 90° along a vertical axis; the
fourth view shows the molecule in the third view after rotation by 90° along a horizontal axis. The positions of residues 340 and 419 are marked
in the third panel from the left.
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are capable of using JAM-A as a receptor, it seems plausible
that 1 interacts with JAM-A through residues that are con-
served among the serotypes, including the newly characterized
type 1 and type 2 field-isolate strains. The observation that
JAM-A is used as a receptor by all reovirus strains tested was
unexpected since the 1 protein is highly divergent among the
three serotypes. For example, a sequence analysis of the pro-
totype strains revealed that the 1 head domains of T1L/53
and T2J/55 share 50% identical residues, while those of T1L/53
and T3D/55 share only 27% of their residues.
Substantial evidence has accumulated to suggest that the 1
head domain binds to cellular receptors. Truncated forms of
1 containing only the head domain are capable of specific cell
interactions (22, 23). Concordantly, proteolysis of T3D/55 viri-
ons leads to the release of a C-terminal receptor-binding frag-
ment of 1 (residues 246 to 455) (13) and a resultant loss in
infectivity (39). This fragment of 1 is capable of binding to
JAM-A on a biosensor surface with an affinity in the nanomo-
lar range (3). Preliminary findings from our laboratory indicate
that an even smaller fragment of T3D/55 1, corresponding to
the head domain and a single -spiral repeat, is capable of
binding to JAM-A (K. M. Guglielmi, P. Schelling, T. Stehle,
and T. S. Dermody, unpublished observations). Thus, the 1
head promotes interactions with JAM-A that are distinct from
the interactions with sialic acid mediated by the 1 tail.
While most of the residues conserved among the 1 proteins
of the strains tested are scattered throughout the molecule, an
examination of the 1 surface revealed a single extended patch
of conserved residues at the lower edge of the 1 head. We
think that this region may form part of a JAM-A-binding
surface. This conserved region is formed mostly by residues in
the vicinity of a long loop connecting -strands D and E of the
eight-stranded -barrel that forms the 1 head. Although it is
easily accessible to ligands, this site is somewhat recessed into
FIG. 7. JAM-A is used as a receptor for a neutralization-resistant
variant of reovirus T3D/55. HeLa cells at equivalent degrees of con-
fluence were pretreated with PBS, an hCAR-specific antiserum, or the
hJAM-A-specific MAb J10.4 prior to adsorption with variant K at an
MOI of 1 FFU per cell. Reovirus proteins were detected by indirect
immunofluorescence at 20 h postinfection. (A) Representative fields of
view. (B) Reovirus-infected cells were quantified by counting fluores-
cent cells in three random fields of view per well for three wells. The
results are presented as the mean FFU per field. Error bars indicate
standard deviations.
FIG. 6. Sequence conservation and structural variability within the 1 proteins of the three reovirus serotypes. (A) Alignment of deduced
amino acid sequences of the 1 proteins of 3 prototype and 10 field-isolate reovirus strains. The alignment was generated by using ALSCRIPT
and the scheme described in the legend to Fig. 5. Gaps in the aligned sequences are indicated by dots. (B) Mapping of residues onto the 1
structure, using the same color code as that depicted in Fig. 5. The four views correspond to those in Fig. 5B.
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the protein surface and is surrounded by protruding, noncon-
served residues on all three edges of the trimer. Only residues
from a single monomer contribute to the putative JAM-A-
binding region and its borders, and the regions are not involved
in 1 intersubunit contacts. Thus, the location of conserved
residues within the trimer suggests that each 1 monomer can
independently bind to a JAM-A molecule.
Although it may serve as the primary contact point for the
receptor, the putative JAM-A-binding site in 1 is relatively
small, measuring about 15 Å long and 10 Å wide. Most other
interactions between viral ligands and proteinaceous receptors
cover somewhat larger areas. It is therefore likely that addi-
tional regions of 1 contribute to interactions with JAM-A. We
noted that the putative JAM-A-binding site lies at the lower
edge of a large, concave surface formed by -strands B, A, D,
and G of 1. Residues on this surface, which almost entirely
covers one side of the -barrel, would easily be accessible to a
receptor and do not participate in intersubunit contacts. The
top of the 1 head is formed by three prominent protrusions,
with one coming from each -barrel. These protrusions are
entirely devoid of conserved residues among the serotypes and
also exhibit significant sequence drift within type 3 1 proteins.
It is therefore highly unlikely that the top of the 1 head
participates in receptor binding, again implicating regions on
the side of each -barrel as the most likely areas of contact
with JAM-A.
Neutralization-resistant variants of the reovirus T3D/55 se-
lected by using the 1-specific MAb 9BG5 contain mutations
in the 1 head that segregate genetically with alterations in
neural tropism (7, 32, 54, 55). Since reovirus tropism in the
murine CNS is determined at least in part by 1-receptor
interactions (19, 60), it is possible that the antibody-selected
mutations in the 1 head alter receptor binding. However, we
found that variant K, which has a Glu-to-Lys mutation at
amino acid 419, uses JAM-A as a receptor. This observation
suggests that the mutation in 1 of variant K alters the inter-
actions of this strain with cell surface receptors other than
JAM-A or influences a postattachment step in reovirus repli-
cation. It is noteworthy that amino acid 419 is adjacent to the
1 head trimer interface in the vicinity of amino acid 340 (16)
(Fig. 5), which is also targeted for mutation in neutralization-
resistant variants of T3D/55 (7). It is possible that mutations at
these sites alter 1 subunit interactions required for viral as-
sembly or disassembly.
Reovirus serotypes exhibit striking differences in tropism
and pathogenesis in the murine CNS. Type 1 reoviruses spread
to the CNS hematogenously and infect ependymal cells (65,
70), resulting in subacute hydrocephalus (69). In contrast, type
3 reoviruses spread to the CNS by neural routes and infect
neurons (38, 65, 70), causing lethal encephalitis (59, 69). An
analysis of reassortant viruses containing gene segments de-
rived from T1L/53 and T3D/55 demonstrated that the pathway
of viral spread in the host (65) and tropism for neural tissues
(19, 70) segregate with the 1-encoding S1 gene. These find-
ings suggest that 1 determines the CNS cell types that serve as
targets for reovirus infection, presumably by its capacity to
bind to receptors expressed by specific CNS cells. Since all
strains of reovirus tested are capable of utilizing JAM-A as a
receptor, the engagement of JAM-A alone does not explain
the differences in tropism and virulence displayed by the dif-
ferent reovirus serotypes in the murine CNS. It is possible that
JAM-A serves as a serotype-independent reovirus receptor at
some sites within the host and that other receptors, perhaps
carbohydrate in nature, confer serotype-dependent tropism. In
support of a role for cell surface carbohydrates in reovirus
disease, the capacity to bind sialic acid enhances the spread of
type 3 reoviruses within the host and targets the virus to bile
duct epithelial cells, leading to obstructive jaundice (4). It is
also possible that serotype-dependent differences in pathogen-
esis are influenced by one or more postbinding events.
The role of JAM-A utilization in reovirus infections in vivo
is not known. JAM-A is expressed on many cell types, includ-
ing intestinal epithelium, bile duct epithelium, lung epithelium,
leukocytes, and CNS endothelial cells (36), which serve as sites
of reovirus infection in mice (68). It will be interesting to
determine whether JAM-A functions as a reovirus receptor at
these sites in infected animals. Mice with a targeted disruption
of the JAM-A gene are viable and fertile (12). These mice
exhibit an accelerated migration of dendritic cells to lymph
nodes, which is associated with enhanced contact hypersensi-
tivity (12). No other developmental or immune abnormalities
have been noted. Studies of reovirus infections using JAM-A-
deficient animals should clarify the function of JAM-A in re-
ovirus pathogenesis and disease.
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B. A PLASMID-BASED REVERSE GENETICS SYSTEM FOR 
ANIMAL DOUBLE-STRANDED RNA VIRUSES 
 
Prior to the publication of this report, an entirely plasmid-based reverse-genetics 
system did not exist for any dsRNA virus of the Reoviridae family. Development of this 
strategy enabled the selective introduction of desired mutations in each viral gene 
segment and recovery of the resultant mutant viruses. In addition to reporting the design 
of the reverse genetics system, experiments using mutant viruses were described in this 
paper. These viruses were tested in vitro and in vivo for various traits including outer-
capsid protease susceptibility and pathogenesis in mice. My contribution to this 
manuscript included infection of mice with viruses containing mutations in the 
attachment protein σ1 that altered susceptibility of σ1 to intestinal proteases.  
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Mammalian orthoreoviruses (reoviruses) are
highly tractable experimental models for stud-
ies of double-stranded (ds) RNA virus rep-
lication and pathogenesis. Reoviruses infect
respiratory and intestinal epithelium and dis-
seminate systemically in newborn animals. Until
now, a strategy to rescue infectious virus from
cloned cDNA has not been available for any
member of the Reoviridae family of dsRNA
viruses. We report the generation of viable reo-
virus following plasmid transfection of murine
L929 (L) cells using a strategy free of helper vi-
rus and independent of selection. We used the
reovirus reverse genetics system to introduce
mutations into viral capsid proteins s1 and s3
and to rescue a virus that expresses a green
fluorescent protein (GFP) transgene, thus dem-
onstrating the tractability of this technology.
The plasmid-based reverse genetics approach
described here can be exploited for studies
of reovirus replication and pathogenesis and
used to develop reovirus as a vaccine vector.
INTRODUCTION
Reoviruses are members of the Reoviridae family, which
includes several genera that cause disease in humans
and animals. Chief among these are the rotaviruses, which
are the most common cause of viral gastroenteritis in hu-
man infants (Kapikian et al., 2001). Reoviruses infect the
respiratory and gastrointestinal tracts of virtually all mam-
mals, including humans (Tyler, 2001). However, disease
associated with reovirus infection occurs primarily in the
very young (Tyler et al., 2004). Reoviruses are highly viru-
lent in newborn mice, the preferred experimental system
for studies of reovirus pathogenesis, and produce injuryCeto a variety of host tissues, including the central nervous
system (CNS), heart, and liver (Tyler, 2001).
Reoviruses contain a genome of 10 dsRNA gene seg-
ments enclosed in two concentric protein shells, termed
outer capsid and core. Reovirus infection is initiated by
viral attachment to host cells via the filamentous attach-
ment protein s1 (Furlong et al., 1988). The s1 protein en-
gages cell-surface carbohydrate (Chappell et al., 1997,
2000) and junctional adhesion molecule-A (JAM-A) (Bar-
ton et al., 2001b; Campbell et al., 2005), an integral com-
ponent of intercellular tight junctions (Martin-Padura et al.,
1998). Following attachment to the cell surface, reovirus
internalization is mediated by b1 integrins (Maginnis
et al., 2006), most likely via clathrin-dependent endocyto-
sis (Ehrlich et al., 2004). In the endocytic compartment, vi-
ral outer-capsid proteins s3 and m1/m1C are cleaved by
acid-dependent cysteine proteases (Baer and Dermody,
1997; Ebert et al., 2002), resulting in generation of infec-
tious subvirion particles (ISVPs) (Borsa et al., 1981). During
ISVP formation, s3 is removed and a hydrophobic con-
former of m1/m1C is exposed, facilitating endosomal mem-
brane penetration and delivery of transcriptionally active
reovirus core particles into the cytoplasm (Chandran
et al., 2002; Odegard et al., 2004), where the remainder
of the replication cycle occurs.
With the exception of dsRNA viruses, a plasmid-based
reverse genetics system exists for all major groups of an-
imal RNA viruses, including bornaviruses, bunyaviruses,
coronaviruses, flaviviruses, orthomyxoviruses, paramyxo-
viruses, picornaviruses, and rhabdoviruses (Table S1 in
the Supplemental Data available with this article online).
Despite extensive efforts in several laboratories, genera-
tion of an animal dsRNA virus entirely from cloned cDNAs
has not been achieved. This critical technological gap is
perhaps the single most important limitation to studies
of these viruses. Previous efforts on reovirus and rotavirus
reverse genetics have resulted in entirely RNA-based
(Roner et al., 1997) or partially plasmid-based (Komoto
et al., 2006) systems that permit replacement of one or
two viral genes. These approaches have been used toll Host & Microbe 1, 147–157, April 2007 ª2007 Elsevier Inc. 147
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Reverse Genetics for ReovirusFigure 1. Experimental Strategy to Generate Reovirus from Cloned cDNA
(A) Prototype reovirus gene segment cDNA in plasmid. Cloned cDNAs representing each of the ten full-length reovirus RNA gene segments are
flanked by the bacteriophage T7 RNA polymerase promoter (T7P) and the antigenomic hepatitis delta virus (HDV) ribozyme (Rib).
(B) Schematic of approach. The ten reovirus cDNA constructs are transfected into murine L cells expressing T7 RNA polymerase from recombinant
vaccinia virus strain rDIs-T7pol, which is replication defective. Nascent transcripts correspond to viral mRNAs containing the native 50 end. Self
cleavage by the HDV ribozyme generates the native viral 30 end. Following 5 days of incubation, transfected cells are lysed by freeze-thaw, and viable
viruses rescued from cloned cDNAs are isolated by plaque assay using L cells.
(C) Kinetics of virus production following plasmid transfection of L cells. Cells were transfected with plasmid DNA according to the protocol in (B) and
lysed at the intervals shown. Viral titers in cell lysates were determined by plaque assay.
(D) Infectious center assay following plasmid transfection of L cells. Cells were transfected with plasmid DNA, trypsinized at the intervals shown post-
transfection, washed, counted, diluted, and applied directly to monolayers of untreated L cells. The number of the infectious centers was determined
by plaque assay.rescue temperature-sensitive reovirus strains (Roner
et al., 1997), define packaging signals in reovirus RNAs
(Roner and Steele, 2007), and isolate rotaviruses contain-
ing engineered changes in the viral attachment protein
(Komoto et al., 2006). However, neither the reovirus nor
rotavirus reverse genetics systems in their current config-
urations permit selective introduction and recovery of
desired mutations in each viral gene segment.
We report the development of an entirely plasmid-
based reverse genetics system for mammalian reovirus
in which viable viruses are generated from cloned cDNAs.
Neither helper virus nor coexpression of viral replication
proteins is required for recovery of wild-type (WT) virus
or engineered viral mutants. Point mutations introduced
into viral capsid proteins s1 and s3 were used to define
sequences that govern susceptibility to cleavage by intes-
tinal proteases. We also recovered a recombinant virus
that expresses green fluorescent protein (GFP) by re-
placement of the s3 open reading frame (ORF) with
GFP. The establishment of plasmid-based reverse genet-
ics for reovirus will allow heretofore technically unap-
proachable problems in dsRNA virus biology to be stud-
ied, provide a platform for development of analogous
marker rescue systems for other segmented dsRNA
viruses, and foster exploration of reovirus as a vaccine148 Cell Host & Microbe 1, 147–157, April 2007 ª2007 Elseviervector to elicit protective immunity against a variety of
mucosal pathogens.
RESULTS
Generation of Viable Reovirus from Cloned cDNA
To generate recombinant reovirus from cloned cDNAs,
plasmids encoding each of the ten viral gene segments
were engineered to facilitate transcription of full-length vi-
ral mRNAs under control of the bacteriophage T7 RNA
polymerase promoter, which directs transcription initia-
tion preferentially from a juxtaposed guanosine residue
(Milligan et al., 1987). As all reovirus (+)-sense RNAs are
terminated with a 50 guanosine (Furuichi et al., 1975a,
1975b), plasmid-generated transcripts are anticipated to
possess native 50 ends (Roner and Joklik, 2001) (Fig-
ure 1A). Murine L929 fibroblast (L) cells, which efficiently
support reovirus replication (Barton et al., 2001a), were in-
fected with the attenuated, T7 RNA polymerase-express-
ing vaccinia virus strain rDIs-T7pol 1 hr prior to transfec-
tion with the ten reovirus cDNA plasmids (Figure 1B).
Nascent transcripts were synthesized with the hepatitis
delta virus (HDV) ribozyme fused to the 30 terminus, which
is expected to generate a native 30 end upon autocatalytic
removal (Roner and Joklik, 2001) (Figure 1A). Thus, thisInc.
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T1LS1
(A) Electropherotypes of T1L, T3D, rsT3D, and
rsT3D/T1LS1. Viral dsRNA was extracted from
purified virions and electrophoresed in an
SDS-polyacrylamide gel, followed by ethidium
bromide staining to visualize viral gene seg-
ments. Size classes of gene segments (L, M,
S) are indicated.
(B) Recombinant viruses contain a novel muta-
tion in the L1 gene. The single nucleotide differ-
ence in L1 unique to rsT3D and rsT3D/T1LS1
is shown in the alignment as an asterisk. The
G/A substitution at position 2205 is a signa-
ture change engineered into the cloned T3D
L1 cDNA used for marker rescue.
(C) Sequence analysis of L1 gene RT-PCR
products from rescued reoviruses. A fragment
of the L1 gene was amplified by one-step RT-PCR performed using viral dsRNA extracted from purified virions of T3D, rsT3D, and rsT3D/T1LS1.
Products were subjected to direct sequence analysis and compared to the L1 sequence of T3D. Shown are sequence chromatograms demonstrating
G/A substitution at position 2205 of the rsT3D and rsT3D/T1LS1 L1 genes.expression strategy should yield ten unique reovirus
mRNA species competent to complete all steps in the viral
RNA life cycle. Accordingly, rescued viruses were recov-
ered from cell-culture supernatants by plaque assay on
L cell monolayers (Figure 1C).
To ensure that viruses isolated following plasmid trans-
fection represented single clones, and to preclude con-
tamination of reovirus stocks by rDIs-T7pol, all viruses
were isolated by plaque purification using L cell mono-
layers. rDIs-T7pol is replication defective and produces
no detectable growth in mammalian cells (Ishii et al.,
2002). Concordantly, no viral plaques arose on L cell
monolayers when the cotransfections were prepared
with nine of the ten reovirus marker-rescue plasmids
(data not shown). Furthermore, vaccinia virus proteins
were not detected by immunoblot analysis of second-
passage stocks of plaque-purified reoviruses (data not
shown).
Infectious center assays were performed to assess the
efficiency of reovirus infection in plasmid-transfected L
cells. At 24–48 hr posttransfection, times corresponding
to the primary round of infection, eight or fewer infectious
centers per 106 cells were detected (Figure 1D). The num-
ber of infectious centers increased substantially between
48 and 72 hr posttransfection to 18 to 90 per 106 cells,
suggesting that a secondary round of infection had en-
sued by the 72 hr time point. Viral titer in transfection ly-
sates was below the limit of detection (10 PFU/ml) at
24 hr but was detectable at 48 hr and increased logarith-
mically at time points thereafter (Figure 1C). The ratio of
viral PFU in transfection lysates to infectious centers
was 10 to 100 at 48 and 72 hr. These results indicate
that initiation of productive reovirus replication from trans-
fected plasmids is inefficient, with approximately 1 cell per
105 to 106 cells giving rise to, on average, 10 to 100 viable
virus particles that establish infection of the culture. In our
experiments, yields of WT virus 5 days after plasmid
transfection are regularly in the range of 104–106 PFU/ml
(Figure 1C).Cell HSeparation of reovirus genomic dsRNA using SDS-
PAGE produces unique electrophoretic patterns that can
be used to discriminate different viral strains (Barton
et al., 2001a). To confirm that viruses isolated using the
plasmid-based rescue procedure contained the expected
combination of gene segments, genomic dsRNA isolated
from recombinant strain (rs) T3D and rsT3D/T1LS1was re-
solved in SDS-polyacrylamide gels and visualized by
ethidium bromide staining (Figure 2A). The electrophero-
type of rsT3D was indistinguishable from that of strain
T3D, the origin of the cloned cDNA sequences used to
generate rsT3D. Likewise, rsT3D/T1LS1 displayed an
electropherotype consistent with nine cloned gene seg-
ments derived from T3D and a single cloned gene seg-
ment, S1, derived from strain T1L. To exclude the possibil-
ity of contamination, a silent point mutation, G to A at
nucleotide 2205, was introduced into the L1 gene of all
virus strains generated from cloned cDNAs (Figure 2B).
This change has not been observed in any reported T3D
L1 sequence (Wiener and Joklik, 1989) and serves as a sig-
nature for viruses derived through plasmid-based rescue.
As anticipated, sequence analysis of rsT3D and rsT3D/
T1LS1 revealed the expected G to A substitution (Fig-
ure 2C), confirming the plasmid origins of these isolates.
Characterization of Reoviruses Generated
by Plasmid Transfection
Reoviruses replicate and assemble within cytoplasmic in-
clusions in infected cells (Fields, 1971). Viral inclusions
contain dsRNA (Silverstein and Schur, 1970), viral proteins
(Fields, 1971), and both complete and incomplete viral
particles (Fields, 1971). Reovirus strain T3D forms large
globular inclusions that localize to the perinuclear space
(Parker et al., 2002). To determine whether rsT3D forms vi-
ral inclusions in a manner similar to native T3D, cells were
infected with T3D and rsT3D and processed 18 hr postin-
fection for image analysis by confocal microscopy (Fig-
ure 3A). Both T3D and rsT3D formed morphologically
indistinguishable large globular inclusions that wereost & Microbe 1, 147–157, April 2007 ª2007 Elsevier Inc. 149
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combinant Reoviruses
(A) Immunofluorescence of cells infected with
T3D and rsT3D. L cells were mock infected or
infected with either T3D or rsT3D, stained at
18 hr postinfection with anti-mNS antiserum to
visualize reovirus inclusions (green) and TO-
PRO3 to visualize nuclei (blue), and imaged
by confocal laser scanning microscopy. Rep-
resentative digital fluorescence (top panel)
and DIC images (bottom panel) for mock-,
T3D-, and rsT3D-infected cells are shown.
Scale bar, 10 mM.
(B) One-step growth curve for T1L, T3D, rsT3D,
and rsT3D/T1LS1 in L cells (left) and MEL cells
(right). Cells were infectedwith virus, incubated
for the intervals shown, and lysed by freeze-
thaw. Viral titers in cell lysates were determined
by plaque assay. The results are presented as
the mean viral titers for triplicate experiments.
Error bars indicate SD.localized to the perinuclear compartment. We conclude
that recombinant rsT3D recapitulates a hallmark of native
T3D infection in cultured cells.
To confirm that the recombinant viruses exhibit replica-
tion kinetics similar to the native strains, T1L, T3D, rsT3D,
and rsT3D/T1LS1 were tested for infection of L cells and
MEL cells (Figure 3B). L cells support replication of all reo-
virus strains tested in our laboratory. In contrast, MEL cells
support replication of only sialic acid-binding reovirus
strains (Rubin et al., 1992; Chappell et al., 1997). T1L,
rsT3D/T1LS1, T3D, and rsT3D produced 1000-fold
yields of viral progeny in L cells. However, only sialic
acid-binding strains T3D and rsT3D were capable of effi-
ciently infecting MEL cells, producing yields in each
case of 100-fold, whereas strains T1L and rsT3D/
T1LS1 produced minimal yields of viral progeny in these
cells (<10-fold). Together, these data indicate that re-
combinant reoviruses display replication characteristics
indistinguishable from native strains.
Susceptibility of Attachment Protein s1
to Proteolytic Cleavage Attenuates Reovirus
Intestinal Infection and Systemic Spread
The s1 protein exhibits strain-specific differences in sus-
ceptibility to cleavage following in vitro treatment with in-
testinal proteases to generate ISVPs (Nibert et al., 1995;
Chappell et al., 1998). This difference in cleavage suscep-
tibility segregates with a single amino acid polymorphism150 Cell Host & Microbe 1, 147–157, April 2007 ª2007 Elseviein the tail domain of s1 (Figure 4A). Strains with a threonine
at residue 249 in s1 are susceptible to cleavage by trypsin
after Arg245, whereas those with an isoleucine at residue
249 are resistant to cleavage (Chappell et al., 1998). The
importance of sequence polymorphism at residue 249
has been confirmed in studies using expressed protein
(Chappell et al., 1998) and recoated core particles (Chan-
dran et al., 2001) but not with intact virions.
To determine whether the single Thr-Ile polymorphism
at residue 249 in s1 protein is sufficient to alter s1 cleav-
age susceptibility during treatment of virions with intesti-
nal proteases to generate ISVPs, we used plasmid-based
rescue to generate rsT3D-s1T249I, which differs from
rsT3D by the presence of an isoleucine in s1 at residue
249 (Table S2). Purified virions of rsT3D and rsT3D-
s1T249I were treated with trypsin and analyzed by SDS-
PAGE. As expected, a digestion pattern consistent with
formation of ISVPs (loss of s3 protein and generation of
the d fragment of m1C protein) was observed for both vi-
ruses (Figure 4B). However, the stability of rsT3D and
rsT3D-s1T249I s1 proteins differed. The band corre-
sponding to rsT3D s1 diminished in intensity immediately
after trypsin addition until it was eventually undetectable
(Figure 4B). However, the rsT3D-s1T249I s1 band was in-
tact even after 60 min of digestion. Thus, the T249I poly-
morphism is an independent determinant of s1 cleavage
susceptibility.
Proteolytic cleavage of s1 at a site adjacent to Thr249
releases the JAM-A-binding s1 head domain, leading tor Inc.
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(A) Model of s1 generated by adding five b spiral repeats to the N terminus of the crystallized fragment of s1 (Chappell et al., 2002). The three mono-
mers in the crystallized fragment are shown in red, yellow, and blue; themodel is shown in gray. The inset shows an enlarged view of the b spiral region
in s1 that influences susceptibility of the molecule to cleavage by intestinal proteases (Chappell et al., 1998). Side chains of Arg245 and Thr249 are
depicted in ball-and-stick representation.
(B) Electrophoretic analysis of viral structural proteins of rsT3D and rsT3D-s1T249I during treatment with trypsin to generate ISVPs. Purified
35S-methionine-labeled virions were treated with trypsin for the indicated intervals and loaded into wells of a 4%–20% polyacrylamide gradient
gel. After electrophoresis, the gel was prepared for fluorography and exposed to film. Samples of untreated virions appear in the lanes labeled
‘‘V.’’ Viral proteins are labeled. Positions of molecular weight standards (in kDa) are indicated. The experiments shown are representative of two per-
formed for each virus.
(C) Infectivity of rsT3D and rsT3D-s1T249I during treatment with trypsin to generate ISVPs. Purified virions were treated with trypsin at 37C for the
intervals shown. Titers of virus in the treatment mixtures were determined by plaque assay. The results are presented as the mean viral titers for trip-
licate experiments. Error bars indicate SD.diminished viral infectivity (Nibert et al., 1995). To test
whether rsT3D and rsT3D-s1T249I differ in infectivity after
protease treatment to generate ISVPs, purified virions of
each strain were exposed to trypsin for various intervals,
and titers of infectious virus in the treatment mixtures
were determined by plaque assay (Figure 4C). As ob-
served with WT T3D in previous experiments (Nibert
et al., 1995), rsT3D lost infectious titer rapidly after prote-
ase treatment. In contrast, titers of rsT3D-s1T249I re-
mained relatively stable throughout the assay time course.
Loss of infectivity of rsT3D correlated with kinetics of s1
cleavage (compare Figures 4B and 4C), indicating that
changes in viral infectivity after trypsin treatment are gov-
erned by the cleavage state of s1. Furthermore, both phe-
notypes are linked to a single s1 polymorphism at amino
acid 249.
Reovirus strains T1L and T3D differ in the capacity to in-
fect the murine intestine after peroral (PO) inoculation
(Bodkin et al., 1989), a property that segregates with the
viral S1 (encoding s1 and s1s) and L2 (encoding l2) genes
(Bodkin and Fields, 1989). Exposure of T3D to an intestinalCell Hwash results in s1 cleavage (Chappell et al., 1998), raising
the possibility that failure of T3D to infect the intestine is in
part attributable to s1 cleavage susceptibility. To test
whether susceptibility of s1 to proteolytic cleavage is as-
sociated with diminished T3D growth in animals, we as-
sessed the capacity of rsT3D and rsT3D-s1T249I to infect
the intestine and disseminate systemically following PO
inoculation (Figure 5A). Newborn mice were inoculated
perorally with each strain, and viral titers in the intestine
and brain were determined at 4, 8, and 12 days after inoc-
ulation. At all time points tested, titers of rsT3D-s1T249I in
the intestine were greater than those produced by rsT3D.
Furthermore, rsT3D-s1T249I produced greater titers in
the brain at days 8 and 12 than did rsT3D. However,
when inoculated by the intracranial (IC) route, rsT3D and
rsT3D-s1T249I produced equivalent titers (Figure 5B), al-
though rsT3D reached peak titers at earlier time points
than did rsT3D-s1T249I. These findings indicate that
a Thr-Ile polymorphism at amino acid 249 in T3D s1 con-
trols viral growth in the murine intestine and systemic
spread to the CNS.ost & Microbe 1, 147–157, April 2007 ª2007 Elsevier Inc. 151
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Polymorphism in Outer-Capsid Protein s3
Previous studies identified a tyrosine-to-histidine substi-
tution at amino acid 354 in T3D s3 as a key regulator of
the kinetics of virion-to-ISVP conversion in vitro (Wetzel
et al., 1997) and viral resistance to growth inhibition by
the cysteine protease inhibitor E64 (Baer and Dermody,
1997; Ebert et al., 2001). Tyr354 is located in the virion-
distal lobe of s3 adjacent to sites in the protein that are
cleaved during formation of ISVPs (Ebert et al., 2002)
(Figure 6A). The importance of this residue in viral replica-
tion has been deduced by analysis of reassortant viruses
containing WT and mutant s3 proteins (Wetzel et al.,
1997; Ebert et al., 2001; Clark et al., 2006) and analysis
of ISVPs recoated withWT andmutant forms ofs3 (Wilson
et al., 2002; Clark et al., 2006).
To determine whether the Y354H mutation in s3 is suf-
ficient to confer enhanced virion-to-ISVP conversion and
resistance to E64, we generated rsT3D-s3Y354H (Table
S2) and compared this virus to rsT3D for kinetics of s3
proteolysis following protease treatment in vitro. Virions
of each strain were treated with chymotrypsin for various
intervals and processed for analysis of viral structural
proteins by SDS-PAGE (Figure 6B). Treatment of rsT3D
and rsT3D-s3Y354H virions with chymotrypsin resulted
in degradation of s3 and cleavage of m1C to form d, indic-
Figure 5. rsT3D-s1T249I Infects the Murine Intestine and
Disseminates to the CNS
Titers of rsT3D and rsT3D-s1T249I after either PO (A) or IC (B) inocu-
lation. Mice were inoculated with virus and euthanized at the indicated
times postinoculation. Viral titers in organ homogenates were deter-
mined by plaque assay. The limit of detectionwas 100 PFU/ml of organ
homogenate. Each data point represents the average viral titer from 3
to 12 mice. Error bars indicate SD.152 Cell Host & Microbe 1, 147–157, April 2007 ª2007 Elsevierative of ISVP formation. Proteolysis of rsT3D-s3Y354H s3
during chymotrypsin treatment occurred with substan-
tially faster kinetics than that of rsT3D s3. This result indi-
cates that amino acid 354 in s3 protein is an independent
determinant of virion susceptibility to proteolytic digestion
and likely functions as an autonomous regulator of viral
disassembly in cellular endosomes.
The role of s3 mutation Y354H in virion disassembly in
cyto was investigated by quantifying yields of rsT3D and
rsT3D-s3Y354H after 24 hr of growth in L cells treated
with 0–200 mM E64 (Figure 6C). Both strains produced
yields of 1000 fold following growth in untreated cells.
However, yields of rsT3D-s3Y354H were 100-fold
greater than those of rsT3D following growth in cells
treated with 200 mM E64 (the highest concentration
tested). Therefore, a single mutation in s3, Y354H, regu-
lates resistance of reovirus to an inhibitor of cysteine pro-
teases within cellular endosomes.
Transduction of GFP by a Recombinant Reovirus
To determine whether reoviruses capable of expressing
a foreign gene can be recovered following plasmid trans-
fection, we introduced sequences encoding GFP into the
s3 ORF of the T3D S4 plasmid (Figure 7A). In this con-
figuration, GFP is expressed as a fusion protein incorpo-
rating amino acids 1–39 of s3 protein at the N terminus.
Recombinant virus rsT3D/S4-GFP was recovered follow-
ing plasmid transfection of L cells stably expressing WT
s3 protein, which is required for propagation of this strain
(Figure S1). RT-PCR analysis using primers specific for
T3DS4andGFPconfirmed incorporation of a recombinant
S4-GFP gene segment into rsT3D/S4-GFP (Figure 7B). In-
fection of L cells with rsT3D/S4-GFP resulted in expres-
sion of GFP and viral inclusion-forming proteins mNS and
sNS but not s3 (Figures 7C and 7D). The capacity of
rsT3D/S4-GFP to express GFP was not altered through
four passages (data not shown). These results demon-
strate that reovirus can be engineered to express foreign
genes.
DISCUSSION
The absence of DNA intermediates in the life cycle of RNA
viruses poses a technical challenge to genetic analysis of
viral phenotypes. Prior to the development of reverse ge-
netics, or ‘‘marker rescue,’’ for RNA viruses of animals, in
which plasmid-borne cDNAs of viral genomes initiate syn-
thesis of replication-competent RNAs, classical Darwinian
methods were used to select viral mutants that could be
subjected to correlative genetic studies—so-called ‘‘for-
ward genetics.’’ However, reverse genetics technology
permits testing of tightly focused, rational hypotheses
about complex questions of virus structure, virus-cell in-
teractions, and viral pathogenesis through direct engi-
neering of the viral genome without a need to devise com-
plicated selection strategies for isolation of viral mutants.
Furthermore, reverse genetics of RNA viruses has sup-
ported rapid generation of vaccines against these and
other infectious agents and propelled their use as geneInc.
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erates Proteolytic Disassembly of Reovirus
(A) Crystal structure of T3D s3 (Olland et al., 2001), in which cathepsin
L cleavage sites are depicted in blue between amino acids 243 and 244
and between 250 and 251 (Ebert et al., 2002). Surrounding residues,
from amino acids 241 to 253, are shown in yellow. The C-terminal res-
idues of s3, from amino acids 340–365, are colored red. Tyr354, which
is altered in several PI (Wetzel et al., 1997), D-EA (Ebert et al., 2001),
and ACA-D viruses (Clark et al., 2006), is shown in green. The virion-
distal end of s3 is at the top of the figure, and the virion-proximal
end and N terminus are at the bottom. The inset shows an enlarged
view of the boxed region of s3 using the same color scheme. Side
chains of amino acids 243, 244, 250, 251, and 354 are depicted in
ball-and-stick representation.
(B) Chymotrypsin treatment of rsT3D and rsT3D-s3Y354H. Purified
virions were treated with chymotrypsin for the indicated intervals
and loaded into wells of 10% polyacrylamide gels. After electrophore-
sis, the gels were stained with Coomassie blue. Viral proteins are la-
beled. The experiments shown are representative of two performed
for each virus.
(C) Growth of rsT3D and rsT3D-s3Y354H in L cells treated with E64. L
cells were preincubated in medium with or without E64 at the concen-
trations shown. The medium was removed, cells were adsorbed withCell Hdelivery vehicles (Blaney et al., 2006; Horimoto and
Kawaoka, 2006; Riezebos-Brilman et al., 2006).
We developed a fully plasmid-based reverse genetics
technology for mammalian reoviruses. This system per-
mits selective introduction of desired mutations into
cloned cDNAs encoding each of the ten viral gene seg-
ments, followed by isolation of mutant viruses from cells
transfected with the plasmid constructs. Moreover, gene
segment cDNAs can be manipulated to facilitate expres-
sion of a transgene. Importantly, recombinant viruses
are generated without a requirement for helper virus and
free of any selection. Thus, this new technology provides
virus for 1 hr, and fresh medium with or without E64 was added. After
24 hr incubation, viral titers in cell lysates were determined by plaque
assay. The results are presented as themean viral yields, calculated by
dividing titer at 24 hr by titer at 0 hr for each concentration of E64, for
triplicate experiments. Error bars indicate SD.
Figure 7. Expression of GFP by rsT3D/S4-GFP
(A) Schematic of pT7-S4GFP. The GFP ORF is flanked by S4 gene nu-
cleotides 1–149 and 769–1196.
(B) RT-PCR analysis of rsT3D and rsT3D/S4-GFP. Viral dsRNAwas ex-
tracted from purified virions and subjected to RT-PCR using primers
specific for T3D S4 and GFP sequences. Numbers delineate the S4
RNA nucleotide position corresponding to the 50 end of S4-specific
primers.
(C) Viral protein expression in cells infected with rsT3D/S4-GFP. L cells
were infected with rsT3D or rsT3D/S4-GFP at an MOI of 1 PFU per cell
and incubated for 24 hr. Cell lysates were analyzed by immunoblotting
using antibodies specific for mNS, sNS, and s3 proteins.
(D) Image analysis of cells infected with rsT3D/S4-GFP. L cells were in-
fected with rsT3D/S4-GFP, stained with antibodies specific for mNS
(blue) and s3 (red) proteins at 24 hr postinfection, and imaged by con-
focal laser scanning microscopy. Scale bar, 10 mM.ost & Microbe 1, 147–157, April 2007 ª2007 Elsevier Inc. 153
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nome in the context of infectious virus.
We used the newly developed plasmid-based reovirus
reverse genetics system to engineer mutations in the s1
and s3 proteins. These proteins form part of the viral outer
capsid, which is responsible for numerous major events in
reovirus interaction with the cell and host, including at-
tachment, disassembly within endosomes, penetration
of cell membranes, induction of apoptosis, growth in the
intestine, pathways of spread, neurovirulence, and tro-
pism within the CNS (for reviews, see Chandran and
Nibert, 2003; O’Donnell et al., 2003; Guglielmi et al., 2006).
Therefore, we initially applied reverse genetics technology
to the study of outer-capsid proteins to better understand
how these proteins mediate critical steps in reovirus
replication and disease.
The infectivity of ISVPs of reovirus strain T1L in L cells is
approximately 10-fold greater than that of T3D ISVPs
(Nibert et al., 1995). This difference in infectivity is hypoth-
esized to be a direct result of s1 cleavage (Nibert et al.,
1995; Chappell et al., 1998), presumably due to removal
of the JAM-A-binding region of the molecule. Although
the T249I substitution in expressed T3D s1 renders it re-
sistant to cleavage by trypsin (Chappell et al., 1998), until
now it has not been possible to define the role of s1 cleav-
age in T3D infectivity for lack of means to generate a mu-
tant T3D virus with the T249I change. This virus has been
generated using reverse genetics, and our findings indi-
cate that cleavage susceptibility of viral attachment pro-
tein s1 due to a single polymorphism at amino acid posi-
tion 249 is the basis for reduced infectivity of T3D ISVPs
relative to virions (Figure 4C) and contributes to dimin-
ished growth of T3D in the murine intestine following PO
inoculation (Figure 5A).
Previous studies of T3D-derived reovirus strains with
altered disassembly kinetics point to a critical role for
sequences in the virion-distal, C-terminal lobe of s3 in
susceptibility to acid-dependent proteolysis. A C-terminal
Y354H mutation in s3 protein of strain T3D was selected
during persistent infection of L cells (PI viruses) (Wetzel
et al., 1997) and by serial passage of virus in L cells treated
with either E64 (D-EA viruses) (Ebert et al., 2001) or ammo-
nium chloride (ACA-D viruses) (Clark et al., 2006). Using
reovirus reverse genetics, the Y354H substitution was in-
troduced into a WT T3D genetic background, and the re-
sultant virus, rsT3D-s3Y354H, demonstrated accelerated
kinetics of s3 cleavage (Figure 6B) and diminished sensi-
tivity to the growth-inhibitory effects of E64 (Figure 6C).
Residue 354 is located in a position thought to be impor-
tant for controlling access to protease-hypersensitive re-
gions in s3, residues 208–214 and 238–242, thereby influ-
encing s3 cleavage kinetics (Jane´-Valbuena et al., 2002).
Therefore, it appears that residue 354 ins3 is a gatekeeper
for the viral outer capsid, serving to regulate the balance
between viral stability and an irreversible, proteolytically
triggered disassembly cascade committing the virion par-
ticle to either replication or inactivation.
We exploited the reovirus reverse genetics system to
develop a gene-delivery vehicle by replacing thes3ORF in154 Cell Host & Microbe 1, 147–157, April 2007 ª2007 Elsevierthe S4 plasmid with a GFP-encoding cDNA (Figure 7). The
resultant virus, rsT3D/S4-GFP, expresses GFP through
successive passages in cell culture. These results reveal
the potential for exploitation of reovirus as a gene-trans-
duction vector with application in the development of
new mucosal vaccines, more effective oncolytic agents
(Coffey et al., 1998), and high-level expression of foreign
genes in animal cells. Ideal reovirus vectors will contain
stable s1 proteins and combine excellent extracellular
stability with highly efficient intracellular disassembly.
We find that each of these parameters can be indepen-
dently adjusted through strategic alterations in outer-
capsid proteins. Manipulation of inner-capsid proteins
and the genomic RNA itself should allow construction of
viruses able to circumvent other aspects of virus-cell
and virus-host interactions that pose potential barriers to
antigen and gene delivery by reovirus.
Our results indicate that productive viral infection is es-
tablished in a small fraction of L cells, approximately 1 in
105–106 cells, transfected with plasmids encoding the
ten reovirus gene segments (Figure 1D). Thus, the reovirus
plasmid-based marker rescue system is suited to the iso-
lation of viable viral clones by plaque assay, followed by
expansion in cell culture to attain quantities of virus suffi-
cient for phenotypic analyses. Manipulations that severely
cripple viral replication or particle assembly aremore chal-
lenging to study because these changes may prohibit
virus isolation. However, recovery of a GFP-expressing vi-
rus, rsT3D/S4-GFP, demonstrates that marker rescue of
lethal mutations is possible by transcomplementation (in
this case with WT s3 protein) (Figure 7 and Figure S1).
This result also agrees with our previous finding that inhi-
bition of reovirus replication by RNAi-mediated reduction
of viral protein synthesis is reversible by transcomplemen-
tation with ectopically expressed WT protein (Kobayashi
et al., 2006). Furthermore, transcomplementation allows
precise definition through systematic mutational analysis
of functional domains in reovirus proteins that are essen-
tial for viral replication (Kobayashi et al., 2006). It should
be possible to apply this technique to the newmarker res-
cue system for delineation of structure-function relation-
ships in reovirus proteins and RNA.
Quantitative success of plasmid-initiated reovirus infec-
tion in this reverse genetics system probably is not limited
by the amount of template or transfection efficiency, since
the molar ratio of plasmid to target cell is approximately
5 3 104, and increasing the amount of plasmid does not
effect higher viral yields from cotransfection lysates
(data not shown). Furthermore, it does not appear that in-
fection efficiency is limited by the absence of viral replica-
tion proteins during early steps of replication because
high-level expression of the replication proteins m2, mNS,
and sNS, which collaborate to form viral inclusions in in-
fected cells (Mbisa et al., 2000; Broering et al., 2002;
Becker et al., 2003; Miller et al., 2003), did not enhance
viral recovery (data not shown). Perhaps the presence
of other viral or cellular factors associated with natural
infection by intact virion particles is required for maximal
reovirus infectivity.Inc.
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system has been described for any other dsRNA virus of
animals. Although each genus within this constellation of
viruses bears unique biologic characteristics and physio-
chemical properties, there are nonetheless numerous uni-
fying features of virion particle structure and replication
mechanisms that should allow principles and techniques
established in this study to be applied broadly across the
group. We expect that new insights into mammalian reovi-
rus replication learnedwith the use of this reverse genetics
system will be quickly extrapolated to other Reoviridae
family members, leading to accelerated development of
analogous marker-rescue technologies for those viruses.
EXPERIMENTAL PROCEDURES
Cells and Viruses
L cells and HeLa cells were maintained as described (Barton et al.,
2001a). Reovirus strains T1L and T3D are laboratory stocks originally
obtained from Dr. Bernard Fields. Virus was purified after growth in
L cells by CsCl-gradient centrifugation (Furlong et al., 1988). Purified
35S-methionine-labeled virions were prepared as described (Nibert
et al., 1995). Attenuated vaccinia virus strain rDIs-T7pol expressing
T7 RNA polymerase was propagated in chick embryo fibroblasts as
described (Ishii et al., 2002).
Plasmid Construction
Full-length reovirus cDNAs were amplified by RT-PCR using viral
dsRNA extracted from purified virions as template. Amplified cDNAs
were initially cloned into pBluescript II SK () (Stratagene) for the
T3D L1, L2, and L3 genes or pCR 2.1 (Invitrogen) for the T3D M1,
M2, M3, S1, S2, S3, and S4 genes and the T1L S1 gene (Table S3).
To generate pT7-L1T3D, pT7-L2T3D, pT7-L3T3D, pT7-M1T3D,
pT7-M2T3D, pT7-M3T3D, pT7-S2T3D, pT7-S3T3D, and pT7-S4T3D,
viral cDNA-containing fragments were subcloned into p3E5EGFP (Wa-
tanabe et al., 2004). Viral cDNAs fused at their native 50 termini to the
phage T7 RNA polymerase promoter were inserted into p3E5EGFP
by partial or complete replacement of plasmid sequences encoding
GFP and the Ebola virus leader and trailer, resulting in ligation of native
30 termini to the HDV ribozyme sequence. To generate pBacT7-S1T3D
and pBacT7-S1T1L, encoding the T3D S1 and T1L S1 genes, respec-
tively, S1 cDNAs fused to the T7 promoter and a portion of the HDV ri-
bozyme were first cloned into the BseRI site of p3E5EGFP, and frag-
ments containing the S1 gene flanked 50 by the T7 promoter and 30
by the HDV ribozyme and T7 terminator sequences were subcloned
into the XbaI site of pBacPAK8 (Clontech). pBacT7-S1T3D and pT7-
S4T3D were used as templates to generate mutant constructs
pBacT7-S1T3DT249I and pT7-S4T3DY354H, respectively, by intro-
duction of specific nucleotide substitutions using the QuickChange
site-directed mutagenesis kit (Stratagene) (Table S4). To generate
pT7-S4GFP, S4 nucleotide sequences 150–768 within pT7-S4T3D
were replaced with the GFP ORF. Nucleotide sequences of recombi-
nant plasmids were confirmed by DNA sequencing. Detailed descrip-
tion of cloning strategies is provided in the Supplemental Data.
Plasmid Transfection and Recovery of Recombinant Virus
Monolayers of L cells at approximately 90% confluence (33 106 cells)
in 60 mm dishes (Costar) were infected with rDIs-T7pol at an MOI of
0.5 TCID50. At 1 hr postinfection, cells were cotransfected with ten
plasmid constructs representing the cloned T3D genome—pT7-
L1T3D (2 mg), pT7-L2T3D (2 mg), pT7-L3T3D (2 mg), pT7-M1T3D
(1.75 mg), pT7-M2T3D (1.75 mg), pT7-M3T3D (1.75 mg), pBacT7-
S1T3D (2 mg), pT7-S2T3D (1.5 mg), pT7-S3T3D (1.5 mg), and pT7-
S4T3D (1.5 mg)—using 3 ml of TransIT-LT1 transfection reagent (Mirus)
per microgram of plasmid DNA. Following 0–5 days of incubation,
recombinant virus was isolated from transfected cells by plaque puri-Cell Hfication on monolayers of L cells (Virgin et al., 1988). Electrophoretic
analysis of viral dsRNA was performed as described (Wilson et al.,
1996). Confirmation of mutations in the S1, S4, and L1 genes of
recombinant viruses was performed using the Onestep RT-PCR kit
(Qiagen), gene-specific primer sets, and viral dsRNA extracted from
purified virions as template. PCR products were analyzed following
electrophoresis in Tris-borate-EDTA agarose gels or purified and sub-
jected directly to sequence analysis.
Infectious Center and Viral Yield Assays
L cells were cotransfected with ten plasmids corresponding to the T3D
genome as described. For infectious center assays, transfected cells
were released from plates by trypsin treatment at various intervals
posttransfection, washed, counted, diluted, and applied directly to
monolayers of untreated L cells (Dermody et al., 1995), which were
processed for plaque assay (Virgin et al., 1988). For viral yield assays,
transfected L cells were lysed by freezing and thawing, and viral titers
in cell lysates were determined by plaque assay (Virgin et al., 1988).
Immunofluorescence Detection of Reovirus Infection
Parental L cells or L cell transfectants selected for stable expression of
s3 protein (5 3 104) were plated on glass coverslips in 24-well plates
(Costar) and infected at an MOI of 10,000 (T3D and rsT3D) or 20,000
(rsT3D/S4-GFP) particles per cell. Following incubation at 37C for var-
ious intervals, cells were fixed and stained for mNS and s3 proteins as
described (Maginnis et al., 2006). Images were acquired using a Zeiss
LSM 510 META inverted confocal system (Carl Zeiss) with a Zeiss
inverted Axiovert 200M microscope and a Plan-APOCHROMAT
633/1.4 NA oil immersion DIC objective. Images were processed
using MetaMorph image analysis software (Molecular Devices).
Infectivity of Recombinant Viruses
Monolayers of L or L-s3 cells (2.5 to 5 3 105) in 24-well plates or sus-
pension cultures of MEL cells (53 105 cells/ml) were infectedwith virus
at an MOI of 1–2 PFU/cell. After 1 hr adsorption at room temperature,
the inoculum was removed, cells were washed twice with PBS, and
fresh medium was added. Cells were incubated at 37C for various in-
tervals, and viral titers in cell lysates were determined by plaque assay
(Virgin et al., 1988).
Analysis of Viral Capsid Proteins after Protease Treatment
Purified virions at a concentration of either 23 1012 particles/ml (tryp-
sin) or 9 3 1012 particles/ml (chymotrypsin) were digested with either
50 mg/ml of N a-p-tosyl-L-sulfonyl phenylalanyl chloromethyl ketone-
treated bovine trypsin (Sigma) or 200 mg/ml of Na-p-tosyl-L-lysine
chloromethyl ketone-treated bovine a-chymotrypsin (Sigma) for vari-
ous intervals at either 25C (trypsin) or 8C (chymotrypsin) as described
(Nibert et al., 1995; Wetzel et al., 1997). Protease digestion was
stopped by adding either 0.5 mg/ml soybean trypsin inhibitor (trypsin)
(Sigma) or 5mMphenylmethyl-sulfonyl fluoride (chymotrypsin) (Sigma)
to the treatment mixtures and cooling at 0C. Viral proteins were re-
solved by SDS-PAGE and visualized by either autoradiography (Nibert
et al., 1995) or staining with Coomassie blue (Wetzel et al., 1997).
Infection of Mice
Newborn C57/BL6 mice weighing 2.0–2.5 grams (2–4 days old) were
inoculated perorally or intracranially with 103 or 102 PFU, respectively,
of purified reovirus virions diluted in PBS. PO inoculations (50 ml) were
delivered intragastrically as described (Rubin and Fields, 1980). IC in-
oculations (5 ml) were delivered to the left cerebral hemisphere using
a Hamilton syringe and 30-gauge needle (Tyler et al., 1985). At various
intervals following inoculation, mice were euthanized, and organs were
harvested into 1ml of PBS and homogenized by freezing, thawing, and
sonication. Viral titers in organ homogenates were determined by pla-
que assay (Virgin et al., 1988). Animal husbandry and experimental
procedures were performed in accordance with Public Health Service
policy and approved by the Vanderbilt University School of Medicine
Institutional Animal Care and Use Committee.ost & Microbe 1, 147–157, April 2007 ª2007 Elsevier Inc. 155
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Monolayers of L cells (2 3 105) in 24-well plates were preincubated in
medium supplemented with 0–200 mM E64 (Sigma) for 4 hr. The me-
dium was removed, and cells were adsorbed with virus at an MOI of
2 PFU/cell. After incubation at 4C for 1 hr, the inoculumwas removed,
cells were washed with PBS, and 1 ml of fresh medium supplemented
with 0 to 200 mM E64 was added. Cells were incubated at 37C for
24 hr and frozen and thawed twice. Viral titers in cell lysates were
determined by plaque assay (Virgin et al., 1988).
Generation of s3-Expressing Cells
L cells stably expressing s3 protein (L-s3 cells) were selected by trans-
fection of cells with pCXN-S4T3D, which encodes the entire T3D s3
ORF, and incubation in the presence of 1mg/ml of geneticin (Invitrogen).
Supplemental Data
The Supplemental Data include Supplemental Experimental Proce-
dures, four supplemental tables, and one supplemental figure and
can be foundwith this article online at http://www.cellhostandmicrobe.
com/cgi/content/full/1/2/147/DC1/.
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C.  NPXY MOTIFS IN THE β1 INTEGRIN CYTOPLASMIC TAIL 
ARE REQUIRED FOR FUNCTIONAL REOVIRUS ENTRY 
 
Reovirus cell entry is mediated by binding to cell-surface carbohydrate and JAM-
A and internalization by β1 integrin (45, 48, 175, 218). The cytoplasmic tail of β1 
integrin contains two NPXY motifs that bind adaptor molecules during clathrin-mediated 
endocytosis and serve as sorting signals in the endocytic pathway (219-223). We 
hypothesized that the NPXY motifs in β1 integrin mediate internalization and transport of 
virus to late endosomes where uncoating takes place. Using imaging techniques and 
pharmacologic inhibitors, we showed that cells expressing wt β1 integrin were capable of 
internalizing virus to the proper endocytic compartment, allowing virus uncoating and 
productive infection. Cells expressing a mutant form of β1 in which the NPXY tyrosine 
residues were changed to phenylalanine were capable of internalizing virus but not 
supporting productive reovirus infection. Viral internalization by wt cells was inhibited 
by the drug chlorpromazine, which blocks clathrin-mediated endocytosis, but 
internalization by mutant cells was not. I participated in this work by developing assays, 
particularly infection of cells following treatment with chlorpromazine and the 
corresponding transferrin uptake assay used as a control. 
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Reovirus cell entry is mediated by attachment to cell surface carbohydrate and junctional adhesion molecule
A (JAM-A) and internalization by 1 integrin. The 1 integrin cytoplasmic tail contains two NPXY motifs,
which function in recruitment of adaptor proteins and clathrin for endocytosis and serve as sorting signals for
internalized cargo. As reovirus infection requires disassembly in the endocytic compartment, we investigated
the role of the 1 integrin NPXY motifs in reovirus internalization. In comparison to wild-type cells (1/
cells), reovirus infectivity was significantly reduced in cells expressing mutant 1 integrin in which the NPXY
motifs were altered to NPXF (1/Y783F/Y795F cells). However, reovirus displayed equivalent binding and
internalization levels following adsorption to 1/ cells and 1/Y783F/Y795F cells, suggesting that the
NPXY motifs are essential for transport of reovirus within the endocytic pathway. Reovirus entry into 1/
cells was blocked by chlorpromazine, an inhibitor of clathrin-mediated endocytosis, while entry into 1/
Y783F/Y795F cells was unaffected. Furthermore, virus was distributed to morphologically distinct endocytic
organelles in 1/ and 1/Y783F/Y795F cells, providing further evidence that the 1 integrin NPXY
motifs mediate sorting of reovirus in the endocytic pathway. Thus, NPXY motifs in the 1 integrin cytoplasmic
tail are required for functional reovirus entry, which indicates a key role for these sequences in endocytosis of
a pathogenic virus.
Virus entry into host cells requires interactions between viral
capsid constituents and receptors expressed on the cell surface.
Many viruses utilize distinct cellular molecules to mediate the
functions of attachment and internalization (36). Mammalian
reoviruses are nonenveloped, double-stranded RNA (dsRNA)
viruses that infect a broad range of hosts in nature (55). Reo-
viruses are pathogenic in newborn mice, infecting most organs,
including the central nervous system, heart, and liver (65).
Reoviruses first attach to the cell surface by binding to carbo-
hydrate (4), which is 2,3- or 2,6-linked sialic acid for sero-
type 3 reovirus strains (19, 46, 47). All reovirus serotypes bind
to proteinaceous receptor junctional adhesion molecule A
(JAM-A) to mediate high-affinity attachment (5, 14, 50). Fol-
lowing receptor binding, reovirus is internalized into cells via a
mechanism involving 1 integrin (34).
The process by which reovirus enters cells is poorly under-
stood. Data gathered from thin-section electron microscopy
(EM) images (11, 12, 52, 59) and video fluorescence micros-
copy (24) suggest that reovirus is internalized by clathrin-de-
pendent endocytosis. However, these studies were performed
using imaging techniques that did not address the role of clath-
rin in productive reovirus infection. Within minutes of inter-
nalization, reovirus undergoes stepwise disassembly, which in
fibroblasts is dependent on acidic pH (35, 59) and endosomal
cysteine-containing proteases cathepsins B and L (23). Viral
disassembly leads to generation of well-defined intermediates,
the first of which is the infectious subvirion particle (ISVP) (12,
17, 57, 59). ISVPs are characterized by the loss of outer capsid
protein 3 and cleavage of outer capsid protein 1 to form
particle-associated fragments  and . Following formation of
ISVPs, 1 is shed and the 1 cleavage fragments undergo
conformational rearrangement, yielding the ISVP* (15, 16).
ISVP*s penetrate endosomes to deliver transcriptionally active
viral cores into the cytoplasm (40, 42). Although the precise
mechanism of membrane penetration is not well understood,
ISVP*s are thought to breach the endosomal membrane by a
process that requires 1-mediated formation of small pores
(1). The cellular compartment in which reovirus disassembly
takes place is unknown, yet cathepsins B and L generally reside
in late endosomes or lysosomes (62), suggesting that reovirus
disassembly occurs in these endocytic organelles.
Integrins are heterodimeric cell surface molecules consisting
of  and  subunits (32). Integrin heterodimers mediate cell
adhesion to the extracellular matrix, regulate cell trafficking,
and transduce both inside-out and outside-in signaling events
(31). In addition to reovirus, several other pathogenic micro-
organisms use the adhesion and signaling properties of various
integrins to bind or enter host cells, including adenovirus
(v3 and v5) (72), cytomegalovirus (21, 61, v3)
(25), echovirus (21) (6), rotavirus (v3, 21, 41) (27,
30), West Nile virus (v3) (20), and Yersinia pseudotubercu-
losis (1) (33). Little is known about the internalization and
the endocytic trafficking of 1 integrin and its cognate cargo.
The 1 integrin cytoplasmic domain is approximately 47 amino
acids in length and contains two Asn-Pro-any amino acid-
tyrosine (NPXY) motifs (51), with tyrosine residues at amino
* Corresponding author. Mailing address: Lamb Center for Pediat-
ric Research, D7235 MCN, Vanderbilt University School of Medicine,
Nashville, TN 37232. Phone: (615) 343-9943. Fax: (615) 343-9723.
E-mail: terry.dermody@vanderbilt.edu.
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acid positions 783 and 795 (51). NPXY motifs are potential
sites of tyrosine phosphorylation (53) and serve as endocytic
sorting signals that can be recognized by adaptor proteins and
clathrin (8, 9, 37, 38, 43). The function of NPXY motifs in
cargo internalization was first deduced in studies of familial
hypercholesterolemia, a disorder in which low-density lipopro-
tein (LDL) cholesterol levels are elevated, leading to prema-
ture atherosclerosis (22). This disease results from a tyrosine-
to-phenylalanine mutation in the NPXY motif of the LDL
receptor (22). The NPXY-to-F mutation renders the receptor
incapable of recognition by adaptor protein disabled 2 (Dab2),
which is engaged by adaptor protein 2 (AP-2) for clathrin-
mediated endocytosis (38).
To determine the function of the 1 integrin NPXY motifs
in reovirus entry and infection, we used 1/ cells stably
expressing either wild-type 1 integrin or 1 integrin with
altered NPXY motifs. Mutation of the 1 integrin NPXY
motifs to NPXF prevents tyrosine phosphorylation but does
not affect 1 integrin surface expression, the capacity of 1 to
form heterodimers with  integrin partners, fibronectin assem-
bly, or cell adhesion (54). However, 1 integrin NPXY-to-F
mutation results in increased focal contacts, shorter actin fila-
ments, and impaired cell motility (54). We found that reovirus
particles enter into 1/ cells via a chlorpromazine-sensitive
mechanism and are delivered to vesicles that morphologically
resemble endosomes and lysosomes, while a chlorpromazine-
resistant mechanism is utilized in cells with altered NPXY
motifs that do not lead to productive infection. These findings
indicate that the 1 integrin NPXY motifs are required for
functional reovirus entry and provide new insights into mech-
anisms by which 1 integrin delivers cargo to the endocytic
compartment.
MATERIALS AND METHODS
Cells, viruses, and antibodies. Spinner-adapted murine L929 (L) cells were
grown in either suspension or monolayer cultures in Joklik’s modified Eagle’s min-
imal essential medium (Sigma-Aldrich, St. Louis, MO) supplemented to contain 5%
fetal bovine serum, 2 mM L-glutamine, 100 U of penicillin per ml, 100 U of strep-
tomycin per ml, and 0.25 mg amphotericin per ml (Gibco Invitrogen Corp., Grand
Island, NY). GD25, GD251A, GD251AY783F, GD251AY795F, and
GD251AY783F/Y795F cells (69, 70) were obtained from Deane Mosher (Univer-
sity of Wisconsin, Madison) and maintained in Dulbecco’s minimal essential me-
dium (Gibco Invitrogen) supplemented to contain 10% fetal bovine serum, 100 U of
penicillin per ml, and 100 U of streptomycin per ml. Medium for all GD251A cells
was supplemented to contain 10 g of puromycin (Sigma-Aldrich) per ml to main-
tain 1 integrin expression (69, 70).
Reovirus strain type 1 Lang (T1L) is a laboratory stock. Working stocks of
virus were prepared by plaque purification and passage using L cells (66). Puri-
fied virions were generated from second-passage L-cell lysate virus stocks. Virus
was purified from infected cell lysates by Freon extraction and CsCl gradient
centrifugation as described previously (26). Bands corresponding to the density
of reovirus particles (1.36 g/cm3) were collected and dialyzed against virion
storage buffer (150 mM NaCl, 15 mM MgCl2, 10 mM Tris [pH 7.4]). The
reovirus particle concentration was determined from the equivalence of 1 unit of
optical density at 260 nm to 2.1 	 1012 particles (58). The viral titer was
determined by fluorescent focus assay (4). ISVPs were generated by the treat-
ment of 2 	 1011 particles with 200 g of -chymotrypsin (Sigma-Aldrich) in a
100-l volume of virion storage buffer at 37°C for 30 min (2). Reactions were
terminated by the addition of 1.0 mM phenylmethylsulfonyl fluoride (Sigma-
Aldrich).
Immunoglobulin G (IgG) fractions of rabbit antisera raised against T1L and
type 3 Dearing (71) were purified by protein A Sepharose as described previously
(4). Fluorescently conjugated secondary Alexa antibodies were obtained from
Molecular Probes (Invitrogen, San Diego, CA). R-phycoerythrin-conjugated sec-
ondary antibodies were obtained from BD Biosciences Pharmingen (Franklin
Lakes, NJ). Murine 1 integrin-specific monoclonal antibody (MAb) MAB1997
(Chemicon, Temecula, CA) and JAM-A-specific MAb H202-106-7-4 (provided
by Beat Imof, Universite´ de Gene`ve) were used to assess cell surface expression
of 1 integrin and JAM-A by flow cytometry. IgG controls used for flow cytom-
etry were purchased from Chemicon.
Flow cytometric analysis. Cells were detached from plates using phosphate-
buffered saline (PBS)-EDTA (20 mM EDTA), washed, and centrifuged at
1,000	 g to form a pellet. Cells were resuspended with antibodies in PBS-bovine
serum albumin (BSA) (Sigma-Aldrich) (5% BSA) and incubated at 4°C for 1 h.
Cells were washed twice and incubated with an appropriate secondary antibody
conjugated to R-phycoerythrin (BD Biosciences Pharmingen) at 4°C for 1 h.
Cells were washed, resuspended in PBS, and analyzed by flow cytometry. Reo-
virus binding to cells was analyzed by adsorbing cells with T1L particles at 4°C for
1 h. Cells were washed and stained with reovirus polyclonal antisera and an
appropriate secondary antibody conjugated to Alexa 546 (Invitrogen) and ana-
lyzed by flow cytometry.
Fluorescent focus assay of viral infection. Cells plated in 24-well plates
(Costar; Corning Life Sciences, Corning, NY) were either untreated or treated
with 5 g per ml chlorpromazine (Alexis Biochemicals, Lausen, Switzerland) at
37°C for 3 h. Cells were adsorbed with virions or ISVPs in incomplete medium
(without serum and antibiotics) at 4°C for 1 h. Inocula were removed, cells were
washed, and complete medium with or without chlorpromazine was added.
Infected cells were incubated at 37°C for 20 h to allow a single cycle of viral
replication. Cells were fixed with cold, absolute methanol at 20°C for at least
30 min. Fixed cells were washed with PBS, incubated with PBS-BSA (5% BSA)
for at least 15 min, and incubated with reovirus-specific polyclonal antiserum
(1:500) in PBS containing 0.5% Triton X-100 (TX-100) at room temperature for
1 h. Cells were washed twice and incubated with an Alexa Fluor 488- or 546-
labeled anti-rabbit IgG (1:1,000) in PBS-TX-100 (0.5% TX-100) at room tem-
perature for 1 h. Cells were washed twice and visualized by indirect immunoflu-
orescence at a magnification of 	20 using an Axiovert 200 fluorescence
microscope (Carl Zeiss, New York, NY). Infected cells (fluorescent focus units
[FFU]) were identified by diffuse cytoplasmic fluorescence staining that was
excluded from the nucleus. Reovirus-infected cells were quantified by counting
random fields in equivalently confluent monolayers for three to five fields of view
for triplicate wells (4).
Confocal imaging of reovirus internalization. Cells plated on coverslips in
24-well plates (Costar) were adsorbed with reovirus virions in incomplete me-
dium and incubated at 4°C for 1 h. Cells were washed and fixed or nonadherent
reovirus was aspirated and replaced with complete medium and incubated at
37°C. At various intervals, cells were washed with PBS and fixed with 10%
formalin (Laboratory Supply Company, Louisville, KY) for 20 min, followed by
washing with PBS. Cells were treated with 1% TX-100 for 5 min and incubated
with PBS-BGT (PBS, 0.5% BSA, 0.1% glycine, and 0.05% Tween 20) for 10 min.
Cells were incubated with reovirus-specific polyclonal antiserum (1:500) in PBS-
BGT for 1 h, washed with PBS-BGT, and incubated with donkey anti-rabbit
immunoglobulin conjugated to Alexa Fluor 488 (Molecular Probes) (1:1,000) to
visualize reovirus and phalloidin conjugated to Alexa Fluor 546 (Molecular
Probes) (1:100) to visualize actin for 1 h in PBS-BGT. Cell nuclei were visualized
by incubating cells with To-Pro 3 conjugated to Alexa Fluor 642 (Molecular
Probes) (1:1,000) in PBS-BGT for 20 min. Cells were washed extensively with
PBS-BGT, and coverslips were removed from wells and placed on slides using
Aqua-Poly/Mount mounting medium (Polysciences, Inc., Warrington, PA). Im-
ages were captured using a Zeiss LSM 510 Meta laser-scanning confocal micro-
scope. Three-dimensional image reconstructions were generated from multiple
images collected in the Z plane and compiled using Zeiss imaging software.
Quantitation of virus internalization. Virus internalization was quantified as a
function of pixel intensity using Metamorph software (Universal Imagining,
Downingtown, PA). Confocal images were collected and analyzed for internal-
ized reovirus particles by capturing multiple images in the Z plane and deter-
mining the center of the cell based on cell thickness as analyzed using Zeiss
imaging software. Cells analyzed for quantitative purposes were selected at
random and counted by an observer blinded to the conditions of the experiment.
The intracellular space was outlined using the trace tool to exclude the plasma
membrane, which was identified by intense actin staining. The region measure-
ment function was used to quantify intensity of green pixels in the trace region
for each cell.
Confocal imaging of transferrin internalization. Cells were plated on cover-
slips in 24-well plates and incubated at 37°C overnight in complete medium.
Following incubation in incomplete medium at 37°C for 30 min, cells were
untreated or treated with 5 g per ml chlorpromazine at 37°C for 3 h. Cells were
incubated with 2.5 g per ml Alexa Fluor 488-conjugated transferrin (Molecular
Probes) in the presence or absence of 5 g per ml chlorpromazine in incomplete
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medium at 37°C for 10 min. The medium was removed, and cells were washed
once with PBS, once with an acid wash (0.2 M acetic acid, 0.5 M NaCl in distilled
H2O [diH2O]), and twice with PBS. Cells were fixed with 10% formalin and
prepared for confocal microscopy. Transferrin internalization was quantified
using Metamorph software (Universal Imaging) as described for virus internal-
ization.
EM. Cells plated in 60-mm dishes (Costar) were prechilled at 4°C for 1 h,
adsorbed with reovirus virions in incomplete medium, and incubated at 4°C for
1 h. Cells were washed twice with PBS, and cells were harvested or nonadherent
virus was aspirated and replaced with warm, complete medium and incubated at
37°C. At 10-min intervals, cells were harvested on ice in 1 ml of PBS using a cell
lifter (Costar) and transferred to a 1.5-ml microcentrifuge tube. Cells were
pelleted at 1,000 	 g at 4°C for 5 min. The supernatant was removed, and 1 ml
of 2% glutaraldehyde was placed over the cell pellet. Cells were incubated at
room temperature for 90 min. Glutaraldehyde was removed and replaced with
fresh 2% glutaraldehyde and incubated overnight at 4°C. Cells were washed
three times in PBS, transferred to 1% osmium tetroxide in diH2O for 1 h, and
washed three times in diH2O. Cells were stained en bloc in 1% aqueous uranyl
acetate for 1 h and washed three times in diH2O. Cells were dehydrated by using
a graded series of ethanol washes and by increasing the incubation times in each
solution starting with 30% for 5 min, followed by two washes with 50% for 5 min,
70% for 5 min, 95% for 10 min, and absolute ethanol for 15 min. Cells were
passed through propylene oxide, transferred to a 1:1 araldite:propylene oxide
mixture, and embedded in Araldite embedding medium (Electron Microscopy
Sciences, Hatfield, PA). Ultra-thin serial sections (50 to 60 nm) were obtained
using a Leica UCT Ultracut microtome (Leica Microsystems, Vienna, Austria),
transferred to Formvar-coated grids, and examined using a Phillips CM10 trans-
mission EM (FEI Company, Hillsboro, OR) equipped with an Advantage Plus
Digital charge-coupled-device system for CM10 transmission EM (Advanced
Microscopy Techniques, Danvers, MA).
Reovirus localization with lysosomal markers. Cells were plated on coverslips
in 24-well plates and incubated with 75 nM Lysotracker-Red DND-99 dye (Mo-
lecular Probes) in incomplete medium at 37°C for 30 min. Cells were prechilled
at 4°C for 1 h, adsorbed with reovirus virions in incomplete medium, and incu-
bated at 4°C for 1 h. Cells were washed on ice three times with PBS, nonadherent
reovirus was removed, and complete medium was added. Following incubation at
37°C for various intervals, cells were washed with PBS, fixed with 10% formalin,
and prepared for confocal immunofluorescence microscopy. Images were ana-
lyzed for colocalization of Lysotracker-Red DND-99 dye and reovirus virions
using ImageJ software (version 1.37v; W. S. Rasband, National Institutes of
Health, Bethesda, MD) Colocalize RGB plug-in.
Statistical analysis. Means for at least triplicate samples were compared by
using unpaired Student’s t test (Microsoft Excel, Redmond, WA). P values of

0.05 were considered to be statistically significant.
RESULTS
Reovirus infection is diminished in cells expressing 1 in-
tegrin with altered NPXY motifs. To determine whether the
NPXY motifs in the cytoplasmic domain of 1 integrin are re-
quired for functional reovirus entry, we tested cells with muta-
tions in the 1 integrin NPXY motifs for the capacity to support
reovirus infection. GD25 (1/) cells are embryonic stem cells
derived from 1-null mouse embryos, while GD251A (1/)
cells stably express full-length, wild-type 1 integrin (70).
GD251AY783F (1/Y783F), GD251AY795F (1/
Y795F), and GD251AY783F/Y795F (1/Y783F/Y795F)
cells stably express 1 integrin in which the tyrosine residues of
the NPXY motifs at amino acid positions 783 and 795 have been
substituted with phenylalanine (69, 70). Cell surface expression of
1 integrin by 1/, 1/, 1/Y783F, 1/Y795F, and
1/Y783F/Y795F cells was assessed using flow cytometry
(Fig. 1A). With the exception of 1/ cells, these cell lines
expressed equivalent levels of cell surface 1 integrin. Importantly
for our studies of reovirus infection, these cells also expressed
equivalent levels of cell surface JAM-A (Fig. 1A). To test for
attachment of reovirus to cells expressing wild-type and mutant
1 integrin, cells were incubated with reovirus particles, and bind-
ing was detected using flow cytometry (Fig. 1B). Reovirus bound
equivalently to all cell types, suggesting that reovirus attachment
is not affected by mutation of the 1 integrin NPXY motifs to
NPXF.
To determine whether mutations in the 1 integrin NPXY
motifs alter reovirus infection, cells were adsorbed with reovi-
rus virions or ISVPs, and infectivity was scored by indirect
immunofluorescence (Fig. 2). In comparison to 1/ cells,
FIG. 1. Reovirus exhibits equivalent binding to 1/, 1/, and
1/ cells with altered NPXY motifs. (A) GD25 (1/), GD251A
(1/), GD251AY783F (1/Y783F), GD251AY795F (1/
Y795F), and GD251AY783F/Y795F (1/Y783F/Y795F) cells were
detached from plates using 20 mM EDTA, washed, collected by centrif-
ugation, and incubated with antibodies specific for either murine 1 in-
tegrin (blue), murine JAM-A (green), or an IgG control antibody (gray).
Cell surface expression of these molecules was detected by flow cytometry.
Data are expressed as fluorescence intensity. (B) 1/, 1/, 1/
Y783F, 1/Y795F, and 1/Y783F/Y795F cells were detached
from plates using 20 mM EDTA, washed, collected by centrifugation, and
incubated with 104 particles per cell of reovirus T1L in incomplete me-
dium (filled) or incomplete medium alone (open) at 4°C for 1 h to allow
attachment. Cells were washed and incubated with reovirus-specific anti-
serum. Reovirus binding was detected by flow cytometry. Data are ex-
pressed as fluorescence intensity.
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1/, 1/Y783F, 1/Y795F, and 1/Y783F/
Y795F cells were less susceptible to infection by reovirus viri-
ons (Fig. 2). While reovirus infection was significantly reduced
in 1/Y783F and 1/Y795F cells, infection was most
dramatically diminished in 1/Y783F/Y795F cells, to an
extent even greater than in 1/ cells (Fig. 2). ISVPs, which
bind to JAM-A (5) but bypass a requirement for endocytosis
and disassembly (2, 59), were capable of infecting all cell types
(Fig. 2). Equivalent infection by ISVPs suggests that the block
to reovirus infection in cells expressing mutant 1 integrin
occurs subsequent to viral attachment but preceding capsid
disassembly.
Reovirus virions are internalized into the cytoplasm of
1/Y783F/Y795F cells. To determine whether the block to
reovirus infection in 1/Y783F/Y795F cells is due to a
defect in internalization, 1/, 1/, and 1/Y783F/
Y795F cells were adsorbed with reovirus particles at 4°C for
1 h to allow virus binding and then incubated at 37°C to allow
internalization over a time course concurrent with reovirus
entry. At 0, 15, and 30 min, cells were fixed, stained using
reovirus-specific antiserum, and examined for reovirus parti-
cles by confocal immunofluorescence microscopy. Representa-
tive confocal micrographic images of 1/, 1/, and
1/Y783F/Y795F cells infected with reovirus and fixed at
30 min postadsorption are shown in Fig. 3A. Although reovirus
particles were observed in the cytoplasm of all cell types, there
was a notable decrease in 1/ cells, as described previously
(34). Surprisingly, reovirus particles were internalized into
both 1/ and 1/Y783F/Y795F cells (Fig. 3A). To de-
termine the distribution of reovirus particles internalized into
1/ and 1/Y783F/Y795F cells, multiple confocal mi-
crograph images in the Z plane were collected and examined
using Z-stack analysis and three-dimensional image recon-
structions (data not shown). Comparisons of the two cell types
revealed that reovirus particles were distributed throughout
the nonnuclear compartment of 1/Y783F/Y795F cells in a
pattern similar to that for 1/ cells. To directly quantify the
fluorescence intensity of internalized reovirus particles, confo-
cal micrographs were obtained over a time course and ana-
lyzed using Metamorph imaging software. The average pixel
intensity representing reovirus particles was significantly
greater in 1/ and 1/Y783F/Y795F cells than in
1/ cells (Fig. 3B). These findings indicate that reovirus
particles are internalized into 1/ and 1/Y783F/
Y795F cells, and in both cases, the number of particles inter-
nalized exceeds that for 1/ cells.
Reovirus uptake into 1/ cells is blocked by chlorprom-
azine. To determine the mechanism required for functional
reovirus entry, 1/ cells were pretreated with chlorproma-
zine, which inhibits clathrin assembly at the plasma membrane
by interfering with AP-2 localization to membranes and forcing
clathrin lattices to form on endosomal membranes (67). Treat-
ment of cells with chlorpromazine blocks clathrin-dependent
endocytosis of a number of viruses, including hepatitis C virus
(7), polyomavirus JC virus (49), and vesicular stomatitis virus
(60). Cells were infected with reovirus virions or ISVPs in the
presence or absence of chlorpromazine and scored for infec-
tion by indirect immunofluorescence (Fig. 4A). Treatment of
cells with 5 g per ml of chlorpromazine decreased viral in-
fectivity by greater than 80% following adsorption with virions
(Fig. 4A). However, infectivity was unaffected by chlorproma-
zine treatment following adsorption with ISVPs, suggesting
that diminished infectivity by reovirus is caused by a block to
entry. Failure of chlorpromazine to inhibit infection by ISVPs
also indicates that the concentration of chlorpromazine used in
these experiments does not affect viral attachment or the ca-
pacity of cells to support the reovirus replication cycle. As a
control, chlorpromazine treatment of 1/ cells diminished
the uptake of transferrin (Fig. 4B and C), which is internalized
by clathrin-dependent endocytosis (29, 48). Chlorpromazine
also blocked reovirus infection and transferrin uptake in ex-
periments using HeLa cells and L cells (data not shown). Thus,
reovirus virions use a chlorpromazine-sensitive pathway, most
likely clathrin-mediated endocytosis, to enter cells.
1 integrin NPXY motifs are required for functional reovi-
rus uptake. To determine the role of the 1 integrin NPXY
motifs in reovirus endocytosis, 1/ and 1/Y783F/Y795F
cells were either treated with chlorpromazine or left untreated,
adsorbed with reovirus particles at 4°C for 1 h to allow virus
binding, and incubated at 37°C to allow internalization. At 0 and
20 min postadsorption, cells were fixed, stained using reovirus-
specific antiserum, and examined by confocal immunofluores-
cence microscopy. Representative confocal micrographic images
of 1/ and 1/Y783F/Y795F cells at 20 min postadsorp-
tion are shown in Fig. 5A. The fluorescence intensities of reovirus
particles internalized into 1/ and 1/Y783F/Y795F cells
were quantified by averaging the pixel intensities for representa-
tive confocal micrographs by using Metamorph imaging software
(Fig. 5B). In 1/ cells treated with chlorpromazine, the aver-
age pixel intensity representing reovirus particles was significantly
diminished in comparison to that in untreated 1/ cells (Fig.
5B). However, chlorpromazine treatment did not diminish the
FIG. 2. Reovirus infection is diminished in cells with altered 1
integrin NPXY motifs. 1/, 1/, 1/Y783F, 1/Y795F,
and 1/Y783F/Y795F cells were adsorbed with T1L virions or
ISVPs at an MOI of 1 FFU per cell at 4°C for 1 h. Cells were washed
with PBS, incubated in complete medium at 37°C for 20 h, fixed, and
stained by indirect immunofluorescence. Infected cells were quantified
by counting cells exhibiting cytoplasmic staining in five visual fields of
equivalently confluent monolayers for triplicate samples. The results
are expressed as mean FFU per visual field for triplicate samples.
Error bars indicate standard deviations. These data are representative
of results of three individual experiments performed in triplicate. *,
P 
 0.05 in comparison to 1/ cells.
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pixel intensity in 1/Y783F/Y795F cells, indicating that reo-
virus internalization into 1/Y783F/Y795F cells is not inhib-
ited by chlorpromazine (Fig. 5B). These data demonstrate that
the reovirus uptake pathway in 1/ cells is chlorpromazine
sensitive, whereas reovirus internalization into 1/Y783F/
Y795F cells is mediated by an alternative uptake mechanism that
is not sensitive to chlorpromazine and does not give rise to pro-
ductive infection.
Intracellular trafficking of reovirus virions. To define the
fate of reovirus virions in the endocytic pathway during internal-
ization and disassembly, we performed an ultrastructural analysis
of reovirus-infected cells. 1/, 1/, and 1/Y783F/
Y795F cells were adsorbed with reovirus particles at 4°C for 1 h
to allow virus binding, incubated at 37°C over a 30-min time
course to allow internalization, and analyzed by transmission EM
(Fig. 6). Fewer reovirus particles were detected in 1/ cells
than in 1/ and 1/Y783F/Y795F cells at all time points
examined, consistent with the quantitative confocal microscopy
data. In 1/ cells, and to a much lesser extent in 1/ cells,
reovirus particles were clearly visible in coated-pit and coated-
vesicle structures at 0 min postadsorption (Fig. 6A, white arrows,
and Fig. 6B). At 10, 20, and 30 min postadsorption, the majority
of reovirus particles (Fig. 6A, black arrows, and data not shown)
appeared in structures that morphologically resemble early endo-
FIG. 3. Reovirus is internalized into 1/ and 1/Y783F/Y795F cells. 1/, 1/, and 1/Y783F/Y795F cells were adsorbed with
5 	 104 particles per cell of T1L virions and incubated at 4°C for 1 h. Nonadherent virus was removed, warm medium was added, and cells were
incubated at 37°C. Cells were fixed over a time course, stained for reovirus (green), actin (red), and DNA (blue), and imaged using confocal
immunofluorescence microscopy. (A) Representative digital fluorescence images of cells fixed at 30 min postadsorption are shown. Scale bars, 10
m. (B) Fluorescent particles internalized into the cytoplasm were analyzed to determine the average pixel intensity of fluorescent particles per
cell. Fluorescent particles localized at the cell periphery were excluded from the analysis. The results are expressed as the average pixel intensity
per cell for five cells at each time point. Error bars indicate standard errors of the means. *, P 
 0.05 in comparison to 1/ cells.
VOL. 82, 2008 1 INTEGRIN AND REOVIRUS ENTRY 3185
 at VAN
D
ER
BILT UNIVERSITY on July 7, 2009 
jvi.asm.org
D
ow
nloaded from
 
somes, which have an electron-lucent appearance, late endo-
somes, which appear larger and more electron dense, and primary
lysosomes, which are small, electron-dense, membrane-bound
vesicles. In 1/Y783F/Y795F cells, few reovirus particles were
observed in coated-pit structures or structures that resemble en-
dosomes. Instead, the majority of reovirus particles in 1/
Y783F/Y795F cells localized in electron-dense, membrane-bound
vesicular structures that morphologically resemble secondary ly-
sosomes or phagolysosomes, which contain a notable amount of
heterogeneous material (Fig. 6A and C, black arrowheads).
These structures were present in both uninfected and infected
1/ and 1/Y783F/Y795F cells, yet there were a greater
number of these structures in the infected 1/Y783F/Y795F
FIG. 4. Uptake of reovirus and transferrin into 1/ cells is chlor-
promazine sensitive. (A) 1/ cells were pretreated with 5 g of chlor-
promazine per ml for 3 h, adsorbed with T1L virions or ISVPs at an MOI
of 1 FFU per cell, and incubated at 4°C for 1 h. Cells were washed,
complete medium with or without chlorpromazine was added, and cells
were incubated at 37°C for 20 h. Cells were fixed and stained by indirect
immunofluorescence. Infected cells were quantified by counting cells ex-
hibiting cytoplasmic staining in three visual fields of equivalently confluent
monolayers for triplicate samples. The results are expressed as mean FFU
per visual field for triplicate samples. Error bars indicate standard devia-
tions. These data are representative of results of three independent ex-
periments performed in triplicate. *, P
 0.05 in comparison to untreated
cells. (B) 1/ cells were pretreated with 5g per ml of chlorpromazine
for 3 h and incubated with 2.5 g per ml Alexa Fluor 488-conjugated
transferrin in the presence or absence of 5 g per ml chlorpromazine in
incomplete medium at 37°C for 10 min. The medium was removed, and
cells were washed, fixed, and imaged by confocal microscopy. Represen-
tative digital fluorescence images of untreated and chlorpromazine-
treated cells incubated with transferrin are shown. Scale bars, 10 m.
(C) Untreated and chlorpromazine-treated cells were analyzed for fluo-
rescent transferrin internalized into the cytoplasm to determine the aver-
age pixel intensity of transferrin per cell. Fluorescent signal localized at
the cell periphery was excluded from the analysis. The results are ex-
pressed as the average pixel intensity per cell for 10 cells. Error bars
indicate standard errors of the means. *, P 
 0.05 in comparison to
untreated cells.
FIG. 5. 1 integrin NPXY motifs are required for functional
reovirus internalization. 1/ and 1/Y783F/Y795F cells
were pretreated with 5 g per ml of chlorpromazine at 37°C for 3 h,
adsorbed with 5 	 104 particles per cell of T1L virions in incomplete
medium, and incubated at 4°C for 1 h. Cells where washed, com-
plete medium with or without chlorpromazine was added, and cells
were incubated at 37°C for 20 min. Cells were fixed, stained for
reovirus (green), actin (red), and DNA (blue), and imaged using
confocal immunofluorescence microscopy. (A) Representative dig-
ital fluorescence images of untreated and chlorpromazine-treated
cells at 20 min postadsorption are shown. Scale bars, 10 m.
(B) Fluorescent particles internalized into the cytoplasm were an-
alyzed to determine the average pixel intensity per cell. Fluorescent
particles localized at the cell periphery were excluded from the
analysis. The results are expressed as the average pixel intensity per
cell for five cells. Error bars indicate standard errors of the means.
*, P 
 0.05 in comparison to untreated cells.
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FIG. 6. Ultrastructural analysis of reovirus internalization. (A) 1/, 1/, and 1/Y783F/Y795F cells were adsorbed with 105 particles per
cell of T1L virions at 4°C for 1 h, washed, and fixed or incubated in complete medium at 37°C. At 10-min intervals, cells were washed, collected by
centrifugation, fixed, and stained for EM. Representative images at 0, 10, and 20 min postadsorption are shown. Reovirus virions localized in coated pits
and coated vesicles are indicated by white arrows. Reovirus virions localized in structures that resemble early and late endosomes and primary lysosomes
are indicated by black arrows. Secondary lysosomes are indicated by black arrowheads. Scale bars, 500 nm. (B) Representative image of reovirus virion
in a coated pit structure in 1/ cells at 0 min postadsorption. Scale bar, 100 nm. (C) Representative images of organelles resembling secondary
lysosomes containing reovirus particles in 1/Y783F/Y795F cells at 10, 20, and 30 min postadsorption (left, center, and right, respectively). Reovirus
virions are indicated by black arrows. Secondary lysosomes are indicated by black arrowheads. Scale bars, 500 nm.
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cells (Fig. 6A). These findings suggest that NPXY-to-F mutations
in the 1 integrin cytoplasmic tail lead to delivery of reovirus
virions to an endocytic compartment incapable of either support-
ing functional capsid disassembly or allowing release of uncoated
particles into the cytoplasm.
In a complementary approach to assess the intracellular
distribution of reovirus particles following internalization into
1/ and 1/Y783F/Y795F cells, both cell types were
pretreated with the lysosomal-specific marker, Lysotracker-
Red DND-99 dye, adsorbed with reovirus virions, and exam-
ined by confocal immunofluorescence microscopy (Fig. 7 and
data not shown). Reovirus particles appeared in vesicles
marked by Lysotracker-Red DND-99 dye in both 1/ and
1/Y783F/Y795F cells, yet substantially more viral parti-
cles were localized to these structures in 1/Y783F/Y795F
cells at 40 min postadsorption than in 1/ cells at that time
point (Fig. 7, white arrowheads). These data suggest that while
reovirus particles are transported to a lysosomal compartment
in both 1/ and 1/Y783F/Y795F cells, virions in
1/ cells egress this compartment to initiate an infectious
cycle, while virions in 1/Y783F/Y795F cells are trapped
and fail to productively infect the cell.
DISCUSSION
The goal of this study was to gain a better understanding of
mechanisms by which 1 integrin mediates reovirus internal-
ization. The data demonstrate a function for the 1 integrin
NPXY motifs in reovirus endocytosis and endocytic transport.
Tyrosine-to-phenylalanine mutation of the 1 integrin NPXY
motifs leads to an aberrant pathway of reovirus internalization
that does not yield infectious progeny. EM analysis indicates
that reovirus virions are internalized into 1/Y783F/Y795F
cells yet localize in organelles that morphologically resemble
secondary lysosomes rather than in endosomes and lysosomes
as they do in 1/ cells. Reovirus internalization into 1/
cells is mediated by a chlorpromazine-sensitive pathway, most
likely clathrin-dependent endocytosis, yet particles internalized
into 1/Y783F/Y95F cells enter by a different route. Col-
lectively, these data indicate that 1 integrin serves to deliver
reovirus to the endocytic compartment required to complete
subsequent steps in the viral life cycle.
Findings presented in this report provide new insights into
mechanisms by which reovirus enters into cells. After attach-
ment to carbohydrate (4, 19, 46, 47) and JAM-A (5, 14, 50),
reovirus is internalized into the endocytic pathway by 1 inte-
grin (34). Our results indicate that this process is dependent on
signals elicited by the NPXY motifs in the 1 integrin cyto-
plasmic tail. Since chlorpromazine diminishes reovirus entry
and infection in 1/ cells, but does not affect reovirus
uptake into 1/Y783F/Y795F cells, it is likely that the 1
integrin NPXY motifs recruit the endocytic machinery to de-
liver reovirus to the endocytic organelle required for capsid
disassembly and release of the viral core into the cytoplasm.
NPXY motifs recruit clathrin and adaptor proteins and serve as
cargo recognition motifs to direct the delivery of cargo to endo-
somes and lysosomes (10, 37). For example, NPXY motifs recruit
AP-2 to the cell surface by directly interacting with the AP-2 2
FIG. 7. Intracellular transport of reovirus particles is altered in 1/Y783F/Y795F cells. 1/ and 1/Y783F/Y795F cells were
pretreated with Lysotracker-Red DND-99 dye (Lysotracker), adsorbed with 5 	 104 particles per cell of T1L virions (Reovirus), and incubated at
4°C for 1 h. Nonadherent virus was removed, warm medium was added, and cells were incubated at 37°C. Cells were fixed over a time course and
stained for reovirus. Images were analyzed for colocalization using ImageJ (version 1.37v) Colocalize RGB plug-in. Representative digital
fluorescence images pseudocolored as monochromatic images or fluorescence images of cells fixed at 40 min postadsorption are shown.
Lysotracker-Red DND-99 dye is colored red; reovirus is colored green. White arrowheads indicate areas of colocalization, which are magnified
in the insets. Scale bars, 10 m.
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subunit (9). The 2 subunit of AP-2 then binds clathrin subunits
(45) and initiates clathrin assembly at the plasma membrane,
which leads to accumulation of clathrin at the cell surface for
clathrin-mediated endocytosis (44). NPXY motifs also recruit
Dab2 (38, 44), which directly interacts with NPXY motifs via the
Dab2 phosphotyrosine binding domain (37). Dab2 induces clath-
rin-mediated endocytosis by binding either to clathrin (37) or to
AP-2 (39). Dab2 recognizes either phosphorylated or nonphos-
phorylated tyrosines of NPXY motifs (37, 38). Therefore, in 1/
Y783F/Y795F-infected cells, Dab2 could potentially engage 1
integrin with NPXY-to-F mutations and mediate reovirus inter-
nalization but direct particles to a nonfunctional endocytic com-
partment. Since reovirus infection requires acid-dependent pro-
teolytic disassembly (2, 23, 59), virus delivery to an intracellular
site other than an endosomal compartment containing the appro-
priate pH (59) and proteolytic enzymes (23) could result in the
failure of reovirus particles to uncoat and penetrate into the
cytoplasm. Our experiments using Lysotracker-Red DND-99 dye
suggest that reovirus virions distribute to a lysosomal compart-
ment in both 1/ and 1/Y783F/Y795F cells (Fig. 7).
However, this marker does not distinguish between primary and
secondary lysosomes, which appear morphologically distinct (Fig.
6). Additional experiments are required to define the intracellular
transport pathways traversed by reovirus following uptake into
wild-type and mutant cells.
Since phenylalanine residues cannot be phosphorylated, our
findings with cells expressing 1 integrin with NPXY-to-F mu-
tations in the cytoplasmic tail raise the possibility that reovirus
interactions with 1 integrin lead to tyrosine phosphorylation
of the NPXY motifs. In support of this hypothesis, v-src trans-
formation of 1/ cells but not 1/Y783F/Y795F cells
results in phosphorylation of 1 integrin (53), suggesting that
the NPXY tyrosine residues can serve as substrates for phos-
phorylation. It is possible that phosphorylation of the 1 inte-
grin NPXY motifs is required for postattachment signaling
events required for reovirus endocytosis or other steps in the
virus life cycle. For example, phosphorylation of the NPXY
tyrosine residues is required for autophosphorylation of focal
adhesion kinase (68). Thus, reovirus-1 integrin interactions
may induce phosphorylation and activation of integrin-linked
signaling pathways.
It is also possible that the 1 integrin NPXY motifs mediate
functional reovirus internalization by an indirect mechanism.
The NPXY motifs in the 1 integrin cytoplasmic tail are sep-
arated by eight residues that form a tight  turn (3, 63). This
region serves as a docking site for phosphotyrosine binding
domain-containing proteins (61), including talin (13) and inte-
grin cytoplasmic domain-associated protein 1- (18). In addi-
tion, two of the intervening residues are threonines at positions
788 and 789, and Thr788 is notably essential for integrin acti-
vation and ligand engagement (41). Therefore, mutation of the
NPXY motifs may result in structural alterations that affect
the 1 integrin cytoplasmic tail and preclude engagement of
the cytosolic molecules required for reovirus uptake or sorting
within the endocytic pathway.
1/Y783F/Y795F cells are surprisingly less permissive
for reovirus infection than 1/ cells (Fig. 2). Since both
1/ and 1/Y783F/Y795F cells express JAM-A on the
cell surface, it is possible that reovirus infection of these cells
occurs via attachment to JAM-A and internalization via a
non-1-integrin-dependent mechanism, resulting in a low level
of infection. However, in the case of 1/Y783F/Y795F
cells, it is possible that virus interactions with the mutant form
of 1 integrin are preferred to non-1 integrin internalization
routes, resulting in delivery of virions to a nonproductive entry
pathway as a consequence of the NPXY-to-F mutations. Thus,
these data do not exclude the possibility that reovirus utilizes
coreceptors other than 1 integrin to internalize into cells after
binding to JAM-A. Additionally, it is possible that reovirus
internalization may occur via both clathrin-dependent and
clathrin-independent mechanisms, which has been reported
for influenza virus (56).
Following adsorption to 1/Y783F/Y795F cells, reovirus
virions localize in electron-dense, membrane-bound vesicular
structures that morphologically resemble secondary lysosomes
or phagolysosomes (Fig. 6). These structures are present in
both uninfected and infected 1/ and 1/Y783F/Y795F
cells at all time points analyzed. However, they are not appar-
ent in either uninfected or infected 1/ cells. These obser-
vations suggest that the lack of 1 integrin signaling or recy-
cling has a detrimental effect on endocytic transport that alters
the morphology of endocytic organelles. As probed by analysis
of reovirus internalization, these alterations are associated
with impairments in the sorting or processing of cargo in the
endocytic compartment.
1 integrin NPXY motifs are required for efficient uptake of
Y. pseudotuberculosis by clathrin-mediated endocytosis (28, 64).
However, mutation of the NPXY motifs to NPXF does not affect
internalization of Y. pseudotuberculosis; instead, mutation to
NPXA leads to abolished Y. pseudotuberculosis uptake. Trans-
genic mice expressing 1 integrin with NPXY-to-F mutations are
viable (21), whereas those expressing NPXY-to-A mutations re-
capitulate the phenotype of 1-null mice and arrest in embryo-
genesis (21). These data indicate that there are key functional
differences mediated by the nature of 1 integrin NPXY motif
alterations. In contrast to studies of Y. pseudotuberculosis, we
found that mutation of NPXY to NPXF results in a nonfunctional
route of internalization for reovirus, suggesting that the 1 inte-
grin NPXY motifs play an important regulatory role in endocytic
uptake and transport in the endocytic pathway. Our findings,
coupled with previous findings made with Y. pseudotuberculosis
(28, 64), provide support for the idea that 1 integrin NPXY
motifs are required for multiple functions in the process of en-
docytosis. Understanding mechanisms by which integrins engage
the endocytic machinery to mediate endocytosis of microbes
should provide a useful avenue to investigate integrin cell biology
and lead to the identification of new targets for anti-infective drug
development.
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